PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34007449-13	2021	These data indicated that oxymatrine can effectively prevent insulin resistance and gluconeogenesis, and its mechanism may be at least partly associated with the regulation of PEPCK and G6Pase expression and AKT phosphorylation in the liver.	oxymatrine	26-36	insulin	Homo sapiens	61-68
34007449-0	2021	Effect of oxymatrine on liver gluconeogenesis is associated with the regulation of PEPCK and G6Pase expression and AKT phosphorylation.	oxymatrine	10-20	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	83-88
34007449-13	2021	These data indicated that oxymatrine can effectively prevent insulin resistance and gluconeogenesis, and its mechanism may be at least partly associated with the regulation of PEPCK and G6Pase expression and AKT phosphorylation in the liver.	oxymatrine	26-36	phosphoenolpyruvate carboxykinase 2, mitochondrial	Homo sapiens	176-181
34007449-0	2021	Effect of oxymatrine on liver gluconeogenesis is associated with the regulation of PEPCK and G6Pase expression and AKT phosphorylation.	oxymatrine	10-20	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	93-99
34007449-0	2021	Effect of oxymatrine on liver gluconeogenesis is associated with the regulation of PEPCK and G6Pase expression and AKT phosphorylation.	oxymatrine	10-20	AKT serine/threonine kinase 1	Rattus norvegicus	115-118
34007449-13	2021	These data indicated that oxymatrine can effectively prevent insulin resistance and gluconeogenesis, and its mechanism may be at least partly associated with the regulation of PEPCK and G6Pase expression and AKT phosphorylation in the liver.	oxymatrine	26-36	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	186-192
34007449-10	2021	In vivo, oxymatrine dose-dependently increased the sensitivity of T2DM rats to insulin, increased AKT phosphorylation and decreased PEPCK and G6Pase expression in the liver, and reversed the liver morphological changes.	oxymatrine	9-19	insulin	Homo sapiens	79-86
34007449-10	2021	In vivo, oxymatrine dose-dependently increased the sensitivity of T2DM rats to insulin, increased AKT phosphorylation and decreased PEPCK and G6Pase expression in the liver, and reversed the liver morphological changes.	oxymatrine	9-19	AKT serine/threonine kinase 1	Rattus norvegicus	98-101
34007449-13	2021	These data indicated that oxymatrine can effectively prevent insulin resistance and gluconeogenesis, and its mechanism may be at least partly associated with the regulation of PEPCK and G6Pase expression and AKT phosphorylation in the liver.	oxymatrine	26-36	AKT serine/threonine kinase 1	Homo sapiens	208-211
34007449-10	2021	In vivo, oxymatrine dose-dependently increased the sensitivity of T2DM rats to insulin, increased AKT phosphorylation and decreased PEPCK and G6Pase expression in the liver, and reversed the liver morphological changes.	oxymatrine	9-19	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	132-137
34007449-10	2021	In vivo, oxymatrine dose-dependently increased the sensitivity of T2DM rats to insulin, increased AKT phosphorylation and decreased PEPCK and G6Pase expression in the liver, and reversed the liver morphological changes.	oxymatrine	9-19	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	142-148
33945797-8	2021	The results indicated that treatment with OMT delayed body weight loss, improved motor performance, and prolonged the survival of SOD1-G93A mice.	oxymatrine	42-45	superoxide dismutase 1, soluble	Mus musculus	130-134
34007449-11	2021	In vitro, oxymatrine dose-dependently increased AKT phosphorylation and glucose uptake of HepG2 cells subjected to high-glucose treatment, which was accompanied by inhibition of the expression of the gluconeogenesis-related genes, PEPCK and G6Pase.	oxymatrine	10-20	AKT serine/threonine kinase 1	Homo sapiens	48-51
34007449-11	2021	In vitro, oxymatrine dose-dependently increased AKT phosphorylation and glucose uptake of HepG2 cells subjected to high-glucose treatment, which was accompanied by inhibition of the expression of the gluconeogenesis-related genes, PEPCK and G6Pase.	oxymatrine	10-20	phosphoenolpyruvate carboxykinase 2, mitochondrial	Homo sapiens	231-236
34007449-11	2021	In vitro, oxymatrine dose-dependently increased AKT phosphorylation and glucose uptake of HepG2 cells subjected to high-glucose treatment, which was accompanied by inhibition of the expression of the gluconeogenesis-related genes, PEPCK and G6Pase.	oxymatrine	10-20	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	241-247
33945797-11	2021	Thus, the treatment with OMT had neuroprotective effects, promoting neuronal survival and extending the lifetime of SOD1-G93A mice by suppressing neuroinflammation.	oxymatrine	25-28	superoxide dismutase 1, soluble	Mus musculus	116-120
32737836-4	2021	Here, we examined the effects of the natural alkaloid oxymatrine on PD-L1 expression in CRC cells and to elucidate the underlying mechanism.	oxymatrine	54-64	CD274 molecule	Homo sapiens	68-73
33876189-7	2021	Finally, we predicted and verified that oxymatrine significantly enhances the infiltration of CD8+ T cells into TME and is a powerful combination agent to enhance the therapeutic effect of anti-PD-L1 in a mouse model of lung adenocarcinoma.	oxymatrine	40-50	CD274 antigen	Mus musculus	194-199
33927621-0	2021	Neuroprotective Effects of Oxymatrine on PI3K/Akt/mTOR Pathway After Hypoxic-Ischemic Brain Damage in Neonatal Rats.	oxymatrine	27-37	AKT serine/threonine kinase 1	Rattus norvegicus	46-49
33927621-0	2021	Neuroprotective Effects of Oxymatrine on PI3K/Akt/mTOR Pathway After Hypoxic-Ischemic Brain Damage in Neonatal Rats.	oxymatrine	27-37	mechanistic target of rapamycin kinase	Rattus norvegicus	50-54
33927621-4	2021	This study was aimed to evaluate whether OMT exerted neuroprotective effects mediated by the (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) PI3K/Akt/mTOR pathway after HIBD.	oxymatrine	41-44	protein tyrosine kinase 2 beta	Homo sapiens	124-140
33927621-4	2021	This study was aimed to evaluate whether OMT exerted neuroprotective effects mediated by the (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) PI3K/Akt/mTOR pathway after HIBD.	oxymatrine	41-44	mechanistic target of rapamycin kinase	Homo sapiens	141-170
33927621-4	2021	This study was aimed to evaluate whether OMT exerted neuroprotective effects mediated by the (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) PI3K/Akt/mTOR pathway after HIBD.	oxymatrine	41-44	AKT serine/threonine kinase 1	Homo sapiens	177-180
33927621-4	2021	This study was aimed to evaluate whether OMT exerted neuroprotective effects mediated by the (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) PI3K/Akt/mTOR pathway after HIBD.	oxymatrine	41-44	mechanistic target of rapamycin kinase	Homo sapiens	181-185
32835761-0	2020	Oxymatrine ameliorates imiquimod-induced psoriasis pruritus and inflammation through inhibiting heat shock protein 90 and heat shock protein 60 expression in keratinocytes.	oxymatrine	0-10	heat shock protein 1 (chaperonin)	Mus musculus	122-143
33626426-0	2021	Oxymatrine improves blood-brain barrier integrity after cerebral ischemia-reperfusion injury by downregulating CAV1 and MMP9 expression.	oxymatrine	0-10	caveolin 1, caveolae protein	Mus musculus	111-115
33626426-0	2021	Oxymatrine improves blood-brain barrier integrity after cerebral ischemia-reperfusion injury by downregulating CAV1 and MMP9 expression.	oxymatrine	0-10	matrix metallopeptidase 9	Mus musculus	120-124
33626426-8	2021	Furthermore, intracranial lentivirus injection of short hairpin RNA targeting Cav1 decreased caveolin-1 expression and inhibited the neuroprotective effects of OMT.	oxymatrine	160-163	caveolin 1, caveolae protein	Mus musculus	78-82
33273999-0	2020	Oxymatrine Ameliorates Memory Impairment in Diabetic Rats by Regulating Oxidative Stress and Apoptosis: Involvement of NOX2/NOX4.	oxymatrine	0-10	cytochrome b-245 beta chain	Rattus norvegicus	119-123
33273999-0	2020	Oxymatrine Ameliorates Memory Impairment in Diabetic Rats by Regulating Oxidative Stress and Apoptosis: Involvement of NOX2/NOX4.	oxymatrine	0-10	NADPH oxidase 4	Rattus norvegicus	124-128
32737836-11	2021	IFNgamma increased the mRNA and protein expression of PD-L1 in the two cell lines, but oxymatrine significantly abolished IFNgamma-elevated PD-L1 levels at both mRNA and protein levels.	oxymatrine	87-97	interferon gamma	Homo sapiens	122-130
32737836-11	2021	IFNgamma increased the mRNA and protein expression of PD-L1 in the two cell lines, but oxymatrine significantly abolished IFNgamma-elevated PD-L1 levels at both mRNA and protein levels.	oxymatrine	87-97	CD274 molecule	Homo sapiens	140-145
32737836-12	2021	Furthermore, DNA demethylase activity was remarkably increased in IFNgamma-treated CRC cells, which was abolished by oxymatrine concentration-dependently.	oxymatrine	117-127	interferon gamma	Homo sapiens	66-74
32737836-13	2021	In addition, DNA methyltransferase inhibitor 5-azacytidine considerably abrogated oxymatrine-induced downregulation of PD-L1 mRNA and protein levels in IFNgamma-stimulated CRC cells.	oxymatrine	82-92	CD274 molecule	Homo sapiens	119-124
32737836-13	2021	In addition, DNA methyltransferase inhibitor 5-azacytidine considerably abrogated oxymatrine-induced downregulation of PD-L1 mRNA and protein levels in IFNgamma-stimulated CRC cells.	oxymatrine	82-92	interferon gamma	Homo sapiens	152-160
32737836-14	2021	CONCLUSION: Oxymatrine suppressed viability and reduced PD-L1 expression in IFNgamma-stimulated CRC cells, which was attributed to enhanced DNA demethylation.	oxymatrine	12-22	CD274 molecule	Homo sapiens	56-61
32737836-14	2021	CONCLUSION: Oxymatrine suppressed viability and reduced PD-L1 expression in IFNgamma-stimulated CRC cells, which was attributed to enhanced DNA demethylation.	oxymatrine	12-22	interferon gamma	Homo sapiens	76-84
32835761-5	2020	Molecular docking and the studies in vivo confirmed that HSP90 and HSP60 participate in the inhibitory effect of oxymatrine on the phenotypes of psoriasis mice.	oxymatrine	113-123	heat shock protein 86, pseudogene 1	Mus musculus	57-62
32835761-5	2020	Molecular docking and the studies in vivo confirmed that HSP90 and HSP60 participate in the inhibitory effect of oxymatrine on the phenotypes of psoriasis mice.	oxymatrine	113-123	heat shock protein 1 (chaperonin)	Mus musculus	67-72
32835761-6	2020	Mechanically, immunofluorescence staining demonstrated that oxymatrine-induced downregulation of HSP90 and HSP60 was mainly in keratinocytes.	oxymatrine	60-70	heat shock protein 86, pseudogene 1	Mus musculus	97-102
32835761-6	2020	Mechanically, immunofluorescence staining demonstrated that oxymatrine-induced downregulation of HSP90 and HSP60 was mainly in keratinocytes.	oxymatrine	60-70	heat shock protein 1 (chaperonin)	Mus musculus	107-112
32835761-7	2020	In vitro results showed that oxymatrine decreases the expression of HSP90 and HSP60 upregulated by TNF-alpha and IFN-gamma in HaCaTs cells and the siRNA mediated HSP90 and HSP60 silencing reverses inflammation inhibited by oxymatrine.	oxymatrine	29-39	heat shock protein 86, pseudogene 1	Mus musculus	68-73
32835761-7	2020	In vitro results showed that oxymatrine decreases the expression of HSP90 and HSP60 upregulated by TNF-alpha and IFN-gamma in HaCaTs cells and the siRNA mediated HSP90 and HSP60 silencing reverses inflammation inhibited by oxymatrine.	oxymatrine	29-39	heat shock protein 1 (chaperonin)	Mus musculus	78-83
32835761-7	2020	In vitro results showed that oxymatrine decreases the expression of HSP90 and HSP60 upregulated by TNF-alpha and IFN-gamma in HaCaTs cells and the siRNA mediated HSP90 and HSP60 silencing reverses inflammation inhibited by oxymatrine.	oxymatrine	29-39	tumor necrosis factor	Mus musculus	99-108
32835761-7	2020	In vitro results showed that oxymatrine decreases the expression of HSP90 and HSP60 upregulated by TNF-alpha and IFN-gamma in HaCaTs cells and the siRNA mediated HSP90 and HSP60 silencing reverses inflammation inhibited by oxymatrine.	oxymatrine	29-39	interferon gamma	Mus musculus	113-122
32835761-7	2020	In vitro results showed that oxymatrine decreases the expression of HSP90 and HSP60 upregulated by TNF-alpha and IFN-gamma in HaCaTs cells and the siRNA mediated HSP90 and HSP60 silencing reverses inflammation inhibited by oxymatrine.	oxymatrine	29-39	heat shock protein 86, pseudogene 1	Mus musculus	162-167
32835761-7	2020	In vitro results showed that oxymatrine decreases the expression of HSP90 and HSP60 upregulated by TNF-alpha and IFN-gamma in HaCaTs cells and the siRNA mediated HSP90 and HSP60 silencing reverses inflammation inhibited by oxymatrine.	oxymatrine	29-39	heat shock protein 1 (chaperonin)	Mus musculus	172-177
32835761-7	2020	In vitro results showed that oxymatrine decreases the expression of HSP90 and HSP60 upregulated by TNF-alpha and IFN-gamma in HaCaTs cells and the siRNA mediated HSP90 and HSP60 silencing reverses inflammation inhibited by oxymatrine.	oxymatrine	223-233	heat shock protein 86, pseudogene 1	Mus musculus	68-73
32835761-7	2020	In vitro results showed that oxymatrine decreases the expression of HSP90 and HSP60 upregulated by TNF-alpha and IFN-gamma in HaCaTs cells and the siRNA mediated HSP90 and HSP60 silencing reverses inflammation inhibited by oxymatrine.	oxymatrine	223-233	heat shock protein 86, pseudogene 1	Mus musculus	162-167
32835761-8	2020	Taken together, these results indicate that oxymatrine relieves psoriasis pruritic and inflammation by inhibiting the expression of HSP90 and HSP60 in keratinocytes through MAPK signaling pathway.	oxymatrine	44-54	heat shock protein 86, pseudogene 1	Mus musculus	132-137
32835761-8	2020	Taken together, these results indicate that oxymatrine relieves psoriasis pruritic and inflammation by inhibiting the expression of HSP90 and HSP60 in keratinocytes through MAPK signaling pathway.	oxymatrine	44-54	heat shock protein 1 (chaperonin)	Mus musculus	142-147
32679144-0	2020	Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease.	oxymatrine	0-10	microRNA 182	Homo sapiens	62-69
33061637-0	2020	Oxymatrine Inhibits Colorectal Cancer Metastasis via Attenuating PKM2-Mediated Aerobic Glycolysis.	oxymatrine	0-10	pyruvate kinase, muscle	Mus musculus	65-69
33061637-10	2020	Subsequent results indicated that pyruvate kinase M2 (PKM2) not hexokinase (HK) and phosphofructokinase (PFK) were involved in oxymatrine blocking glycolysis as the PKM2 kinase activity and expression were inhibited by oxymatrine and the PKM2 activator, TEPP-46, can reverse in part the effect of oxymatrine induced in CRC cells.	oxymatrine	127-137	pyruvate kinase, muscle	Mus musculus	34-52
33061637-10	2020	Subsequent results indicated that pyruvate kinase M2 (PKM2) not hexokinase (HK) and phosphofructokinase (PFK) were involved in oxymatrine blocking glycolysis as the PKM2 kinase activity and expression were inhibited by oxymatrine and the PKM2 activator, TEPP-46, can reverse in part the effect of oxymatrine induced in CRC cells.	oxymatrine	127-137	pyruvate kinase, muscle	Mus musculus	54-58
33061637-10	2020	Subsequent results indicated that pyruvate kinase M2 (PKM2) not hexokinase (HK) and phosphofructokinase (PFK) were involved in oxymatrine blocking glycolysis as the PKM2 kinase activity and expression were inhibited by oxymatrine and the PKM2 activator, TEPP-46, can reverse in part the effect of oxymatrine induced in CRC cells.	oxymatrine	127-137	pyruvate kinase, muscle	Mus musculus	165-169
33061637-10	2020	Subsequent results indicated that pyruvate kinase M2 (PKM2) not hexokinase (HK) and phosphofructokinase (PFK) were involved in oxymatrine blocking glycolysis as the PKM2 kinase activity and expression were inhibited by oxymatrine and the PKM2 activator, TEPP-46, can reverse in part the effect of oxymatrine induced in CRC cells.	oxymatrine	127-137	pyruvate kinase, muscle	Mus musculus	165-169
33061637-10	2020	Subsequent results indicated that pyruvate kinase M2 (PKM2) not hexokinase (HK) and phosphofructokinase (PFK) were involved in oxymatrine blocking glycolysis as the PKM2 kinase activity and expression were inhibited by oxymatrine and the PKM2 activator, TEPP-46, can reverse in part the effect of oxymatrine induced in CRC cells.	oxymatrine	219-229	pyruvate kinase, muscle	Mus musculus	34-52
33061637-10	2020	Subsequent results indicated that pyruvate kinase M2 (PKM2) not hexokinase (HK) and phosphofructokinase (PFK) were involved in oxymatrine blocking glycolysis as the PKM2 kinase activity and expression were inhibited by oxymatrine and the PKM2 activator, TEPP-46, can reverse in part the effect of oxymatrine induced in CRC cells.	oxymatrine	219-229	pyruvate kinase, muscle	Mus musculus	54-58
33061637-10	2020	Subsequent results indicated that pyruvate kinase M2 (PKM2) not hexokinase (HK) and phosphofructokinase (PFK) were involved in oxymatrine blocking glycolysis as the PKM2 kinase activity and expression were inhibited by oxymatrine and the PKM2 activator, TEPP-46, can reverse in part the effect of oxymatrine induced in CRC cells.	oxymatrine	219-229	pyruvate kinase, muscle	Mus musculus	34-52
33061637-10	2020	Subsequent results indicated that pyruvate kinase M2 (PKM2) not hexokinase (HK) and phosphofructokinase (PFK) were involved in oxymatrine blocking glycolysis as the PKM2 kinase activity and expression were inhibited by oxymatrine and the PKM2 activator, TEPP-46, can reverse in part the effect of oxymatrine induced in CRC cells.	oxymatrine	219-229	pyruvate kinase, muscle	Mus musculus	54-58
33061637-12	2020	Finally, the in vivo metastatic model in mice showed both 20 mg/kg and 40 mg/kg oxymatrine significantly inhibit liver metastasis of CRC cells in mice, and PKM2 and GLUT1 expression in liver of the oxymatrine-treated group is declined.	oxymatrine	198-208	pyruvate kinase, muscle	Mus musculus	156-160
33061637-12	2020	Finally, the in vivo metastatic model in mice showed both 20 mg/kg and 40 mg/kg oxymatrine significantly inhibit liver metastasis of CRC cells in mice, and PKM2 and GLUT1 expression in liver of the oxymatrine-treated group is declined.	oxymatrine	198-208	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	165-170
33061637-13	2020	Conclusion: Oxymatrine exerted anti-metastatic activity dependent on inhibition of PKM2-mediated aerobic glycolysis.	oxymatrine	12-22	pyruvate kinase, muscle	Mus musculus	83-87
32679144-1	2020	AIMS: This study aimed to investigate oxymatrine via regulating miR-182 improved the hepatic lipid accumulation in non-alcoholic fatty liver disease (NAFLD) model.	oxymatrine	38-48	microRNA 182	Homo sapiens	64-71
32679144-8	2020	Oxymatrine reduced body weight, and improved glucose tolerance and insulin resistance in the HFDHFr + OMT group compared with HFDHFr group.	oxymatrine	0-10	insulin	Homo sapiens	67-74
32679144-10	2020	The levels of SREBP-1c, ACC, and FAS were significantly decreased, while the CPT-1A level was obviously elevated after oxymatrine intervention (P < 0.05).	oxymatrine	119-129	carnitine palmitoyltransferase 1A	Homo sapiens	77-83
32679144-12	2020	Additionally, oxymatrine attenuated the effects of miR-182 inhibitor on lipid accumulation.	oxymatrine	14-24	microRNA 182	Homo sapiens	51-58
32679144-13	2020	SIGNIFICANCE: We presented a possible mechanism that oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in NAFLD model.	oxymatrine	53-63	microRNA 182	Homo sapiens	115-122
33241020-4	2020	Oxymatrine treatment could suppress the proliferation of HSCs and degrade the extracellular cell matrix (ECM), presumed to be associated with HF.	oxymatrine	0-10	multimerin 1	Homo sapiens	105-108
33241020-12	2020	Conclusions: Oxymatrine treatment could improve calcium homeostasis and attenuate ER stress to reverse NaAsO2-induced HSC activation and ECM secretion, which are the significant phenotypes of HF.	oxymatrine	13-23	fucosyltransferase 1 (H blood group)	Homo sapiens	118-121
33241020-10	2020	Results: NaAsO2 exposure promoted apoptosis, increased ECM secretion, produced ER stress, and disrupted calcium homeostasis, which could be attenuated by oxymatrine treatment.	oxymatrine	154-164	multimerin 1	Homo sapiens	55-58
33241020-12	2020	Conclusions: Oxymatrine treatment could improve calcium homeostasis and attenuate ER stress to reverse NaAsO2-induced HSC activation and ECM secretion, which are the significant phenotypes of HF.	oxymatrine	13-23	multimerin 1	Homo sapiens	137-140
33167097-13	2020	CONCLUSION: Oxymatrine combined with vincristine can reduce the drug resistance of HCT-8/VCR cells, which may be related to the regulation of autophagy activity and TLR4 signal activation.	oxymatrine	12-22	toll like receptor 4	Homo sapiens	165-169
31102745-0	2020	Oxymatrine protects neonatal rat against hypoxic-ischemic brain damage via PI3K/Akt/GSK3beta pathway.	oxymatrine	0-10	AKT serine/threonine kinase 1	Rattus norvegicus	80-83
31102745-0	2020	Oxymatrine protects neonatal rat against hypoxic-ischemic brain damage via PI3K/Akt/GSK3beta pathway.	oxymatrine	0-10	glycogen synthase kinase 3 beta	Rattus norvegicus	84-92
31102745-6	2020	KEY FINDINGS: The results shown that oxymatrine regulated brain damage and cell apoptosis by controlling NR2B-PI3K/Akt/GSK3beta signaling pathway.	oxymatrine	37-47	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	105-109
31102745-6	2020	KEY FINDINGS: The results shown that oxymatrine regulated brain damage and cell apoptosis by controlling NR2B-PI3K/Akt/GSK3beta signaling pathway.	oxymatrine	37-47	AKT serine/threonine kinase 1	Rattus norvegicus	115-118
31102745-6	2020	KEY FINDINGS: The results shown that oxymatrine regulated brain damage and cell apoptosis by controlling NR2B-PI3K/Akt/GSK3beta signaling pathway.	oxymatrine	37-47	glycogen synthase kinase 3 beta	Rattus norvegicus	119-127
31102745-11	2020	The utilization of LY293004 (PI3K signaling pathway inhibitor) also supported that oxymatrine ameliorated neonatal hypoxic-ischemic brain damage and cell injury by controlling NR2B-PI3K/Akt/GSK3beta signaling pathway.	oxymatrine	83-93	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	176-180
31102745-11	2020	The utilization of LY293004 (PI3K signaling pathway inhibitor) also supported that oxymatrine ameliorated neonatal hypoxic-ischemic brain damage and cell injury by controlling NR2B-PI3K/Akt/GSK3beta signaling pathway.	oxymatrine	83-93	AKT serine/threonine kinase 1	Rattus norvegicus	186-189
31102745-11	2020	The utilization of LY293004 (PI3K signaling pathway inhibitor) also supported that oxymatrine ameliorated neonatal hypoxic-ischemic brain damage and cell injury by controlling NR2B-PI3K/Akt/GSK3beta signaling pathway.	oxymatrine	83-93	glycogen synthase kinase 3 beta	Rattus norvegicus	190-198
33167097-8	2020	Compared with the blank control group, the content of autophagosome and the content of IL-6 in the oxymatrine group and the combination group were also decreased significantly (P<0.01).	oxymatrine	99-109	interleukin 6	Homo sapiens	87-91
33167097-10	2020	Compared with the oxymatrine group, the combination group had higher autophagosome content, while IL-6 content was decreased (P<0.01); Western blot experiments showed that compared with the blank control group, the expression of P62 in the oxymatrine group was decreased (P<0.05), while the expressions of LC3-II / LC3-I, Beclin-1 and TLR4 were all increased (P<0.05).	oxymatrine	18-28	nucleoporin 62	Homo sapiens	229-232
33167097-10	2020	Compared with the oxymatrine group, the combination group had higher autophagosome content, while IL-6 content was decreased (P<0.01); Western blot experiments showed that compared with the blank control group, the expression of P62 in the oxymatrine group was decreased (P<0.05), while the expressions of LC3-II / LC3-I, Beclin-1 and TLR4 were all increased (P<0.05).	oxymatrine	240-250	nucleoporin 62	Homo sapiens	229-232
32636757-0	2020	Oxymatrine Inhibits Twist-Mediated Renal Tubulointerstitial Fibrosis by Upregulating Id2 Expression.	oxymatrine	0-10	twist family bHLH transcription factor 1	Rattus norvegicus	20-25
32636757-0	2020	Oxymatrine Inhibits Twist-Mediated Renal Tubulointerstitial Fibrosis by Upregulating Id2 Expression.	oxymatrine	0-10	inhibitor of DNA binding 2	Rattus norvegicus	85-88
32528295-0	2020	Oxymatrine Attenuates Dopaminergic Neuronal Damage and Microglia-Mediated Neuroinflammation Through Cathepsin D-Dependent HMGB1/TLR4/NF-kappaB Pathway in Parkinson"s Disease.	oxymatrine	0-10	cathepsin D	Mus musculus	100-111
32581789-0	2020	Oxymatrine Inhibits Renal Cell Carcinoma Progression by Suppressing beta-Catenin Expression.	oxymatrine	0-10	catenin (cadherin associated protein), beta 1	Mus musculus	68-80
32581789-4	2020	The modulation of oxymatrine on beta-catenin was analyzed through western blot and immunofluorescence assay.	oxymatrine	18-28	catenin (cadherin associated protein), beta 1	Mus musculus	32-44
32581789-5	2020	beta-catenin overexpression was employed to determine the key role of beta-catenin in oxymatrine-inhibited renal cell carcinoma in vitro.	oxymatrine	86-96	catenin (cadherin associated protein), beta 1	Mus musculus	70-82
32581789-8	2020	Further mechanistic studies demonstrated that oxymatrine exerted its antineoplastic effect through suppressing the expression of beta-catenin.	oxymatrine	46-56	catenin (cadherin associated protein), beta 1	Mus musculus	129-141
32528295-0	2020	Oxymatrine Attenuates Dopaminergic Neuronal Damage and Microglia-Mediated Neuroinflammation Through Cathepsin D-Dependent HMGB1/TLR4/NF-kappaB Pathway in Parkinson"s Disease.	oxymatrine	0-10	high mobility group box 1	Mus musculus	122-127
32528295-0	2020	Oxymatrine Attenuates Dopaminergic Neuronal Damage and Microglia-Mediated Neuroinflammation Through Cathepsin D-Dependent HMGB1/TLR4/NF-kappaB Pathway in Parkinson"s Disease.	oxymatrine	0-10	toll-like receptor 4	Mus musculus	128-132
32528295-0	2020	Oxymatrine Attenuates Dopaminergic Neuronal Damage and Microglia-Mediated Neuroinflammation Through Cathepsin D-Dependent HMGB1/TLR4/NF-kappaB Pathway in Parkinson"s Disease.	oxymatrine	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	133-142
32528295-8	2020	It is worth noting that overexpression of CathD reversed OMT-targeted inhibition of HMGB1/TLR4/NF-kappaB signaling and OMT-produced neuroprotection in reconstituted neuron-microglia co-cultures.	oxymatrine	57-60	cathepsin D	Mus musculus	42-47
32528295-8	2020	It is worth noting that overexpression of CathD reversed OMT-targeted inhibition of HMGB1/TLR4/NF-kappaB signaling and OMT-produced neuroprotection in reconstituted neuron-microglia co-cultures.	oxymatrine	57-60	high mobility group box 1	Mus musculus	84-89
32528295-8	2020	It is worth noting that overexpression of CathD reversed OMT-targeted inhibition of HMGB1/TLR4/NF-kappaB signaling and OMT-produced neuroprotection in reconstituted neuron-microglia co-cultures.	oxymatrine	57-60	toll-like receptor 4	Mus musculus	90-94
32528295-8	2020	It is worth noting that overexpression of CathD reversed OMT-targeted inhibition of HMGB1/TLR4/NF-kappaB signaling and OMT-produced neuroprotection in reconstituted neuron-microglia co-cultures.	oxymatrine	57-60	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	95-104
32528295-8	2020	It is worth noting that overexpression of CathD reversed OMT-targeted inhibition of HMGB1/TLR4/NF-kappaB signaling and OMT-produced neuroprotection in reconstituted neuron-microglia co-cultures.	oxymatrine	119-122	cathepsin D	Mus musculus	42-47
31897166-0	2020	Oxymatrine reverses 5-fluorouracil resistance by inhibition of colon cancer cell epithelial-mesenchymal transition and NF-kappaB signaling in vitro.	oxymatrine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	119-128
32210812-0	2020	Hepatic Proteomic Changes and Sirt1/AMPK Signaling Activation by Oxymatrine Treatment in Rats With Non-alcoholic Steatosis.	oxymatrine	65-75	sirtuin 1	Rattus norvegicus	30-35
32210812-0	2020	Hepatic Proteomic Changes and Sirt1/AMPK Signaling Activation by Oxymatrine Treatment in Rats With Non-alcoholic Steatosis.	oxymatrine	65-75	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	36-40
32210812-9	2020	Conclusion: The present study has confirmed the significant efficacy of OMT for improving steatosis and revealed hepatic proteomic changes and Sirt1/AMPK signaling activation by OMT treatment in rats with steatosis.	oxymatrine	178-181	sirtuin 1	Rattus norvegicus	143-148
32210812-9	2020	Conclusion: The present study has confirmed the significant efficacy of OMT for improving steatosis and revealed hepatic proteomic changes and Sirt1/AMPK signaling activation by OMT treatment in rats with steatosis.	oxymatrine	178-181	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	149-153
31657676-0	2020	Probucol-induced hERG channel reduction can be rescued by matrine and oxymatrine in vitro.	oxymatrine	70-80	ETS transcription factor ERG	Homo sapiens	17-21
31657676-5	2020	In this study, we demonstrated that 1 muM matrine and oxymatrine could rescue the hERG current and hERG surface expression inhibited by probucol.	oxymatrine	54-64	ETS transcription factor ERG	Homo sapiens	82-86
31657676-5	2020	In this study, we demonstrated that 1 muM matrine and oxymatrine could rescue the hERG current and hERG surface expression inhibited by probucol.	oxymatrine	54-64	ETS transcription factor ERG	Homo sapiens	99-103
31657676-8	2020	We also demonstrated that matrine and oxymatrine were able to upregulate Sp1 expression which may be one of the possible mechanisms that by which matrine and oxymatrine rescued probucol-induced hERG channel deficiency.	oxymatrine	38-48	ETS transcription factor ERG	Homo sapiens	194-198
31657676-8	2020	We also demonstrated that matrine and oxymatrine were able to upregulate Sp1 expression which may be one of the possible mechanisms that by which matrine and oxymatrine rescued probucol-induced hERG channel deficiency.	oxymatrine	158-168	ETS transcription factor ERG	Homo sapiens	194-198
31657676-9	2020	Therefore, these results demonstrate that matrine and oxymatrine could rescue probucol-induced hERG deficiency, which may lead to potentially effective clinical therapeutic drugs for treating cardiotoxicity in the future.	oxymatrine	54-64	ETS transcription factor ERG	Homo sapiens	95-99
32256113-0	2020	Oxymatrine Inhibits Proliferation and Migration of Vulvar Squamous Cell Carcinoma Cells via Attenuation of the RAS/RAF/MEK/ERK Pathway.	oxymatrine	0-10	zinc fingers and homeoboxes 2	Homo sapiens	115-118
32256113-0	2020	Oxymatrine Inhibits Proliferation and Migration of Vulvar Squamous Cell Carcinoma Cells via Attenuation of the RAS/RAF/MEK/ERK Pathway.	oxymatrine	0-10	mitogen-activated protein kinase kinase 7	Homo sapiens	119-122
32256113-0	2020	Oxymatrine Inhibits Proliferation and Migration of Vulvar Squamous Cell Carcinoma Cells via Attenuation of the RAS/RAF/MEK/ERK Pathway.	oxymatrine	0-10	mitogen-activated protein kinase 1	Homo sapiens	123-126
32256113-8	2020	Oxymatrine induced cell cycle arrest in the G2/M phase by increasing the protein expression of P21 and decreasing levels of cyclin B1 and CDC2.	oxymatrine	0-10	H3 histone pseudogene 16	Homo sapiens	95-98
32256113-8	2020	Oxymatrine induced cell cycle arrest in the G2/M phase by increasing the protein expression of P21 and decreasing levels of cyclin B1 and CDC2.	oxymatrine	0-10	cyclin B1	Homo sapiens	124-133
32256113-8	2020	Oxymatrine induced cell cycle arrest in the G2/M phase by increasing the protein expression of P21 and decreasing levels of cyclin B1 and CDC2.	oxymatrine	0-10	cyclin dependent kinase 1	Homo sapiens	138-142
32256113-9	2020	Oxymatrine upregulated the expression of cleaved-caspase 3 and BAX and downregulated the expression of BCL2, which led to an increase in apoptosis.	oxymatrine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	63-66
32256113-9	2020	Oxymatrine upregulated the expression of cleaved-caspase 3 and BAX and downregulated the expression of BCL2, which led to an increase in apoptosis.	oxymatrine	0-10	BCL2 apoptosis regulator	Homo sapiens	103-107
32256113-10	2020	Oxymatrine also suppressed the migration and invasion of SW962 and A431 cells by reducing levels of MMP2 and MMP9.	oxymatrine	0-10	matrix metallopeptidase 2	Homo sapiens	100-104
32256113-10	2020	Oxymatrine also suppressed the migration and invasion of SW962 and A431 cells by reducing levels of MMP2 and MMP9.	oxymatrine	0-10	matrix metallopeptidase 9	Homo sapiens	109-113
32256113-11	2020	After treatment with oxymatrine or a RAS inhibitor (salirasib), expression levels of RAS, p-RAF, p-MEK, p-ERK, C-MYC, and MMP2 were reduced.	oxymatrine	21-31	zinc fingers and homeoboxes 2	Homo sapiens	92-95
32256113-11	2020	After treatment with oxymatrine or a RAS inhibitor (salirasib), expression levels of RAS, p-RAF, p-MEK, p-ERK, C-MYC, and MMP2 were reduced.	oxymatrine	21-31	mitogen-activated protein kinase kinase 7	Homo sapiens	99-102
32256113-11	2020	After treatment with oxymatrine or a RAS inhibitor (salirasib), expression levels of RAS, p-RAF, p-MEK, p-ERK, C-MYC, and MMP2 were reduced.	oxymatrine	21-31	mitogen-activated protein kinase 1	Homo sapiens	106-109
32256113-11	2020	After treatment with oxymatrine or a RAS inhibitor (salirasib), expression levels of RAS, p-RAF, p-MEK, p-ERK, C-MYC, and MMP2 were reduced.	oxymatrine	21-31	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	111-116
32256113-11	2020	After treatment with oxymatrine or a RAS inhibitor (salirasib), expression levels of RAS, p-RAF, p-MEK, p-ERK, C-MYC, and MMP2 were reduced.	oxymatrine	21-31	matrix metallopeptidase 2	Homo sapiens	122-126
32256113-12	2020	When TGF-beta1 was used to stimulate SW962 and A431 cells, the expression of the above proteins increased; this increase was reversed by using oxymatrine or salirasib again.	oxymatrine	143-153	transforming growth factor beta 1	Homo sapiens	5-14
32256113-13	2020	Conclusion: Oxymatrine inhibits proliferation and migration of VSCC cells by blocking the RAS/RAF/MEK/ERK pathway.	oxymatrine	12-22	zinc fingers and homeoboxes 2	Homo sapiens	94-97
32256113-13	2020	Conclusion: Oxymatrine inhibits proliferation and migration of VSCC cells by blocking the RAS/RAF/MEK/ERK pathway.	oxymatrine	12-22	mitogen-activated protein kinase kinase 7	Homo sapiens	98-101
32256113-13	2020	Conclusion: Oxymatrine inhibits proliferation and migration of VSCC cells by blocking the RAS/RAF/MEK/ERK pathway.	oxymatrine	12-22	mitogen-activated protein kinase 1	Homo sapiens	102-105
31979980-0	2020	Oxymatrine suppresses IL-1beta-induced degradation of the nucleus pulposus cell and extracellular matrix through the TLR4/NF-kappaB signaling pathway.	oxymatrine	0-10	interleukin 1 alpha	Homo sapiens	22-30
31979980-0	2020	Oxymatrine suppresses IL-1beta-induced degradation of the nucleus pulposus cell and extracellular matrix through the TLR4/NF-kappaB signaling pathway.	oxymatrine	0-10	toll like receptor 4	Homo sapiens	117-121
31897166-6	2020	The combination of oxymatrine and 5-FU reduced the protein expression of snail family transcriptional repressor 2 and vimentin, phosphorylated p65 and induced the expression of E-cadherin, by inhibiting the nuclear factor kappaB (NF-kappaB) signaling pathway.	oxymatrine	19-29	snail family transcriptional repressor 2	Homo sapiens	73-113
31897166-6	2020	The combination of oxymatrine and 5-FU reduced the protein expression of snail family transcriptional repressor 2 and vimentin, phosphorylated p65 and induced the expression of E-cadherin, by inhibiting the nuclear factor kappaB (NF-kappaB) signaling pathway.	oxymatrine	19-29	vimentin	Homo sapiens	118-126
31897166-6	2020	The combination of oxymatrine and 5-FU reduced the protein expression of snail family transcriptional repressor 2 and vimentin, phosphorylated p65 and induced the expression of E-cadherin, by inhibiting the nuclear factor kappaB (NF-kappaB) signaling pathway.	oxymatrine	19-29	RELA proto-oncogene, NF-kB subunit	Homo sapiens	143-146
31897166-6	2020	The combination of oxymatrine and 5-FU reduced the protein expression of snail family transcriptional repressor 2 and vimentin, phosphorylated p65 and induced the expression of E-cadherin, by inhibiting the nuclear factor kappaB (NF-kappaB) signaling pathway.	oxymatrine	19-29	cadherin 1	Homo sapiens	177-187
31897166-6	2020	The combination of oxymatrine and 5-FU reduced the protein expression of snail family transcriptional repressor 2 and vimentin, phosphorylated p65 and induced the expression of E-cadherin, by inhibiting the nuclear factor kappaB (NF-kappaB) signaling pathway.	oxymatrine	19-29	nuclear factor kappa B subunit 1	Homo sapiens	222-228
31897166-6	2020	The combination of oxymatrine and 5-FU reduced the protein expression of snail family transcriptional repressor 2 and vimentin, phosphorylated p65 and induced the expression of E-cadherin, by inhibiting the nuclear factor kappaB (NF-kappaB) signaling pathway.	oxymatrine	19-29	nuclear factor kappa B subunit 1	Homo sapiens	230-239
31897166-8	2020	Oxymatrine may regulate tumor cell EMT and inactivate the NF-kappaB signaling pathway, and may therefore serve as a potential therapeutic drug to reverse 5-FU resistance in colon cancer cells.	oxymatrine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	58-67
31853201-12	2019	Addition of oxymatrine to BC cells attenuated the PI3K/Akt signaling pathway cascade, as evidenced by dephosphorylation of P13K and Akt.	oxymatrine	12-22	AKT serine/threonine kinase 1	Homo sapiens	55-58
31853201-12	2019	Addition of oxymatrine to BC cells attenuated the PI3K/Akt signaling pathway cascade, as evidenced by dephosphorylation of P13K and Akt.	oxymatrine	12-22	AKT serine/threonine kinase 1	Homo sapiens	132-135
31853201-11	2019	Oxymatrine inhibited expression of B-cell lymphoma-2 while increasing that of Bax as well as increasing expression of caspase-3 and caspase-9.	oxymatrine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	78-81
31853201-11	2019	Oxymatrine inhibited expression of B-cell lymphoma-2 while increasing that of Bax as well as increasing expression of caspase-3 and caspase-9.	oxymatrine	0-10	caspase 3	Homo sapiens	118-127
30822359-9	2019	In addition, oxymatrine treatment reduced cellular apoptosis as shown by increased Bcl-2 expression and a decrease in TUNEL-positive cells.	oxymatrine	13-23	BCL2 apoptosis regulator	Homo sapiens	83-88
31853201-11	2019	Oxymatrine inhibited expression of B-cell lymphoma-2 while increasing that of Bax as well as increasing expression of caspase-3 and caspase-9.	oxymatrine	0-10	caspase 9	Homo sapiens	132-141
31586637-13	2019	These results suggest that OMT prevents Hcy-induced endothelial injury by regulating mitochondrial-dependent apoptosis and Akt-eNOS-NO signaling pathways concomitantly with accentuation of Nrf2 expression.	oxymatrine	27-30	NFE2 like bZIP transcription factor 2	Homo sapiens	189-193
31586637-0	2019	Protective effects of oxymatrine on homocysteine-induced endothelial injury: Involvement of mitochondria-dependent apoptosis and Akt-eNOS-NO signaling pathways.	oxymatrine	22-32	AKT serine/threonine kinase 1	Homo sapiens	129-132
31586637-10	2019	OMT reversed the Hcy-induced decrease in the protein expression of nuclear factor erythroid-2-related factor 2 (Nrf2).	oxymatrine	0-3	NFE2 like bZIP transcription factor 2	Homo sapiens	67-110
31586637-10	2019	OMT reversed the Hcy-induced decrease in the protein expression of nuclear factor erythroid-2-related factor 2 (Nrf2).	oxymatrine	0-3	NFE2 like bZIP transcription factor 2	Homo sapiens	112-116
31586637-11	2019	In addition, OMT reversed the Hcy-induced apoptosis related biochemical changes such as decreased mitochondrial membrane potential and Bcl-2/Bax protein ratio, and increased protein expression of caspase-9 and caspase-3.	oxymatrine	13-16	BCL2 apoptosis regulator	Homo sapiens	135-140
31586637-11	2019	In addition, OMT reversed the Hcy-induced apoptosis related biochemical changes such as decreased mitochondrial membrane potential and Bcl-2/Bax protein ratio, and increased protein expression of caspase-9 and caspase-3.	oxymatrine	13-16	BCL2 associated X, apoptosis regulator	Homo sapiens	141-144
31586637-11	2019	In addition, OMT reversed the Hcy-induced apoptosis related biochemical changes such as decreased mitochondrial membrane potential and Bcl-2/Bax protein ratio, and increased protein expression of caspase-9 and caspase-3.	oxymatrine	13-16	caspase 9	Homo sapiens	196-205
31586637-11	2019	In addition, OMT reversed the Hcy-induced apoptosis related biochemical changes such as decreased mitochondrial membrane potential and Bcl-2/Bax protein ratio, and increased protein expression of caspase-9 and caspase-3.	oxymatrine	13-16	caspase 3	Homo sapiens	210-219
31586637-12	2019	Furthermore, OMT elevated the phosphorylation levels of Akt and eNOS, and the formation of nitric oxide (NO) in injured cells.	oxymatrine	13-16	AKT serine/threonine kinase 1	Homo sapiens	56-59
31586637-13	2019	These results suggest that OMT prevents Hcy-induced endothelial injury by regulating mitochondrial-dependent apoptosis and Akt-eNOS-NO signaling pathways concomitantly with accentuation of Nrf2 expression.	oxymatrine	27-30	AKT serine/threonine kinase 1	Homo sapiens	123-126
31496325-10	2019	In vivo, OMT (50 mg/kg) inhibited 250 mg/100 g of Arg-induced AP involving intestinal injury, including inhibiting Arg-induced inflammatory in pancreas and intestine, inhibiting Arg-induced increase of TNF-alpha, IL-6, IL-1beta, NF-kappaB and p-p38/p-ERK-MAPK signalling, and inhibiting Arg-induced increase of IL-17A/IL-17F, IFN-gamma, ROR-gammat and T-bet.	oxymatrine	9-12	tumor necrosis factor	Rattus norvegicus	202-211
31496325-10	2019	In vivo, OMT (50 mg/kg) inhibited 250 mg/100 g of Arg-induced AP involving intestinal injury, including inhibiting Arg-induced inflammatory in pancreas and intestine, inhibiting Arg-induced increase of TNF-alpha, IL-6, IL-1beta, NF-kappaB and p-p38/p-ERK-MAPK signalling, and inhibiting Arg-induced increase of IL-17A/IL-17F, IFN-gamma, ROR-gammat and T-bet.	oxymatrine	9-12	interleukin 6	Rattus norvegicus	213-217
31496325-10	2019	In vivo, OMT (50 mg/kg) inhibited 250 mg/100 g of Arg-induced AP involving intestinal injury, including inhibiting Arg-induced inflammatory in pancreas and intestine, inhibiting Arg-induced increase of TNF-alpha, IL-6, IL-1beta, NF-kappaB and p-p38/p-ERK-MAPK signalling, and inhibiting Arg-induced increase of IL-17A/IL-17F, IFN-gamma, ROR-gammat and T-bet.	oxymatrine	9-12	interleukin 1 beta	Rattus norvegicus	219-227
31496325-10	2019	In vivo, OMT (50 mg/kg) inhibited 250 mg/100 g of Arg-induced AP involving intestinal injury, including inhibiting Arg-induced inflammatory in pancreas and intestine, inhibiting Arg-induced increase of TNF-alpha, IL-6, IL-1beta, NF-kappaB and p-p38/p-ERK-MAPK signalling, and inhibiting Arg-induced increase of IL-17A/IL-17F, IFN-gamma, ROR-gammat and T-bet.	oxymatrine	9-12	Eph receptor B1	Rattus norvegicus	251-254
31496325-10	2019	In vivo, OMT (50 mg/kg) inhibited 250 mg/100 g of Arg-induced AP involving intestinal injury, including inhibiting Arg-induced inflammatory in pancreas and intestine, inhibiting Arg-induced increase of TNF-alpha, IL-6, IL-1beta, NF-kappaB and p-p38/p-ERK-MAPK signalling, and inhibiting Arg-induced increase of IL-17A/IL-17F, IFN-gamma, ROR-gammat and T-bet.	oxymatrine	9-12	interleukin 17A	Rattus norvegicus	311-317
31496325-10	2019	In vivo, OMT (50 mg/kg) inhibited 250 mg/100 g of Arg-induced AP involving intestinal injury, including inhibiting Arg-induced inflammatory in pancreas and intestine, inhibiting Arg-induced increase of TNF-alpha, IL-6, IL-1beta, NF-kappaB and p-p38/p-ERK-MAPK signalling, and inhibiting Arg-induced increase of IL-17A/IL-17F, IFN-gamma, ROR-gammat and T-bet.	oxymatrine	9-12	interleukin 17F	Rattus norvegicus	318-324
31496325-10	2019	In vivo, OMT (50 mg/kg) inhibited 250 mg/100 g of Arg-induced AP involving intestinal injury, including inhibiting Arg-induced inflammatory in pancreas and intestine, inhibiting Arg-induced increase of TNF-alpha, IL-6, IL-1beta, NF-kappaB and p-p38/p-ERK-MAPK signalling, and inhibiting Arg-induced increase of IL-17A/IL-17F, IFN-gamma, ROR-gammat and T-bet.	oxymatrine	9-12	interferon gamma	Rattus norvegicus	326-335
31177033-8	2019	Treatment of OMT can significantly reduce the densities of Abeta plaques and astrocyte clusters in the neocortex and hippocampus of AD mice.	oxymatrine	13-16	amyloid beta (A4) precursor protein	Mus musculus	59-64
31087709-6	2019	On the basis of these observations, we concluded that oxymatrine can protect T2DM rats from insulin resistance through the regulation of the KSRP, PETN, and AKT expression in the liver.	oxymatrine	54-64	KH-type splicing regulatory protein	Rattus norvegicus	141-145
31087709-0	2019	Oxymatrine ameliorates insulin resistance in rats with type 2 diabetes by regulating the expression of KSRP, PETN, and AKT in the liver.	oxymatrine	0-10	KH-type splicing regulatory protein	Rattus norvegicus	103-107
31087709-6	2019	On the basis of these observations, we concluded that oxymatrine can protect T2DM rats from insulin resistance through the regulation of the KSRP, PETN, and AKT expression in the liver.	oxymatrine	54-64	AKT serine/threonine kinase 1	Rattus norvegicus	157-160
31087709-0	2019	Oxymatrine ameliorates insulin resistance in rats with type 2 diabetes by regulating the expression of KSRP, PETN, and AKT in the liver.	oxymatrine	0-10	AKT serine/threonine kinase 1	Rattus norvegicus	119-122
31497360-0	2019	Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/beta-Catenin signaling pathway.	oxymatrine	0-10	catenin beta 1	Homo sapiens	108-120
31087709-2	2019	Recent studies found that insulin resistance was associated with the dysfunction of KH-type splicing regulatory protein (KSRP) expression and AKT pathway, and that oxymatrine possesses an antidiabetic effect.	oxymatrine	164-174	KH-type splicing regulatory protein	Rattus norvegicus	121-125
31087709-2	2019	Recent studies found that insulin resistance was associated with the dysfunction of KH-type splicing regulatory protein (KSRP) expression and AKT pathway, and that oxymatrine possesses an antidiabetic effect.	oxymatrine	164-174	AKT serine/threonine kinase 1	Rattus norvegicus	142-145
31087709-3	2019	The aim of the present study was to investigate whether the protection of oxymatrine against T2DM was associated with the modulation of the KSRP expression and AKT pathway.	oxymatrine	74-84	KH-type splicing regulatory protein	Rattus norvegicus	140-144
31087709-3	2019	The aim of the present study was to investigate whether the protection of oxymatrine against T2DM was associated with the modulation of the KSRP expression and AKT pathway.	oxymatrine	74-84	AKT serine/threonine kinase 1	Rattus norvegicus	160-163
31087709-5	2019	The administration of oxymatrine decreased blood glucose levels and insulin resistance, increased insulin sensitivity, and improved glycogen synthesis in the liver of T2DM rats, through a reversal in the expression of KSRP, PTEN, and AKT.	oxymatrine	22-32	KH-type splicing regulatory protein	Rattus norvegicus	218-222
31087709-5	2019	The administration of oxymatrine decreased blood glucose levels and insulin resistance, increased insulin sensitivity, and improved glycogen synthesis in the liver of T2DM rats, through a reversal in the expression of KSRP, PTEN, and AKT.	oxymatrine	22-32	phosphatase and tensin homolog	Rattus norvegicus	224-228
31087709-5	2019	The administration of oxymatrine decreased blood glucose levels and insulin resistance, increased insulin sensitivity, and improved glycogen synthesis in the liver of T2DM rats, through a reversal in the expression of KSRP, PTEN, and AKT.	oxymatrine	22-32	AKT serine/threonine kinase 1	Rattus norvegicus	234-237
31632484-0	2019	Oxymatrine inhibits the migration and invasion of hepatocellular carcinoma cells by reducing the activity of MMP-2/-9 via regulating p38 signaling pathway.	oxymatrine	0-10	matrix metallopeptidase 2	Homo sapiens	109-117
31632484-0	2019	Oxymatrine inhibits the migration and invasion of hepatocellular carcinoma cells by reducing the activity of MMP-2/-9 via regulating p38 signaling pathway.	oxymatrine	0-10	mitogen-activated protein kinase 14	Homo sapiens	133-136
31632484-4	2019	Oxymatrine could also inhibit the protein levels of MMP-2/-9 in a dose-dependent relationship.	oxymatrine	0-10	matrix metallopeptidase 2	Homo sapiens	52-60
31632484-5	2019	Moreover, oxymatrine reduces the activity of p38 signaling pathway via inhibiting the phosphorylation of p38.	oxymatrine	10-20	mitogen-activated protein kinase 14	Homo sapiens	45-48
31632484-5	2019	Moreover, oxymatrine reduces the activity of p38 signaling pathway via inhibiting the phosphorylation of p38.	oxymatrine	10-20	mitogen-activated protein kinase 14	Homo sapiens	105-108
31632484-6	2019	The inhibition effect of oxymatrine on the expression of MMP-2/-9 and the phosphorylated of p38 was also detected in vivo.	oxymatrine	25-35	matrix metallopeptidase 2	Homo sapiens	57-65
31632484-6	2019	The inhibition effect of oxymatrine on the expression of MMP-2/-9 and the phosphorylated of p38 was also detected in vivo.	oxymatrine	25-35	mitogen-activated protein kinase 14	Homo sapiens	92-95
31632484-7	2019	Combined treatment with p38 signaling pathway inhibitor and oxymatrine may have a synergistic effect on MMP-2/-9 and invasion of HCC cells.	oxymatrine	60-70	matrix metallopeptidase 2	Homo sapiens	104-112
31632484-8	2019	Therefore, oxymatrine may have inhibited GBC invasiveness by reducing the expression of MMP-2/-9 via inhibiting the activity of p38 signaling pathway.	oxymatrine	11-21	matrix metallopeptidase 2	Homo sapiens	88-96
31632484-8	2019	Therefore, oxymatrine may have inhibited GBC invasiveness by reducing the expression of MMP-2/-9 via inhibiting the activity of p38 signaling pathway.	oxymatrine	11-21	mitogen-activated protein kinase 14	Homo sapiens	128-131
31207405-6	2019	Furthermore, OMT inhibited phosphorylation of JNK, ERK 1/2, P-p38 and NF-kappaB in Abeta1-42-induced microglia cells.	oxymatrine	13-16	mitogen-activated protein kinase 8	Rattus norvegicus	46-49
31207405-6	2019	Furthermore, OMT inhibited phosphorylation of JNK, ERK 1/2, P-p38 and NF-kappaB in Abeta1-42-induced microglia cells.	oxymatrine	13-16	mitogen activated protein kinase 3	Rattus norvegicus	51-58
31207405-6	2019	Furthermore, OMT inhibited phosphorylation of JNK, ERK 1/2, P-p38 and NF-kappaB in Abeta1-42-induced microglia cells.	oxymatrine	13-16	mitogen activated protein kinase 14	Rattus norvegicus	62-65
31496729-0	2019	Oxymatrine reverses epithelial-mesenchymal transition in breast cancer cells by depressing alphaVbeta3 integrin/FAK/PI3K/Akt signaling activation.	oxymatrine	0-10	protein tyrosine kinase 2	Homo sapiens	112-115
31496729-0	2019	Oxymatrine reverses epithelial-mesenchymal transition in breast cancer cells by depressing alphaVbeta3 integrin/FAK/PI3K/Akt signaling activation.	oxymatrine	0-10	AKT serine/threonine kinase 1	Homo sapiens	121-124
31496729-10	2019	Oxymatrine significantly inhibited cell migration and invasion, downregulated the expression of N-cadherin, vimentin, and Snail in MDA-MB-231 and 4T1 cells, but upregulated the expression of E-cadherin in 4T1 cells.	oxymatrine	0-10	cadherin 2	Homo sapiens	96-106
31496729-10	2019	Oxymatrine significantly inhibited cell migration and invasion, downregulated the expression of N-cadherin, vimentin, and Snail in MDA-MB-231 and 4T1 cells, but upregulated the expression of E-cadherin in 4T1 cells.	oxymatrine	0-10	vimentin	Homo sapiens	108-116
31496729-10	2019	Oxymatrine significantly inhibited cell migration and invasion, downregulated the expression of N-cadherin, vimentin, and Snail in MDA-MB-231 and 4T1 cells, but upregulated the expression of E-cadherin in 4T1 cells.	oxymatrine	0-10	snail family transcriptional repressor 1	Homo sapiens	122-127
31496729-10	2019	Oxymatrine significantly inhibited cell migration and invasion, downregulated the expression of N-cadherin, vimentin, and Snail in MDA-MB-231 and 4T1 cells, but upregulated the expression of E-cadherin in 4T1 cells.	oxymatrine	0-10	cadherin 1	Mus musculus	191-201
31496729-13	2019	Furthermore, oxymatrine prevented fibronectin-induced EMT and alphaVbeta3 integrin/FAK/PI3K/Akt signaling activation.	oxymatrine	13-23	fibronectin 1	Homo sapiens	34-45
31496729-13	2019	Furthermore, oxymatrine prevented fibronectin-induced EMT and alphaVbeta3 integrin/FAK/PI3K/Akt signaling activation.	oxymatrine	13-23	protein tyrosine kinase 2	Homo sapiens	83-86
31496729-13	2019	Furthermore, oxymatrine prevented fibronectin-induced EMT and alphaVbeta3 integrin/FAK/PI3K/Akt signaling activation.	oxymatrine	13-23	AKT serine/threonine kinase 1	Homo sapiens	92-95
31496729-14	2019	Conclusion: Our results revealed that oxymatrine effectively reversed EMT in breast cancer cells by depressing alphaVbeta3 integrin/FAK/PI3K/Akt signaling.	oxymatrine	38-48	protein tyrosine kinase 2	Homo sapiens	132-135
31496729-14	2019	Conclusion: Our results revealed that oxymatrine effectively reversed EMT in breast cancer cells by depressing alphaVbeta3 integrin/FAK/PI3K/Akt signaling.	oxymatrine	38-48	AKT serine/threonine kinase 1	Homo sapiens	141-144
31262517-6	2019	We also suggest that the oxymatrine reduces the metastatic potential by inhibition of the EMT process, as A549 cells treated with chosen doses of the compound were characterized by a decrease in the expression of the N-cadherin, vimentin and the elevation of E-cadherin level.	oxymatrine	25-35	IL2 inducible T cell kinase	Homo sapiens	90-93
31262517-6	2019	We also suggest that the oxymatrine reduces the metastatic potential by inhibition of the EMT process, as A549 cells treated with chosen doses of the compound were characterized by a decrease in the expression of the N-cadherin, vimentin and the elevation of E-cadherin level.	oxymatrine	25-35	cadherin 2	Homo sapiens	217-227
31262517-6	2019	We also suggest that the oxymatrine reduces the metastatic potential by inhibition of the EMT process, as A549 cells treated with chosen doses of the compound were characterized by a decrease in the expression of the N-cadherin, vimentin and the elevation of E-cadherin level.	oxymatrine	25-35	vimentin	Homo sapiens	229-237
31262517-6	2019	We also suggest that the oxymatrine reduces the metastatic potential by inhibition of the EMT process, as A549 cells treated with chosen doses of the compound were characterized by a decrease in the expression of the N-cadherin, vimentin and the elevation of E-cadherin level.	oxymatrine	25-35	cadherin 1	Homo sapiens	259-269
31497360-5	2019	Here, by screening a small library of traditional Chinese medicine, we identified a Chinese herb derived Oxymatrine, which could target Wnt/beta-Catenin signaling and compromise the oncogenic effects of Bevacizumab.	oxymatrine	105-115	catenin beta 1	Homo sapiens	140-152
31262973-0	2019	Protective effects of oxymatrine against DSS-induced acute intestinal inflammation in mice via blocking the RhoA/ROCK signaling pathway.	oxymatrine	22-32	ras homolog family member A	Mus musculus	108-112
31325292-0	2019	Inhibitory Effects of Oxymatrine on Transdifferentiation of Neonatal Rat Cardiac Fibroblasts to Myofibroblasts Induced by Aldosterone via Keap1/Nrf2 Signaling Pathways In Vitro.	oxymatrine	22-32	Kelch-like ECH-associated protein 1	Rattus norvegicus	138-143
31325292-0	2019	Inhibitory Effects of Oxymatrine on Transdifferentiation of Neonatal Rat Cardiac Fibroblasts to Myofibroblasts Induced by Aldosterone via Keap1/Nrf2 Signaling Pathways In Vitro.	oxymatrine	22-32	NFE2 like bZIP transcription factor 2	Rattus norvegicus	144-148
31325292-13	2019	OMT alleviated the elevated levels of alpha-SMA, Collagen I, Collagen III, and CTGF, which were abrogated by the Nrf2 siRNA transfection.	oxymatrine	0-3	cellular communication network factor 2	Rattus norvegicus	79-83
31325292-13	2019	OMT alleviated the elevated levels of alpha-SMA, Collagen I, Collagen III, and CTGF, which were abrogated by the Nrf2 siRNA transfection.	oxymatrine	0-3	NFE2 like bZIP transcription factor 2	Rattus norvegicus	113-117
31325292-15	2019	CONCLUSIONS Our results confirm that OMT alleviates transdifferentiation of cardiac fibroblasts to myofibroblasts induced by aldosterone via activating the Nrf2/Keap1 pathway in vitro.	oxymatrine	37-40	NFE2 like bZIP transcription factor 2	Rattus norvegicus	156-160
31325292-15	2019	CONCLUSIONS Our results confirm that OMT alleviates transdifferentiation of cardiac fibroblasts to myofibroblasts induced by aldosterone via activating the Nrf2/Keap1 pathway in vitro.	oxymatrine	37-40	Kelch-like ECH-associated protein 1	Rattus norvegicus	161-166
31262973-6	2019	Our results showed that OMT treatment could protect the integrity of the epithelial barrier, relieve oxidative stress, inhibit the expression of inflammatory mediators and pro-inflammatory cytokines, restrain the differentiation of Th17 cells and promote the differentiation of Treg cells via inhibition of the RhoA/ROCK pathway, thus providing therapeutic benefits for ulcerative colitis (UC).	oxymatrine	24-27	ras homolog family member A	Mus musculus	311-315
31262973-3	2019	Therefore, we sought to determine whether OMT could ameliorate acute intestinal inflammation by targeting the RhoA/ROCK signaling pathway.	oxymatrine	42-45	ras homolog family member A	Mus musculus	110-114
30929340-0	2019	[Oxymatrine affects chemotherapy resistance via the mitochondrial pathway of apoptosis in hepatocellular carcinoma cells HepG2/ADM].	oxymatrine	1-11	adrenomedullin	Homo sapiens	127-130
31221141-0	2019	Inhibitory effects of oxymatrine on hepatic stellate cells activation through TGF-beta/miR-195/Smad signaling pathway.	oxymatrine	22-32	transforming growth factor, beta 1	Rattus norvegicus	78-86
31221141-0	2019	Inhibitory effects of oxymatrine on hepatic stellate cells activation through TGF-beta/miR-195/Smad signaling pathway.	oxymatrine	22-32	microRNA 195	Rattus norvegicus	87-94
31221141-0	2019	Inhibitory effects of oxymatrine on hepatic stellate cells activation through TGF-beta/miR-195/Smad signaling pathway.	oxymatrine	22-32	SMAD family member 7	Rattus norvegicus	95-99
30896871-0	2019	Oxymatrine-mediated maturation of dendritic cells leads to activation of FOXP3+/CD4+ Treg cells and reversal of cisplatin-resistance in lung cancer cells.	oxymatrine	0-10	forkhead box P3	Homo sapiens	73-78
30896871-0	2019	Oxymatrine-mediated maturation of dendritic cells leads to activation of FOXP3+/CD4+ Treg cells and reversal of cisplatin-resistance in lung cancer cells.	oxymatrine	0-10	CD4 molecule	Homo sapiens	80-83
30896871-3	2019	The expressions of CD83 antigen, T-lymphocyte activation antigen CD86, CD11 antigen-like family member C and major histocompatibility complex II in DCs were increased upon treatment with 1 mg/ml OMT, as detected by flow cytometry.	oxymatrine	195-198	CD83 molecule	Homo sapiens	19-23
30896871-3	2019	The expressions of CD83 antigen, T-lymphocyte activation antigen CD86, CD11 antigen-like family member C and major histocompatibility complex II in DCs were increased upon treatment with 1 mg/ml OMT, as detected by flow cytometry.	oxymatrine	195-198	CD86 molecule	Homo sapiens	33-69
30896871-3	2019	The expressions of CD83 antigen, T-lymphocyte activation antigen CD86, CD11 antigen-like family member C and major histocompatibility complex II in DCs were increased upon treatment with 1 mg/ml OMT, as detected by flow cytometry.	oxymatrine	195-198	integrin subunit alpha X	Homo sapiens	71-104
30925456-0	2019	Oxymatrine ameliorates agomelatine-induced hepatocyte injury through promoting proteasome-mediated CHOP degradation.	oxymatrine	0-10	DNA damage inducible transcript 3	Homo sapiens	99-103
30925456-7	2019	Agomelatine treatment resulted in accumulation of CHOP protein in L02 cells, and this phenomenon could be significantly reduced by OMT, whereas abolished by MG132 treatment.	oxymatrine	131-134	DNA damage inducible transcript 3	Homo sapiens	50-54
30925456-8	2019	CONCLUSION: We have demonstrated for the first time that OMT ameliorates the hepatocyte toxicity induced by agomelatine through decreasing CHOP on protein level.	oxymatrine	57-60	DNA damage inducible transcript 3	Homo sapiens	139-143
30419238-6	2019	Meanwhile, oxymatrine normalized the level of pulmonary asymmetric ADMA and attenuated the upregulated expression of protein arginine methyltransferase 1 (PRMT1).	oxymatrine	11-21	protein arginine methyltransferase 1	Rattus norvegicus	117-153
30485133-8	2019	Furthermore, OMT inhibited the activation of MAP kinase (ERK 1/2, JNK) and nuclear factor kappaB.	oxymatrine	13-16	mitogen activated protein kinase 3	Rattus norvegicus	57-64
30485133-8	2019	Furthermore, OMT inhibited the activation of MAP kinase (ERK 1/2, JNK) and nuclear factor kappaB.	oxymatrine	13-16	mitogen-activated protein kinase 8	Rattus norvegicus	66-69
30621055-0	2019	Oxymatrine Attenuates Tumor Growth and Deactivates STAT5 Signaling in a Lung Cancer Xenograft Model.	oxymatrine	0-10	signal transducer and activator of transcription 5A	Mus musculus	51-56
30621055-4	2019	We found that OMT can inhibit the constitutive activation of STAT5 by suppressing the activation of JAK1/2 and c-Src, nuclear localization, as well as STAT5 binding to DNA in A549 cells and abrogated IL-6-induced STAT5 phosphorylation in H1299 cells.	oxymatrine	14-17	signal transducer and activator of transcription 5A	Homo sapiens	61-66
30621055-4	2019	We found that OMT can inhibit the constitutive activation of STAT5 by suppressing the activation of JAK1/2 and c-Src, nuclear localization, as well as STAT5 binding to DNA in A549 cells and abrogated IL-6-induced STAT5 phosphorylation in H1299 cells.	oxymatrine	14-17	Janus kinase 1	Homo sapiens	100-106
30621055-4	2019	We found that OMT can inhibit the constitutive activation of STAT5 by suppressing the activation of JAK1/2 and c-Src, nuclear localization, as well as STAT5 binding to DNA in A549 cells and abrogated IL-6-induced STAT5 phosphorylation in H1299 cells.	oxymatrine	14-17	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	111-116
30621055-4	2019	We found that OMT can inhibit the constitutive activation of STAT5 by suppressing the activation of JAK1/2 and c-Src, nuclear localization, as well as STAT5 binding to DNA in A549 cells and abrogated IL-6-induced STAT5 phosphorylation in H1299 cells.	oxymatrine	14-17	signal transducer and activator of transcription 5A	Homo sapiens	151-156
30621055-4	2019	We found that OMT can inhibit the constitutive activation of STAT5 by suppressing the activation of JAK1/2 and c-Src, nuclear localization, as well as STAT5 binding to DNA in A549 cells and abrogated IL-6-induced STAT5 phosphorylation in H1299 cells.	oxymatrine	14-17	interleukin 6	Homo sapiens	200-204
30621055-4	2019	We found that OMT can inhibit the constitutive activation of STAT5 by suppressing the activation of JAK1/2 and c-Src, nuclear localization, as well as STAT5 binding to DNA in A549 cells and abrogated IL-6-induced STAT5 phosphorylation in H1299 cells.	oxymatrine	14-17	signal transducer and activator of transcription 5A	Homo sapiens	151-156
30419238-6	2019	Meanwhile, oxymatrine normalized the level of pulmonary asymmetric ADMA and attenuated the upregulated expression of protein arginine methyltransferase 1 (PRMT1).	oxymatrine	11-21	protein arginine methyltransferase 1	Rattus norvegicus	155-160
30032345-0	2018	Oxymatrine attenuates brain hypoxic-ischemic injury from apoptosis and oxidative stress: role of p-Akt/GSK3beta/HO-1/Nrf-2 signaling pathway.	oxymatrine	0-10	AKT serine/threonine kinase 1	Rattus norvegicus	99-102
29714135-6	2019	RESULTS: In-vitro and in-vivo evidence supports the effect of berberine, trigonelline, piperine, oxymatrine, vindoneline, evodiamine and neferine on insulin-signaling and related cascades in beta-cells, myocytes, adipocytes, hepatocytes and other cells.	oxymatrine	97-107	insulin	Homo sapiens	149-156
30914108-1	2019	Objective To investigate the effect of oxymatrine on CD11c+ CD103+ E-cadherin+ cells in rats with colitis induced by a mixture of 2, 4, 6-trinitrobenzene sulfonic acid(TNBS)and ethanol.	oxymatrine	39-49	integrin subunit alpha X	Homo sapiens	53-58
30914108-1	2019	Objective To investigate the effect of oxymatrine on CD11c+ CD103+ E-cadherin+ cells in rats with colitis induced by a mixture of 2, 4, 6-trinitrobenzene sulfonic acid(TNBS)and ethanol.	oxymatrine	39-49	integrin subunit alpha E	Homo sapiens	60-65
30914108-1	2019	Objective To investigate the effect of oxymatrine on CD11c+ CD103+ E-cadherin+ cells in rats with colitis induced by a mixture of 2, 4, 6-trinitrobenzene sulfonic acid(TNBS)and ethanol.	oxymatrine	39-49	cadherin 1	Homo sapiens	67-77
30914108-13	2019	Conclusion Oxymatrine can alleviate colonic inflammation on laboratory rats by regulating the levels of IL-10, IL-2 and ICAM-1 and increasing the quantity of CD11c+ CD103+ E-cadherin+ cells.	oxymatrine	11-21	interleukin 10	Rattus norvegicus	104-109
30914108-13	2019	Conclusion Oxymatrine can alleviate colonic inflammation on laboratory rats by regulating the levels of IL-10, IL-2 and ICAM-1 and increasing the quantity of CD11c+ CD103+ E-cadherin+ cells.	oxymatrine	11-21	interleukin 2	Rattus norvegicus	111-115
30914108-13	2019	Conclusion Oxymatrine can alleviate colonic inflammation on laboratory rats by regulating the levels of IL-10, IL-2 and ICAM-1 and increasing the quantity of CD11c+ CD103+ E-cadherin+ cells.	oxymatrine	11-21	intercellular adhesion molecule 1	Rattus norvegicus	120-126
30914108-13	2019	Conclusion Oxymatrine can alleviate colonic inflammation on laboratory rats by regulating the levels of IL-10, IL-2 and ICAM-1 and increasing the quantity of CD11c+ CD103+ E-cadherin+ cells.	oxymatrine	11-21	integrin subunit alpha X	Homo sapiens	158-163
30914108-13	2019	Conclusion Oxymatrine can alleviate colonic inflammation on laboratory rats by regulating the levels of IL-10, IL-2 and ICAM-1 and increasing the quantity of CD11c+ CD103+ E-cadherin+ cells.	oxymatrine	11-21	integrin subunit alpha E	Homo sapiens	165-170
30914108-13	2019	Conclusion Oxymatrine can alleviate colonic inflammation on laboratory rats by regulating the levels of IL-10, IL-2 and ICAM-1 and increasing the quantity of CD11c+ CD103+ E-cadherin+ cells.	oxymatrine	11-21	cadherin 1	Homo sapiens	172-182
30619765-0	2018	Oxymatrine and Cisplatin Synergistically Enhance Anti-tumor Immunity of CD8+ T Cells in Non-small Cell Lung Cancer.	oxymatrine	0-10	CD8a molecule	Homo sapiens	72-75
31091971-0	2019	Proliferation and Migration of Lung Cancer Could be Inhibited by Oxymatrine through the Regulation for miR-520/VEGF.	oxymatrine	65-75	membrane associated ring-CH-type finger 8	Homo sapiens	103-106
31091971-0	2019	Proliferation and Migration of Lung Cancer Could be Inhibited by Oxymatrine through the Regulation for miR-520/VEGF.	oxymatrine	65-75	vascular endothelial growth factor A	Homo sapiens	111-115
31091971-10	2019	Our findings indicate that OMT inhibited cancer progression and metastasis by upregulation of miR-520 and downregulation of VEGF, which provide new support for OMT may be as a novel anticancer drug for the treatment of lung cancer in the future.	oxymatrine	27-30	membrane associated ring-CH-type finger 8	Homo sapiens	94-97
31091971-10	2019	Our findings indicate that OMT inhibited cancer progression and metastasis by upregulation of miR-520 and downregulation of VEGF, which provide new support for OMT may be as a novel anticancer drug for the treatment of lung cancer in the future.	oxymatrine	27-30	vascular endothelial growth factor A	Homo sapiens	124-128
30032345-0	2018	Oxymatrine attenuates brain hypoxic-ischemic injury from apoptosis and oxidative stress: role of p-Akt/GSK3beta/HO-1/Nrf-2 signaling pathway.	oxymatrine	0-10	glycogen synthase kinase 3 beta	Rattus norvegicus	103-111
30032345-0	2018	Oxymatrine attenuates brain hypoxic-ischemic injury from apoptosis and oxidative stress: role of p-Akt/GSK3beta/HO-1/Nrf-2 signaling pathway.	oxymatrine	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	117-122
30032345-3	2018	Our results showed that infarct volume and the apoptosis of NeuN-positive cells were significantly reduced in rats that administrated oxymatrine, with a corresponding improvement in neurological function after H/I.	oxymatrine	134-144	RNA binding fox-1 homolog 3	Rattus norvegicus	60-64
30032345-4	2018	Upregulated p-Akt, p-GSK3beta, Nrf-2 and HO-1 expressions were observed in response to oxymatrine treatment.	oxymatrine	87-97	AKT serine/threonine kinase 1	Rattus norvegicus	14-17
30032345-4	2018	Upregulated p-Akt, p-GSK3beta, Nrf-2 and HO-1 expressions were observed in response to oxymatrine treatment.	oxymatrine	87-97	glycogen synthase kinase 3 beta	Rattus norvegicus	21-29
30032345-4	2018	Upregulated p-Akt, p-GSK3beta, Nrf-2 and HO-1 expressions were observed in response to oxymatrine treatment.	oxymatrine	87-97	NFE2 like bZIP transcription factor 2	Rattus norvegicus	31-36
30032345-6	2018	To conclude, our results suggested that oxymatrine could exert efficacious neuroprotective effect against H/I injury by inhibiting apoptosis and oxidative stress, which might be related to the activation of Akt and GSK3beta and modulation of Nrf-2/HO-1 signaling pathway.	oxymatrine	40-50	AKT serine/threonine kinase 1	Rattus norvegicus	207-210
30032345-6	2018	To conclude, our results suggested that oxymatrine could exert efficacious neuroprotective effect against H/I injury by inhibiting apoptosis and oxidative stress, which might be related to the activation of Akt and GSK3beta and modulation of Nrf-2/HO-1 signaling pathway.	oxymatrine	40-50	glycogen synthase kinase 3 beta	Rattus norvegicus	215-223
30032345-6	2018	To conclude, our results suggested that oxymatrine could exert efficacious neuroprotective effect against H/I injury by inhibiting apoptosis and oxidative stress, which might be related to the activation of Akt and GSK3beta and modulation of Nrf-2/HO-1 signaling pathway.	oxymatrine	40-50	NFE2 like bZIP transcription factor 2	Rattus norvegicus	242-247
29526865-0	2018	Oxymatrine attenuates lipopolysaccharide-induced acute lung injury by activating the epithelial sodium channel and suppressing the JNK signaling pathway.	oxymatrine	0-10	mitogen-activated protein kinase 8	Rattus norvegicus	131-134
30517321-0	2018	Oxymatrine alleviates periodontitis in rats by inhibiting inflammatory factor secretion and regulating MMPs/TIMP protein expression1.	oxymatrine	0-10	matrix metallopeptidase 2	Rattus norvegicus	103-107
30517321-0	2018	Oxymatrine alleviates periodontitis in rats by inhibiting inflammatory factor secretion and regulating MMPs/TIMP protein expression1.	oxymatrine	0-10	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	108-112
30519359-10	2018	Taken together, this study highlights that the co-treatment with OMT and CDDP exerted synergistic antitumor effects in GC cells, and that these effects may be mediated by ROS generation and inactivation of the AKT/ERK pathways.	oxymatrine	65-68	AKT serine/threonine kinase 1	Homo sapiens	210-213
30519359-10	2018	Taken together, this study highlights that the co-treatment with OMT and CDDP exerted synergistic antitumor effects in GC cells, and that these effects may be mediated by ROS generation and inactivation of the AKT/ERK pathways.	oxymatrine	65-68	mitogen-activated protein kinase 1	Homo sapiens	214-217
30196308-0	2018	Oxymatrine Inhibits Transforming Growth Factor beta1 (TGF-beta1)-Induced Cardiac Fibroblast-to-Myofibroblast Transformation (FMT) by Mediating the Notch Signaling Pathway In Vitro.	oxymatrine	0-10	transforming growth factor, beta 1	Rattus norvegicus	20-52
30196308-0	2018	Oxymatrine Inhibits Transforming Growth Factor beta1 (TGF-beta1)-Induced Cardiac Fibroblast-to-Myofibroblast Transformation (FMT) by Mediating the Notch Signaling Pathway In Vitro.	oxymatrine	0-10	transforming growth factor, beta 1	Rattus norvegicus	54-63
30196308-0	2018	Oxymatrine Inhibits Transforming Growth Factor beta1 (TGF-beta1)-Induced Cardiac Fibroblast-to-Myofibroblast Transformation (FMT) by Mediating the Notch Signaling Pathway In Vitro.	oxymatrine	0-10	notch receptor 1	Rattus norvegicus	147-152
30196308-4	2018	In the present study, we investigated the inhibitory effect and mechanism of oxymatrine on cardiac fibrosis induced by TGF-beta1.	oxymatrine	77-87	transforming growth factor, beta 1	Rattus norvegicus	119-128
30196308-12	2018	RESULTS Oxymatrine and Notch signaling pathway inhibitor DAPT could attenuated TGF-beta1 induced the capacity of proliferation and migration increased in cardiac fibroblasts, as well as the secretion of collagen and hydroxyproline colorimetric content in medium.	oxymatrine	8-18	transforming growth factor, beta 1	Rattus norvegicus	79-88
30196308-13	2018	TGF-beta1 induced the biomarker alpha-SMA of fibroblast-to-myofibroblast transformation (FMT), which was inhibited by oxymatrine and DAPT.	oxymatrine	118-128	transforming growth factor, beta 1	Rattus norvegicus	0-9
30196308-14	2018	Western blotting confirmed that oxymatrine blocked the activation of Notch induced by TGF-beta1.	oxymatrine	32-42	notch receptor 1	Rattus norvegicus	69-74
30196308-14	2018	Western blotting confirmed that oxymatrine blocked the activation of Notch induced by TGF-beta1.	oxymatrine	32-42	transforming growth factor, beta 1	Rattus norvegicus	86-95
30196308-15	2018	CONCLUSIONS Oxymatrine is a potential inhibitor FMT induced by TGF-beta1, which is at least in part mediated via inhibition of Notch signaling.	oxymatrine	12-22	transforming growth factor, beta 1	Rattus norvegicus	63-72
30196308-15	2018	CONCLUSIONS Oxymatrine is a potential inhibitor FMT induced by TGF-beta1, which is at least in part mediated via inhibition of Notch signaling.	oxymatrine	12-22	notch receptor 1	Rattus norvegicus	127-132
29989652-0	2018	Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3.	oxymatrine	0-10	epidermal growth factor receptor	Homo sapiens	119-123
29989652-0	2018	Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3.	oxymatrine	0-10	AKT serine/threonine kinase 1	Homo sapiens	129-132
29989652-0	2018	Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3.	oxymatrine	0-10	mechanistic target of rapamycin kinase	Homo sapiens	133-137
29989652-0	2018	Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3.	oxymatrine	0-10	signal transducer and activator of transcription 3	Homo sapiens	160-165
30456880-0	2018	Oxymatrine ameliorates diabetes-induced aortic endothelial dysfunction via the regulation of eNOS and NOX4.	oxymatrine	0-10	NADPH oxidase 4	Rattus norvegicus	102-106
30196826-0	2018	Oxymatrine attenuates cognitive deficits through SIRT1-mediated autophagy in ischemic stroke.	oxymatrine	0-10	sirtuin 1	Rattus norvegicus	49-54
30196826-6	2018	Oxymatrine treatment alleviated histological injury in I/R rats, inhibiting apoptosis, promoting autophagy and accompanied by upregulated expression of SIRT1 proteins.	oxymatrine	0-10	sirtuin 1	Rattus norvegicus	152-157
30196826-7	2018	Oxymatrine may attenuate hippocampus ischemia/reperfusion injury through upregulation SIRT1, further influencing the processes of apoptosis and autophagy.	oxymatrine	0-10	sirtuin 1	Rattus norvegicus	86-91
29526865-9	2018	OMT significantly increased the three subunits of ENaC proteins in vivo and in vitro, while it decreased p-ERK/ERK, p-p38/p38, and p-JNK/JNK ratios in vivo.	oxymatrine	0-3	Eph receptor B1	Rattus norvegicus	107-110
29526865-9	2018	OMT significantly increased the three subunits of ENaC proteins in vivo and in vitro, while it decreased p-ERK/ERK, p-p38/p38, and p-JNK/JNK ratios in vivo.	oxymatrine	0-3	Eph receptor B1	Rattus norvegicus	111-114
29526865-9	2018	OMT significantly increased the three subunits of ENaC proteins in vivo and in vitro, while it decreased p-ERK/ERK, p-p38/p38, and p-JNK/JNK ratios in vivo.	oxymatrine	0-3	mitogen activated protein kinase 14	Rattus norvegicus	118-121
29526865-9	2018	OMT significantly increased the three subunits of ENaC proteins in vivo and in vitro, while it decreased p-ERK/ERK, p-p38/p38, and p-JNK/JNK ratios in vivo.	oxymatrine	0-3	mitogen activated protein kinase 14	Rattus norvegicus	122-125
29526865-9	2018	OMT significantly increased the three subunits of ENaC proteins in vivo and in vitro, while it decreased p-ERK/ERK, p-p38/p38, and p-JNK/JNK ratios in vivo.	oxymatrine	0-3	mitogen-activated protein kinase 8	Rattus norvegicus	133-136
29526865-9	2018	OMT significantly increased the three subunits of ENaC proteins in vivo and in vitro, while it decreased p-ERK/ERK, p-p38/p38, and p-JNK/JNK ratios in vivo.	oxymatrine	0-3	mitogen-activated protein kinase 8	Rattus norvegicus	137-140
29526865-10	2018	However, only the JNK pathway was markedly inhibited in vitro following pretreatment with OMT.	oxymatrine	90-93	mitogen-activated protein kinase 8	Rattus norvegicus	18-21
29526865-11	2018	Collectively, the results suggested that OMT might alleviate LPS-induced ALI by elevating ENaC proteins and inhibiting the JNK signaling pathway.	oxymatrine	41-44	mitogen-activated protein kinase 8	Rattus norvegicus	123-126
29754474-0	2018	Oxymatrine Causes Hepatotoxicity by Promoting the Phosphorylation of JNK and Induction of Endoplasmic Reticulum Stress Mediated by ROS in LO2 Cells.	oxymatrine	0-10	mitogen-activated protein kinase 8	Homo sapiens	69-72
29754474-7	2018	Pre-treatment with Z-VAD-fmk, JNK inhibitor SP600125 and N-acetyl-l-cysteine (NAC), a ROS scavenger, partly improved the survival rates and restored OMT-induced cellular damage, and reduced caspase-3 cleavage.	oxymatrine	149-152	caspase 3	Homo sapiens	190-199
29754474-7	2018	Pre-treatment with Z-VAD-fmk, JNK inhibitor SP600125 and N-acetyl-l-cysteine (NAC), a ROS scavenger, partly improved the survival rates and restored OMT-induced cellular damage, and reduced caspase-3 cleavage.	oxymatrine	149-152	mitogen-activated protein kinase 8	Homo sapiens	30-33
29754474-8	2018	SP600125 or NAC reduced OMT-induced p-JNK and NAC significantly lowered caspase-4.	oxymatrine	24-27	mitogen-activated protein kinase 8	Homo sapiens	38-41
29799160-6	2018	As subchondral bone remodelling is involved in OA progression, and osteoclasts are a unique cell type in bone resorption, we investigated the effects of OMT on osteoclastogenesis, and the results demonstrated that OMT suppresses RANKL-induced osteoclastogenesis by suppressing the RANKL-induced NFATc1 and c-fos signalling pathway in vitro.	oxymatrine	214-217	TNF superfamily member 11	Homo sapiens	229-234
29754474-8	2018	SP600125 or NAC reduced OMT-induced p-JNK and NAC significantly lowered caspase-4.	oxymatrine	24-27	caspase 4	Homo sapiens	72-81
29754474-11	2018	Therefore, OMT-induced injury in L02 cells was related to ROS mediated p-JNK and ER stress induction.	oxymatrine	11-14	mitogen-activated protein kinase 8	Homo sapiens	73-76
29754474-12	2018	Antioxidant, by inhibition of p-JNK or ER stress, may be a feasible method to alleviate OMT-induced liver injury.	oxymatrine	88-91	mitogen-activated protein kinase 8	Homo sapiens	32-35
29799160-6	2018	As subchondral bone remodelling is involved in OA progression, and osteoclasts are a unique cell type in bone resorption, we investigated the effects of OMT on osteoclastogenesis, and the results demonstrated that OMT suppresses RANKL-induced osteoclastogenesis by suppressing the RANKL-induced NFATc1 and c-fos signalling pathway in vitro.	oxymatrine	214-217	TNF superfamily member 11	Homo sapiens	281-286
29799160-6	2018	As subchondral bone remodelling is involved in OA progression, and osteoclasts are a unique cell type in bone resorption, we investigated the effects of OMT on osteoclastogenesis, and the results demonstrated that OMT suppresses RANKL-induced osteoclastogenesis by suppressing the RANKL-induced NFATc1 and c-fos signalling pathway in vitro.	oxymatrine	214-217	nuclear factor of activated T cells 1	Homo sapiens	295-301
29799160-6	2018	As subchondral bone remodelling is involved in OA progression, and osteoclasts are a unique cell type in bone resorption, we investigated the effects of OMT on osteoclastogenesis, and the results demonstrated that OMT suppresses RANKL-induced osteoclastogenesis by suppressing the RANKL-induced NFATc1 and c-fos signalling pathway in vitro.	oxymatrine	214-217	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	306-311
29218605-0	2018	Oxymatrine Sensitizes the HaCaT Cells to the IFN-gamma Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.	oxymatrine	0-10	interferon gamma	Homo sapiens	45-54
29668780-0	2018	The role of oxymatrine in regulating TGF-beta1 in rats with hepatic fibrosis.	oxymatrine	12-22	transforming growth factor, beta 1	Rattus norvegicus	37-46
29668780-1	2018	PURPOSE: To investigate whether oxymatrine (OMT) prevents hepatic fibrosis in rats by regulating liver transforming growth factor beta1 (TGF-beta1) level.	oxymatrine	32-42	transforming growth factor, beta 1	Rattus norvegicus	103-135
29668780-1	2018	PURPOSE: To investigate whether oxymatrine (OMT) prevents hepatic fibrosis in rats by regulating liver transforming growth factor beta1 (TGF-beta1) level.	oxymatrine	32-42	transforming growth factor, beta 1	Rattus norvegicus	137-146
29668780-1	2018	PURPOSE: To investigate whether oxymatrine (OMT) prevents hepatic fibrosis in rats by regulating liver transforming growth factor beta1 (TGF-beta1) level.	oxymatrine	44-47	transforming growth factor, beta 1	Rattus norvegicus	103-135
29668780-1	2018	PURPOSE: To investigate whether oxymatrine (OMT) prevents hepatic fibrosis in rats by regulating liver transforming growth factor beta1 (TGF-beta1) level.	oxymatrine	44-47	transforming growth factor, beta 1	Rattus norvegicus	137-146
29668780-7	2018	OMT significantly reduced serum ALT and AST but increased GSH levels in rats with hepatic fibrosis.	oxymatrine	0-3	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	40-43
29668780-11	2018	CONCLUSION: Oxymatrine is effective in protecting rats from thioacetamide-induced hepatic fibrosis by regulating TGF-beta1 expression.	oxymatrine	12-22	transforming growth factor, beta 1	Rattus norvegicus	113-122
29218605-0	2018	Oxymatrine Sensitizes the HaCaT Cells to the IFN-gamma Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.	oxymatrine	0-10	C-C motif chemokine ligand 22	Homo sapiens	81-84
29218605-0	2018	Oxymatrine Sensitizes the HaCaT Cells to the IFN-gamma Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.	oxymatrine	0-10	intercellular adhesion molecule 1	Homo sapiens	86-92
29218605-0	2018	Oxymatrine Sensitizes the HaCaT Cells to the IFN-gamma Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.	oxymatrine	0-10	suppressor of cytokine signaling 1	Homo sapiens	98-103
29218605-0	2018	Oxymatrine Sensitizes the HaCaT Cells to the IFN-gamma Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.	oxymatrine	0-10	mitogen-activated protein kinase 14	Homo sapiens	118-121
29218605-0	2018	Oxymatrine Sensitizes the HaCaT Cells to the IFN-gamma Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.	oxymatrine	0-10	mitogen-activated protein kinase 8	Homo sapiens	123-126
29218605-0	2018	Oxymatrine Sensitizes the HaCaT Cells to the IFN-gamma Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.	oxymatrine	0-10	AKT serine/threonine kinase 1	Homo sapiens	132-135
29328383-0	2018	Oxymatrine protects against the effects of cardiopulmonary resuscitation via modulation of the TGF-beta1/Smad3 signaling pathway.	oxymatrine	0-10	transforming growth factor, beta 1	Rattus norvegicus	95-104
29328383-0	2018	Oxymatrine protects against the effects of cardiopulmonary resuscitation via modulation of the TGF-beta1/Smad3 signaling pathway.	oxymatrine	0-10	SMAD family member 3	Rattus norvegicus	105-110
29328383-2	2018	The present study investigated whether oxymatrine treatment protects against the effects of cardiopulmonary resuscitation (CPR) via regulation of the transforming growth factor-beta1 (TGF-beta1)/mothers against decapentaplegic (Smad) signaling pathway.	oxymatrine	39-49	transforming growth factor, beta 1	Rattus norvegicus	150-182
29328383-2	2018	The present study investigated whether oxymatrine treatment protects against the effects of cardiopulmonary resuscitation (CPR) via regulation of the transforming growth factor-beta1 (TGF-beta1)/mothers against decapentaplegic (Smad) signaling pathway.	oxymatrine	39-49	transforming growth factor, beta 1	Rattus norvegicus	184-193
29328383-7	2018	Treatment with oxymatrine following CPR significantly inhibited the protein expression levels of TGF-beta1, TGF-beta1 receptor type 1 and Smad homolog 3 (Smad3) in model rats.	oxymatrine	15-25	transforming growth factor, beta 1	Rattus norvegicus	97-106
29328383-7	2018	Treatment with oxymatrine following CPR significantly inhibited the protein expression levels of TGF-beta1, TGF-beta1 receptor type 1 and Smad homolog 3 (Smad3) in model rats.	oxymatrine	15-25	transforming growth factor, beta 1	Rattus norvegicus	108-117
29328383-7	2018	Treatment with oxymatrine following CPR significantly inhibited the protein expression levels of TGF-beta1, TGF-beta1 receptor type 1 and Smad homolog 3 (Smad3) in model rats.	oxymatrine	15-25	SMAD family member 3	Rattus norvegicus	154-159
29328383-8	2018	The results of this research indicated that oxymatrine treatment may protect against the effects of CPR via regulation of the TGF-beta1/Smad3 signaling pathway and may be a novel drug for CPR in a clinical setting.	oxymatrine	44-54	transforming growth factor, beta 1	Rattus norvegicus	126-135
29328383-8	2018	The results of this research indicated that oxymatrine treatment may protect against the effects of CPR via regulation of the TGF-beta1/Smad3 signaling pathway and may be a novel drug for CPR in a clinical setting.	oxymatrine	44-54	SMAD family member 3	Rattus norvegicus	136-141
29170841-0	2018	Oxymatrine induces apoptosis and inhibits invasion in Gallbladder carcinoma via PTEN/PI3K/AKT pathway.	oxymatrine	0-10	phosphatase and tensin homolog	Homo sapiens	80-84
29170841-6	2018	In addition, pretreatment with a specific PI3K/AKT activator (IGF-1) significantly antagonized the oxymatrine-mediated inhibition of GBC-SD cells.	oxymatrine	99-109	AKT serine/threonine kinase 1	Homo sapiens	47-50
29328404-0	2018	Chronic oxymatrine treatment induces resistance and epithelial-mesenchymal transition through targeting the long non-coding RNA MALAT1 in colorectal cancer cells.	oxymatrine	8-18	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	128-134
29328404-6	2018	The established HT29 oxymatrine resistant cells showed an EMT phenotype including specific morphologic changes, enhanced migratory and invasive capacity, and downregulation of E-cadherin protein expression.	oxymatrine	21-31	cadherin 1	Homo sapiens	176-186
29328404-7	2018	Subsequently, high-throughput HiSeq sequencing and RT-qPCR showed that lncRNA MALAT1 was significantly upregulated in the oxymatrine resistant cells (P&lt;0.01), while knockdown of MALAT1 partially reversed the EMT phenotype in HT29 resistant cells.	oxymatrine	122-132	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	78-84
29328404-7	2018	Subsequently, high-throughput HiSeq sequencing and RT-qPCR showed that lncRNA MALAT1 was significantly upregulated in the oxymatrine resistant cells (P&lt;0.01), while knockdown of MALAT1 partially reversed the EMT phenotype in HT29 resistant cells.	oxymatrine	122-132	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	181-187
29328404-8	2018	Furthermore, oxymatrine treatment suppressed the migration and invasion ability of CRC cells, however, this effect was significantly reversed by overexpression of MALAT1.	oxymatrine	13-23	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	163-169
29328404-9	2018	Finally, we investigated the clinical role of MALAT1 and found that high lncRNA MALAT1 expression level is associated with poor prognosis in CRC patients receiving oxymatrine treatment (P&lt;0.01).	oxymatrine	164-174	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	80-86
29328404-10	2018	In conclusion, we demonstrate that lncRNA MALAT1 is a stimulator for oxymatrine resistance in CRC and it may provide therapeutic and prognostic information for CRC patients.	oxymatrine	69-79	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	42-48
29170841-6	2018	In addition, pretreatment with a specific PI3K/AKT activator (IGF-1) significantly antagonized the oxymatrine-mediated inhibition of GBC-SD cells.	oxymatrine	99-109	insulin like growth factor 1	Homo sapiens	62-67
29170841-8	2018	In conclusion, these findings indicated that the inhibition of cells proliferation, migration, invasion and the induction of apoptosis in response to oxymatrine in GBC cells, may function through the suppression of PTEN/PI3K/AKT pathway, which was considered as the vital signaling pathway in regulating tumorigenesis.	oxymatrine	150-160	phosphatase and tensin homolog	Homo sapiens	215-219
29170841-8	2018	In conclusion, these findings indicated that the inhibition of cells proliferation, migration, invasion and the induction of apoptosis in response to oxymatrine in GBC cells, may function through the suppression of PTEN/PI3K/AKT pathway, which was considered as the vital signaling pathway in regulating tumorigenesis.	oxymatrine	150-160	AKT serine/threonine kinase 1	Homo sapiens	225-228
29170841-0	2018	Oxymatrine induces apoptosis and inhibits invasion in Gallbladder carcinoma via PTEN/PI3K/AKT pathway.	oxymatrine	0-10	AKT serine/threonine kinase 1	Homo sapiens	90-93
30103640-0	2018	Oxymatrine exhibits anti-tumor activity in gastric cancer through inhibition of IL-21R-mediated JAK2/STAT3 pathway.	oxymatrine	0-10	interleukin 21 receptor	Homo sapiens	80-86
29239135-0	2018	Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway.	oxymatrine	0-10	epidermal growth factor receptor	Homo sapiens	66-70
29239135-2	2018	In this study, oxymatrine was identified as an EGFR signaling pathway inhibitor in NSCLC.	oxymatrine	15-25	epidermal growth factor receptor	Homo sapiens	47-51
29239135-4	2018	We found that exposure to oxymatrine not only suppressed the activity of wild-type EGFR but also inhibited the activation of exon 19 deletion and L858R/T790M mutated EGFR.	oxymatrine	26-36	epidermal growth factor receptor	Homo sapiens	83-87
29239135-4	2018	We found that exposure to oxymatrine not only suppressed the activity of wild-type EGFR but also inhibited the activation of exon 19 deletion and L858R/T790M mutated EGFR.	oxymatrine	26-36	epidermal growth factor receptor	Homo sapiens	166-170
29239135-5	2018	Flow cytometry analysis suggested that oxymatrine-induced cell cycle G0/G1 arrest was dependent on EGFR-Akt signaling.	oxymatrine	39-49	epidermal growth factor receptor	Homo sapiens	99-103
29239135-5	2018	Flow cytometry analysis suggested that oxymatrine-induced cell cycle G0/G1 arrest was dependent on EGFR-Akt signaling.	oxymatrine	39-49	AKT serine/threonine kinase 1	Homo sapiens	104-107
29510402-0	2018	Oxymatrine Inhibits Homocysteine-Mediated Autophagy via MIF/mTOR Signaling in Human Umbilical Vein Endothelial Cells.	oxymatrine	0-10	mechanistic target of rapamycin kinase	Homo sapiens	60-64
29510402-13	2018	CONCLUSIONS: These results suggest that Hcy can evokeautophagy-activated HUVEC apoptosis/death via a MIF/mTOR signaling pathway, which can be reversed by OMT.	oxymatrine	154-157	macrophage migration inhibitory factor	Homo sapiens	101-104
29510402-13	2018	CONCLUSIONS: These results suggest that Hcy can evokeautophagy-activated HUVEC apoptosis/death via a MIF/mTOR signaling pathway, which can be reversed by OMT.	oxymatrine	154-157	mechanistic target of rapamycin kinase	Homo sapiens	105-109
29402837-16	2018	In addition, the results revealed that the expression of CCL5, IL-1beta and TNF-alpha was increased in the high-glucose group, and that the NO produced by HUVECs decreased due to hyperglycemia; however, co-culture with OMT or A2B siRNA abolished these effects.	oxymatrine	219-222	C-C motif chemokine ligand 5	Homo sapiens	57-61
29402837-16	2018	In addition, the results revealed that the expression of CCL5, IL-1beta and TNF-alpha was increased in the high-glucose group, and that the NO produced by HUVECs decreased due to hyperglycemia; however, co-culture with OMT or A2B siRNA abolished these effects.	oxymatrine	219-222	interleukin 1 beta	Homo sapiens	63-71
29402837-16	2018	In addition, the results revealed that the expression of CCL5, IL-1beta and TNF-alpha was increased in the high-glucose group, and that the NO produced by HUVECs decreased due to hyperglycemia; however, co-culture with OMT or A2B siRNA abolished these effects.	oxymatrine	219-222	tumor necrosis factor	Homo sapiens	76-85
29402837-19	2018	Moreover, the phosphorylation of p38 and ERK1/2 in HUVECs in the high-glucose group was significantly higher than that of the control group; these effects were reversed after co-treatment with OMT or A2B siRNA.	oxymatrine	193-196	mitogen-activated protein kinase 1	Homo sapiens	33-36
29402837-19	2018	Moreover, the phosphorylation of p38 and ERK1/2 in HUVECs in the high-glucose group was significantly higher than that of the control group; these effects were reversed after co-treatment with OMT or A2B siRNA.	oxymatrine	193-196	mitogen-activated protein kinase 3	Homo sapiens	41-47
30103640-0	2018	Oxymatrine exhibits anti-tumor activity in gastric cancer through inhibition of IL-21R-mediated JAK2/STAT3 pathway.	oxymatrine	0-10	Janus kinase 2	Homo sapiens	96-100
30103640-0	2018	Oxymatrine exhibits anti-tumor activity in gastric cancer through inhibition of IL-21R-mediated JAK2/STAT3 pathway.	oxymatrine	0-10	signal transducer and activator of transcription 3	Homo sapiens	101-106
30103640-4	2018	Interleukin 21 receptor (IL-21R) was identified to be differentially expressed between OMT treatment group (4 mg/mL) and control group (0 mg/mL), and knockdown of IL-21R repressed cell proliferation and invasion via inactivation of the JAK2/STAT3 pathway.	oxymatrine	87-90	interleukin 21 receptor	Homo sapiens	0-23
30103640-4	2018	Interleukin 21 receptor (IL-21R) was identified to be differentially expressed between OMT treatment group (4 mg/mL) and control group (0 mg/mL), and knockdown of IL-21R repressed cell proliferation and invasion via inactivation of the JAK2/STAT3 pathway.	oxymatrine	87-90	interleukin 21 receptor	Homo sapiens	25-31
30103640-5	2018	The rescue experiment showed that IL-21R overexpression attenuated the anti-tumor effects of OMT through activation of the JAK2/STAT3 pathway.	oxymatrine	93-96	interleukin 21 receptor	Homo sapiens	34-40
30103640-5	2018	The rescue experiment showed that IL-21R overexpression attenuated the anti-tumor effects of OMT through activation of the JAK2/STAT3 pathway.	oxymatrine	93-96	Janus kinase 2	Homo sapiens	123-127
30103640-5	2018	The rescue experiment showed that IL-21R overexpression attenuated the anti-tumor effects of OMT through activation of the JAK2/STAT3 pathway.	oxymatrine	93-96	signal transducer and activator of transcription 3	Homo sapiens	128-133
29107215-0	2017	Oxymatrine protects against DSS-induced colitis via inhibiting the PI3K/AKT signaling pathway.	oxymatrine	0-10	thymoma viral proto-oncogene 1	Mus musculus	72-75
29115629-6	2018	The caspase-3, 8 and 9 activities of oxymatrine-treated cells were activated, which suggested that extrinsic and intrinsic apoptotic pathways were involved in the anti-proliferative effects of oxymatrine in A549 cells.	oxymatrine	37-47	caspase 3	Homo sapiens	4-13
29115629-6	2018	The caspase-3, 8 and 9 activities of oxymatrine-treated cells were activated, which suggested that extrinsic and intrinsic apoptotic pathways were involved in the anti-proliferative effects of oxymatrine in A549 cells.	oxymatrine	193-203	caspase 3	Homo sapiens	4-13
29138821-0	2018	Protective effects of oxymatrine against lipopolysaccharide/D-galactosamine-induced acute liver failure through oxidative damage, via activation of Nrf2/HO-1 and modulation of inflammatory TLR4-signaling pathways.	oxymatrine	22-32	nuclear factor, erythroid derived 2, like 2	Mus musculus	148-152
29138821-0	2018	Protective effects of oxymatrine against lipopolysaccharide/D-galactosamine-induced acute liver failure through oxidative damage, via activation of Nrf2/HO-1 and modulation of inflammatory TLR4-signaling pathways.	oxymatrine	22-32	heme oxygenase 1	Mus musculus	153-157
29138821-0	2018	Protective effects of oxymatrine against lipopolysaccharide/D-galactosamine-induced acute liver failure through oxidative damage, via activation of Nrf2/HO-1 and modulation of inflammatory TLR4-signaling pathways.	oxymatrine	22-32	toll-like receptor 4	Mus musculus	189-193
29138821-2	2018	The present study aimed to investigate the protective effects of oxymatrine against lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver failure and the associated underlying mechanisms.	oxymatrine	65-75	galanin and GMAP prepropeptide	Mus musculus	128-132
29138821-5	2018	Oxymatrine treatment increased survival rate, decreased plasma aspartate transaminase and alanine aminotransferase activity, increased superoxide dismutase and glutathione peroxidase and decreased malondialdehyde, tumor necrosis factor- and myeloperoxidase activities in mice with LPS/D-GalN-induced liver failure.	oxymatrine	0-10	galanin and GMAP prepropeptide	Mus musculus	287-291
29138821-6	2018	Furthermore, Oxymatrine activated nuclear factor erythroid 2-related factor (Nrf) 2 and heme oxygenase (HO)-1 protein expression, and suppressed Toll like receptor (TLR)4, myeloid differentiation primary response 88 and nuclear factor-kappaB protein expression in mice LPS/D-GalN mice.	oxymatrine	13-23	nuclear factor, erythroid derived 2, like 2	Mus musculus	34-83
29138821-6	2018	Furthermore, Oxymatrine activated nuclear factor erythroid 2-related factor (Nrf) 2 and heme oxygenase (HO)-1 protein expression, and suppressed Toll like receptor (TLR)4, myeloid differentiation primary response 88 and nuclear factor-kappaB protein expression in mice LPS/D-GalN mice.	oxymatrine	13-23	heme oxygenase 1	Mus musculus	88-109
29138821-6	2018	Furthermore, Oxymatrine activated nuclear factor erythroid 2-related factor (Nrf) 2 and heme oxygenase (HO)-1 protein expression, and suppressed Toll like receptor (TLR)4, myeloid differentiation primary response 88 and nuclear factor-kappaB protein expression in mice LPS/D-GalN mice.	oxymatrine	13-23	toll-like receptor 4	Mus musculus	165-170
29138821-6	2018	Furthermore, Oxymatrine activated nuclear factor erythroid 2-related factor (Nrf) 2 and heme oxygenase (HO)-1 protein expression, and suppressed Toll like receptor (TLR)4, myeloid differentiation primary response 88 and nuclear factor-kappaB protein expression in mice LPS/D-GalN mice.	oxymatrine	13-23	galanin and GMAP prepropeptide	Mus musculus	275-279
29138821-7	2018	Overall, the present study suggests that oxymatrine effectively attenuates LPS/D-GalN-induced acute liver failure by oxidative damage via activation of Nrf2/HO-1 and modulation of TLR4-dependent inflammatory signaling pathways.	oxymatrine	41-51	galanin and GMAP prepropeptide	Mus musculus	81-85
29138821-7	2018	Overall, the present study suggests that oxymatrine effectively attenuates LPS/D-GalN-induced acute liver failure by oxidative damage via activation of Nrf2/HO-1 and modulation of TLR4-dependent inflammatory signaling pathways.	oxymatrine	41-51	nuclear factor, erythroid derived 2, like 2	Mus musculus	152-156
29138821-7	2018	Overall, the present study suggests that oxymatrine effectively attenuates LPS/D-GalN-induced acute liver failure by oxidative damage via activation of Nrf2/HO-1 and modulation of TLR4-dependent inflammatory signaling pathways.	oxymatrine	41-51	heme oxygenase 1	Mus musculus	157-161
29138821-7	2018	Overall, the present study suggests that oxymatrine effectively attenuates LPS/D-GalN-induced acute liver failure by oxidative damage via activation of Nrf2/HO-1 and modulation of TLR4-dependent inflammatory signaling pathways.	oxymatrine	41-51	toll-like receptor 4	Mus musculus	180-184
29107215-5	2017	Thus, we aim to explore whether OMT protects against UC by targeting PI3K/AKT pathway.	oxymatrine	32-35	thymoma viral proto-oncogene 1	Mus musculus	74-77
29107215-8	2017	This study reveals that PI3K/AKT signaling pathway is a potential mechanism of OMT-induced UC remission and suggests that OMT is a promising therapeutic agent for the treatment of UC.	oxymatrine	79-82	thymoma viral proto-oncogene 1	Mus musculus	29-32
28849213-0	2017	Inhibitory effects of oxymatrine on TGF-beta1-induced proliferation and abnormal differentiation in rat cardiac fibroblasts via the p38MAPK and ERK1/2 signaling pathways.	oxymatrine	22-32	transforming growth factor, beta 1	Rattus norvegicus	36-45
29152662-0	2017	Oxymatrine induces nasopharyngeal cancer cell death through inhibition of PI3K/AKT and NF-kappaB pathways.	oxymatrine	0-10	AKT serine/threonine kinase 1	Homo sapiens	79-82
29152662-5	2017	Oxymatrine treatment also induced apoptosis, induced the activities of caspase-3 and caspase-9, promoted p53 and Bax protein expression, and suppressed cyclin D protein expression in these cells.	oxymatrine	0-10	caspase 3	Homo sapiens	71-80
29152662-5	2017	Oxymatrine treatment also induced apoptosis, induced the activities of caspase-3 and caspase-9, promoted p53 and Bax protein expression, and suppressed cyclin D protein expression in these cells.	oxymatrine	0-10	caspase 9	Homo sapiens	85-94
29152662-5	2017	Oxymatrine treatment also induced apoptosis, induced the activities of caspase-3 and caspase-9, promoted p53 and Bax protein expression, and suppressed cyclin D protein expression in these cells.	oxymatrine	0-10	tumor protein p53	Homo sapiens	105-108
29152662-5	2017	Oxymatrine treatment also induced apoptosis, induced the activities of caspase-3 and caspase-9, promoted p53 and Bax protein expression, and suppressed cyclin D protein expression in these cells.	oxymatrine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	113-116
29152662-7	2017	In conclusion, results from the present study suggested that oxymatrine may induce NPC cell death through the inhibition of PI3K/AKT and NF-kappaB signaling pathways.	oxymatrine	61-71	AKT serine/threonine kinase 1	Homo sapiens	129-132
28849213-8	2017	In conclusion, the present study revealed that OMT treatment inhibited CFB proliferation and the CFB-myofibroblast transition induced by TGF-beta1, at least in part through inhibition of ERK1/2 and p38MAPK signaling.	oxymatrine	47-50	transforming growth factor, beta 1	Rattus norvegicus	137-146
28849213-0	2017	Inhibitory effects of oxymatrine on TGF-beta1-induced proliferation and abnormal differentiation in rat cardiac fibroblasts via the p38MAPK and ERK1/2 signaling pathways.	oxymatrine	22-32	mitogen activated protein kinase 3	Rattus norvegicus	144-150
28849213-8	2017	In conclusion, the present study revealed that OMT treatment inhibited CFB proliferation and the CFB-myofibroblast transition induced by TGF-beta1, at least in part through inhibition of ERK1/2 and p38MAPK signaling.	oxymatrine	47-50	mitogen activated protein kinase 3	Rattus norvegicus	187-193
28849213-6	2017	Treatment with OMT and SB431542 (a TGF-beta1 receptor inhibitor) attenuated the proliferation and abnormal differentiation of CFBs induced by TGF-beta1, and decreased p38MAPK and ERK1/2 phosphorylation.	oxymatrine	15-18	transforming growth factor, beta 1	Rattus norvegicus	35-44
28849213-6	2017	Treatment with OMT and SB431542 (a TGF-beta1 receptor inhibitor) attenuated the proliferation and abnormal differentiation of CFBs induced by TGF-beta1, and decreased p38MAPK and ERK1/2 phosphorylation.	oxymatrine	15-18	transforming growth factor, beta 1	Rattus norvegicus	142-151
28849213-6	2017	Treatment with OMT and SB431542 (a TGF-beta1 receptor inhibitor) attenuated the proliferation and abnormal differentiation of CFBs induced by TGF-beta1, and decreased p38MAPK and ERK1/2 phosphorylation.	oxymatrine	15-18	mitogen activated protein kinase 3	Rattus norvegicus	179-185
28810657-0	2017	Anti-exudation effects of sodium ferulate and oxymatrine combination via modulation of aquaporin 1.	oxymatrine	46-56	aquaporin 1	Mus musculus	87-98
28810657-3	2017	Treatment with sodium ferulate combined with oxymatrine was shown to significantly inhibit acetic acid-induced vascular permeability in the peritonitis model mice and furthermore to significantly decrease the optical density of Evans blue, the leukocyte number and the levels of interleukin-6, C-reactive protein and interferon-gamma in peritoneal lavage fluid.	oxymatrine	45-55	interleukin 6	Mus musculus	279-292
28450041-8	2017	Immunohistochemical analysis indicates Oxymatrine significantly suppresses the expression of Pan-Cytokeratin, p63 and keratin 10.	oxymatrine	39-49	tumor protein p63	Homo sapiens	110-113
28810657-3	2017	Treatment with sodium ferulate combined with oxymatrine was shown to significantly inhibit acetic acid-induced vascular permeability in the peritonitis model mice and furthermore to significantly decrease the optical density of Evans blue, the leukocyte number and the levels of interleukin-6, C-reactive protein and interferon-gamma in peritoneal lavage fluid.	oxymatrine	45-55	C-reactive protein, pentraxin-related	Mus musculus	294-312
28810657-3	2017	Treatment with sodium ferulate combined with oxymatrine was shown to significantly inhibit acetic acid-induced vascular permeability in the peritonitis model mice and furthermore to significantly decrease the optical density of Evans blue, the leukocyte number and the levels of interleukin-6, C-reactive protein and interferon-gamma in peritoneal lavage fluid.	oxymatrine	45-55	interferon gamma	Mus musculus	317-333
28810657-7	2017	These results indicated that sodium ferulate and oxymatrine combination treatment possessed prominent anti-exudative effects and that the underlying mechanisms are likely to include the improvement of vascular endothelial cellular edema, possibly by upregulation of AQP1 expression on their membrane, which requires further exploration.	oxymatrine	49-59	aquaporin 1	Mus musculus	266-270
28638224-0	2017	Inhibitory effect of oxymatrine on hepatocyte apoptosis via TLR4/PI3K/Akt/GSK-3beta signaling pathway.	oxymatrine	21-31	toll-like receptor 4	Rattus norvegicus	60-64
28638224-0	2017	Inhibitory effect of oxymatrine on hepatocyte apoptosis via TLR4/PI3K/Akt/GSK-3beta signaling pathway.	oxymatrine	21-31	AKT serine/threonine kinase 1	Rattus norvegicus	70-73
28638224-0	2017	Inhibitory effect of oxymatrine on hepatocyte apoptosis via TLR4/PI3K/Akt/GSK-3beta signaling pathway.	oxymatrine	21-31	glycogen synthase kinase 3 beta	Rattus norvegicus	74-83
28638224-11	2017	The levels of AST, ALT, TNF-alpha and IL-1beta in the model group increased significantly, and were significantly reduced by OMT pretreatment.	oxymatrine	125-128	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	14-17
28638224-11	2017	The levels of AST, ALT, TNF-alpha and IL-1beta in the model group increased significantly, and were significantly reduced by OMT pretreatment.	oxymatrine	125-128	tumor necrosis factor	Rattus norvegicus	24-33
28638224-11	2017	The levels of AST, ALT, TNF-alpha and IL-1beta in the model group increased significantly, and were significantly reduced by OMT pretreatment.	oxymatrine	125-128	interleukin 1 beta	Rattus norvegicus	38-46
28450041-8	2017	Immunohistochemical analysis indicates Oxymatrine significantly suppresses the expression of Pan-Cytokeratin, p63 and keratin 10.	oxymatrine	39-49	keratin 10	Homo sapiens	118-128
28450041-9	2017	The results indicate that the suppression of p63 expression may lead to the anti-proliferation effect of Oxymatrine on human skin keratinocytes.	oxymatrine	105-115	tumor protein p63	Homo sapiens	45-48
29029415-0	2017	Oxymatrine suppresses the growth and invasion of MG63 cells by up-regulating PTEN and promoting its nuclear translocation.	oxymatrine	0-10	phosphatase and tensin homolog	Homo sapiens	77-81
28588714-8	2017	Oxymatrine also induced apoptosis and cell cycle arrest in the cells, in association with the upregulation of caspase-3 and Bax, and the downregulation of survivin, Bcl-2 and p53 expression.	oxymatrine	0-10	caspase 3	Homo sapiens	110-119
28588714-8	2017	Oxymatrine also induced apoptosis and cell cycle arrest in the cells, in association with the upregulation of caspase-3 and Bax, and the downregulation of survivin, Bcl-2 and p53 expression.	oxymatrine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	124-127
28588714-8	2017	Oxymatrine also induced apoptosis and cell cycle arrest in the cells, in association with the upregulation of caspase-3 and Bax, and the downregulation of survivin, Bcl-2 and p53 expression.	oxymatrine	0-10	BCL2 apoptosis regulator	Homo sapiens	165-170
28588714-8	2017	Oxymatrine also induced apoptosis and cell cycle arrest in the cells, in association with the upregulation of caspase-3 and Bax, and the downregulation of survivin, Bcl-2 and p53 expression.	oxymatrine	0-10	tumor protein p53	Homo sapiens	175-178
28588714-9	2017	Overall, oxymatrine inhibits the proliferation of human bladder cancer cells by inducing apoptosis and cell cycle arrest via mechanisms that involve p53-Bax signaling and the downregulation of survivin expression.	oxymatrine	9-19	tumor protein p53	Homo sapiens	149-152
28588714-9	2017	Overall, oxymatrine inhibits the proliferation of human bladder cancer cells by inducing apoptosis and cell cycle arrest via mechanisms that involve p53-Bax signaling and the downregulation of survivin expression.	oxymatrine	9-19	BCL2 associated X, apoptosis regulator	Homo sapiens	153-156
29029415-6	2017	Oxymatrine could increase the expression of PTEN and promote its nuclear translocation in MG63 cells.	oxymatrine	0-10	phosphatase and tensin homolog	Homo sapiens	44-48
29029415-9	2017	Oxymatrine could suppress the growth and invasion of MG63 human osteosarcoma cells by up-regulating PTEN and promoting its nuclear translocation and inhibiting PI3K/Akt signaling pathway.	oxymatrine	0-10	phosphatase and tensin homolog	Homo sapiens	100-104
29029415-9	2017	Oxymatrine could suppress the growth and invasion of MG63 human osteosarcoma cells by up-regulating PTEN and promoting its nuclear translocation and inhibiting PI3K/Akt signaling pathway.	oxymatrine	0-10	AKT serine/threonine kinase 1	Homo sapiens	165-168
28115196-10	2017	Furthermore, oxymatrine treatment reduced the expression of Coxsackievirus B3 NTR and mouse TNF-alpha genes compared to the controls.	oxymatrine	13-23	tumor necrosis factor	Mus musculus	92-101
27497639-9	2016	Three-dimensional structure modeling of the UQCRB with oxymatrine showed that their binding interfaces matched and oxymatrine inserted into a deeper pocket of UQCRB, which mainly involved amino acid residues Tyr21, Arg33, Tyr83, Glu84, Asp86, Pro88, and Glu91.	oxymatrine	55-65	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	44-49
27959430-0	2017	Oxymatrine inhibits the migration of human colorectal carcinoma RKO cells via inhibition of PAI-1 and the TGF-beta1/Smad signaling pathway.	oxymatrine	0-10	serpin family E member 1	Homo sapiens	92-97
27959430-0	2017	Oxymatrine inhibits the migration of human colorectal carcinoma RKO cells via inhibition of PAI-1 and the TGF-beta1/Smad signaling pathway.	oxymatrine	0-10	transforming growth factor beta 1	Homo sapiens	106-115
27959430-0	2017	Oxymatrine inhibits the migration of human colorectal carcinoma RKO cells via inhibition of PAI-1 and the TGF-beta1/Smad signaling pathway.	oxymatrine	0-10	SMAD family member 4	Homo sapiens	116-120
28959845-0	2017	[Effect of oxymatrine on apoptosis of hippocampal neurons by p38/JNK signaling pathway].	oxymatrine	11-21	mitogen-activated protein kinase 14	Homo sapiens	61-64
28959845-0	2017	[Effect of oxymatrine on apoptosis of hippocampal neurons by p38/JNK signaling pathway].	oxymatrine	11-21	mitogen-activated protein kinase 8	Homo sapiens	65-68
27713174-8	2017	Furthermore, oxymatrine attenuated the retention of arsenic in liver tissues and improved the expression of Nrf2 and HO-1.	oxymatrine	13-23	NFE2 like bZIP transcription factor 2	Rattus norvegicus	108-112
27713174-8	2017	Furthermore, oxymatrine attenuated the retention of arsenic in liver tissues and improved the expression of Nrf2 and HO-1.	oxymatrine	13-23	heme oxygenase 1	Rattus norvegicus	117-121
27713174-9	2017	In conclusion, our results suggested that oxymatrine protected against As2O3-induced oxidative damage by activating Nrf2/HO-1 signaling pathway.	oxymatrine	42-52	NFE2 like bZIP transcription factor 2	Rattus norvegicus	116-120
27713174-9	2017	In conclusion, our results suggested that oxymatrine protected against As2O3-induced oxidative damage by activating Nrf2/HO-1 signaling pathway.	oxymatrine	42-52	heme oxygenase 1	Rattus norvegicus	121-125
28769005-6	2017	Oxymatrine also triggered apoptosis in breast cancer cells by modulating apoptosis-related proteins, such as cleaved Caspase-3, cleaved Caspase-9 and poly(ADP-ribose)polymerase (PARP).	oxymatrine	0-10	caspase 3	Homo sapiens	117-126
28769005-6	2017	Oxymatrine also triggered apoptosis in breast cancer cells by modulating apoptosis-related proteins, such as cleaved Caspase-3, cleaved Caspase-9 and poly(ADP-ribose)polymerase (PARP).	oxymatrine	0-10	caspase 9	Homo sapiens	136-145
28769005-6	2017	Oxymatrine also triggered apoptosis in breast cancer cells by modulating apoptosis-related proteins, such as cleaved Caspase-3, cleaved Caspase-9 and poly(ADP-ribose)polymerase (PARP).	oxymatrine	0-10	poly(ADP-ribose) polymerase 1	Homo sapiens	150-176
28769005-6	2017	Oxymatrine also triggered apoptosis in breast cancer cells by modulating apoptosis-related proteins, such as cleaved Caspase-3, cleaved Caspase-9 and poly(ADP-ribose)polymerase (PARP).	oxymatrine	0-10	poly(ADP-ribose) polymerase 1	Homo sapiens	178-182
28769005-7	2017	The remarkable reduction in the ratio of Bcl-2/Bax was also observed in oxymatrine treated breast cancer cells.	oxymatrine	72-82	BCL2 apoptosis regulator	Homo sapiens	41-46
28769005-7	2017	The remarkable reduction in the ratio of Bcl-2/Bax was also observed in oxymatrine treated breast cancer cells.	oxymatrine	72-82	BCL2 associated X, apoptosis regulator	Homo sapiens	47-50
27497639-7	2016	Ubiquinol-cytochrome c reductase binding protein (UQCRB) was one of the candidate binding proteins of oxymatrine.	oxymatrine	102-112	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	0-48
27497639-7	2016	Ubiquinol-cytochrome c reductase binding protein (UQCRB) was one of the candidate binding proteins of oxymatrine.	oxymatrine	102-112	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	50-55
27497639-8	2016	UQCRB-displaying T7 phage binding numbers in the oxymatrine group were significantly higher than that in the control group, biotin group, and matrine group (p&lt;0.05 or p&lt;0.01).	oxymatrine	49-59	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	0-5
27497639-9	2016	Three-dimensional structure modeling of the UQCRB with oxymatrine showed that their binding interfaces matched and oxymatrine inserted into a deeper pocket of UQCRB, which mainly involved amino acid residues Tyr21, Arg33, Tyr83, Glu84, Asp86, Pro88, and Glu91.	oxymatrine	55-65	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	159-164
27497639-9	2016	Three-dimensional structure modeling of the UQCRB with oxymatrine showed that their binding interfaces matched and oxymatrine inserted into a deeper pocket of UQCRB, which mainly involved amino acid residues Tyr21, Arg33, Tyr83, Glu84, Asp86, Pro88, and Glu91.	oxymatrine	115-125	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	44-49
27497639-9	2016	Three-dimensional structure modeling of the UQCRB with oxymatrine showed that their binding interfaces matched and oxymatrine inserted into a deeper pocket of UQCRB, which mainly involved amino acid residues Tyr21, Arg33, Tyr83, Glu84, Asp86, Pro88, and Glu91.	oxymatrine	115-125	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	159-164
27497639-12	2016	The binding of oxymatrine to UQCRB was driven by strong enthalpy forces such as hydrogen bonds and polar interactions as the heat released was about 157kcal/mol and DeltaG was less than zero.	oxymatrine	15-25	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	29-34
27497639-13	2016	CONCLUSIONS: In this study, using the T7 phage display system, we have identified UQCRB as a direct binding protein of oxymatrine.	oxymatrine	119-129	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	82-87
27497639-14	2016	Furthermore, the specificity and molecular interaction of oxymatrine with UQCRB were also determined.	oxymatrine	58-68	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	74-79
27497639-15	2016	The binding of UQCRB to oxymatrine suggests that UQCRB is a potential target of oxymatrine in treating CHB.	oxymatrine	24-34	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	15-20
27497639-15	2016	The binding of UQCRB to oxymatrine suggests that UQCRB is a potential target of oxymatrine in treating CHB.	oxymatrine	24-34	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	49-54
27497639-15	2016	The binding of UQCRB to oxymatrine suggests that UQCRB is a potential target of oxymatrine in treating CHB.	oxymatrine	80-90	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	15-20
27497639-15	2016	The binding of UQCRB to oxymatrine suggests that UQCRB is a potential target of oxymatrine in treating CHB.	oxymatrine	80-90	ubiquinol-cytochrome c reductase binding protein	Homo sapiens	49-54
27748797-6	2016	Furthermore, we detected that oxymatrine induced a significant increase in DNA damage and the expression of PARP and phosphorylated H2AX, and a significant decrease in that of nuclear APE1 and AP endonuclease activity in A549 cells.	oxymatrine	30-40	collagen type XI alpha 2 chain	Homo sapiens	108-112
27671687-0	2016	Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.	oxymatrine	0-10	thymoma viral proto-oncogene 1	Mus musculus	102-105
27671687-0	2016	Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.	oxymatrine	0-10	mechanistic target of rapamycin kinase	Mus musculus	106-110
27671687-5	2016	Co-treatment with OMT and OXA caused G0/G1 phase arrest by upregulating P21, P27 and downregulating cyclin D, and induced apoptosis through decreasing the expression of p-PI3K, p-AKT, p-mTOR, p-p70S6K.	oxymatrine	18-21	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	72-75
27671687-5	2016	Co-treatment with OMT and OXA caused G0/G1 phase arrest by upregulating P21, P27 and downregulating cyclin D, and induced apoptosis through decreasing the expression of p-PI3K, p-AKT, p-mTOR, p-p70S6K.	oxymatrine	18-21	cyclin-dependent kinase inhibitor 1B	Mus musculus	77-80
27671687-5	2016	Co-treatment with OMT and OXA caused G0/G1 phase arrest by upregulating P21, P27 and downregulating cyclin D, and induced apoptosis through decreasing the expression of p-PI3K, p-AKT, p-mTOR, p-p70S6K.	oxymatrine	18-21	thymoma viral proto-oncogene 1	Mus musculus	179-182
27671687-5	2016	Co-treatment with OMT and OXA caused G0/G1 phase arrest by upregulating P21, P27 and downregulating cyclin D, and induced apoptosis through decreasing the expression of p-PI3K, p-AKT, p-mTOR, p-p70S6K.	oxymatrine	18-21	mechanistic target of rapamycin kinase	Mus musculus	186-190
27671687-5	2016	Co-treatment with OMT and OXA caused G0/G1 phase arrest by upregulating P21, P27 and downregulating cyclin D, and induced apoptosis through decreasing the expression of p-PI3K, p-AKT, p-mTOR, p-p70S6K.	oxymatrine	18-21	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	194-200
27671687-6	2016	In addition, pretreatment with a specific PI3K/AKT activator (IGF-1) significantly neutralized the pro-apoptotic activity of OXA + OMT, demonstrating the important role of PI3K/AKT in this process.	oxymatrine	131-134	thymoma viral proto-oncogene 1	Mus musculus	47-50
27671687-6	2016	In addition, pretreatment with a specific PI3K/AKT activator (IGF-1) significantly neutralized the pro-apoptotic activity of OXA + OMT, demonstrating the important role of PI3K/AKT in this process.	oxymatrine	131-134	insulin-like growth factor 1	Mus musculus	62-67
27671687-6	2016	In addition, pretreatment with a specific PI3K/AKT activator (IGF-1) significantly neutralized the pro-apoptotic activity of OXA + OMT, demonstrating the important role of PI3K/AKT in this process.	oxymatrine	131-134	thymoma viral proto-oncogene 1	Mus musculus	177-180
27671687-9	2016	In conclusion, our findings highlight that the combination therapy with OMT and OXA exerted synergistic antitumor effects in colon cancer cells through PI3K/AKT/mTOR pathway and combination treatment with OMT and OXA would be a promising therapeutic strategy for colon carcinoma treatment.	oxymatrine	72-75	thymoma viral proto-oncogene 1	Mus musculus	157-160
27671687-9	2016	In conclusion, our findings highlight that the combination therapy with OMT and OXA exerted synergistic antitumor effects in colon cancer cells through PI3K/AKT/mTOR pathway and combination treatment with OMT and OXA would be a promising therapeutic strategy for colon carcinoma treatment.	oxymatrine	72-75	mechanistic target of rapamycin kinase	Mus musculus	161-165
27802898-0	2016	Oxymatrine attenuated isoproterenol-induced heart failure in rats via regulation of COX-2/PGI2 pathway.	oxymatrine	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	84-89
27802898-2	2016	Our previous studies have demonstrated that OMT has protective effects on isoproterenol-induced heart failure in rats through regulation of DDAH/ADMA metabolism pathway.In this study,we further investigated whether OMT could attenuate isoproterenol-induced heart failure through the regulation of COX-2/PGI2 pathway.	oxymatrine	44-47	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	297-302
27802898-6	2016	Administration of OMT significantly reduced the increased BNP in plasm of isoproterenol-induced rats, attenuated cardiac fibrosis,suppressed overexpression of myocardial COX-1 expression, up-regulated COX-2 and PGIS expression, but had no effects on isoproterenol-induced elevated protein cPLA2.	oxymatrine	18-21	natriuretic peptide B	Rattus norvegicus	58-61
27802898-6	2016	Administration of OMT significantly reduced the increased BNP in plasm of isoproterenol-induced rats, attenuated cardiac fibrosis,suppressed overexpression of myocardial COX-1 expression, up-regulated COX-2 and PGIS expression, but had no effects on isoproterenol-induced elevated protein cPLA2.	oxymatrine	18-21	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	170-175
27802898-6	2016	Administration of OMT significantly reduced the increased BNP in plasm of isoproterenol-induced rats, attenuated cardiac fibrosis,suppressed overexpression of myocardial COX-1 expression, up-regulated COX-2 and PGIS expression, but had no effects on isoproterenol-induced elevated protein cPLA2.	oxymatrine	18-21	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	201-206
27802898-6	2016	Administration of OMT significantly reduced the increased BNP in plasm of isoproterenol-induced rats, attenuated cardiac fibrosis,suppressed overexpression of myocardial COX-1 expression, up-regulated COX-2 and PGIS expression, but had no effects on isoproterenol-induced elevated protein cPLA2.	oxymatrine	18-21	prostaglandin I2 synthase	Rattus norvegicus	211-215
27802898-6	2016	Administration of OMT significantly reduced the increased BNP in plasm of isoproterenol-induced rats, attenuated cardiac fibrosis,suppressed overexpression of myocardial COX-1 expression, up-regulated COX-2 and PGIS expression, but had no effects on isoproterenol-induced elevated protein cPLA2.	oxymatrine	18-21	phospholipase A2 group IVA	Rattus norvegicus	289-294
27802898-8	2016	These results demonstrated that OMT has cardioprotective effects on isoproterenol-induced heart failure in rats by regulating COX-2/PGI2 pathway.	oxymatrine	32-35	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	126-131
27748797-6	2016	Furthermore, we detected that oxymatrine induced a significant increase in DNA damage and the expression of PARP and phosphorylated H2AX, and a significant decrease in that of nuclear APE1 and AP endonuclease activity in A549 cells.	oxymatrine	30-40	H2A.X variant histone	Homo sapiens	132-136
27748797-6	2016	Furthermore, we detected that oxymatrine induced a significant increase in DNA damage and the expression of PARP and phosphorylated H2AX, and a significant decrease in that of nuclear APE1 and AP endonuclease activity in A549 cells.	oxymatrine	30-40	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	184-188
27897164-0	2016	HMGB1-mediated autophagy decreases sensitivity to oxymatrine in SW982 human synovial sarcoma cells.	oxymatrine	50-60	high mobility group box 1	Homo sapiens	0-5
27897164-9	2016	OMT-induced autophagy may be mediated by the Akt/mTOR pathway, and HMGB1 plays a vital role in the regulation of autophagy.	oxymatrine	0-3	mechanistic target of rapamycin kinase	Homo sapiens	49-53
27897164-10	2016	Therefore, we believe that combining OMT with an inhibitor of autophagy or HMGB1 may make OMT more effective in the treatment of human synovial sarcoma.	oxymatrine	90-93	high mobility group box 1	Homo sapiens	75-80
27050799-0	2016	Oxymatrine inhibits renal fibrosis of obstructive nephropathy by downregulating the TGF-beta1-Smad3 pathway.	oxymatrine	0-10	transforming growth factor, beta 1	Mus musculus	84-93
27882228-0	2016	Oxymatrine inhibits microglia activation via HSP60-TLR4 signaling.	oxymatrine	0-10	heat shock protein 1 (chaperonin)	Mus musculus	45-50
27882228-0	2016	Oxymatrine inhibits microglia activation via HSP60-TLR4 signaling.	oxymatrine	0-10	toll-like receptor 4	Mus musculus	51-55
27882228-10	2016	In light of these results, it was concluded that OMT may exert its neuroprotective effects via HSP60/TLR-4/MYD88/NF-kappaB signaling pathways to inhibit microglial activation.	oxymatrine	49-52	heat shock protein 1 (chaperonin)	Mus musculus	95-100
27882228-10	2016	In light of these results, it was concluded that OMT may exert its neuroprotective effects via HSP60/TLR-4/MYD88/NF-kappaB signaling pathways to inhibit microglial activation.	oxymatrine	49-52	toll-like receptor 4	Mus musculus	101-106
27882228-10	2016	In light of these results, it was concluded that OMT may exert its neuroprotective effects via HSP60/TLR-4/MYD88/NF-kappaB signaling pathways to inhibit microglial activation.	oxymatrine	49-52	myeloid differentiation primary response gene 88	Mus musculus	107-112
27097917-0	2016	Oxymatrine Induces Liver Injury through JNK Signalling Pathway Mediated by TNF-alpha In Vivo.	oxymatrine	0-10	mitogen-activated protein kinase 8	Mus musculus	40-43
27097917-0	2016	Oxymatrine Induces Liver Injury through JNK Signalling Pathway Mediated by TNF-alpha In Vivo.	oxymatrine	0-10	tumor necrosis factor	Mus musculus	75-84
27097917-6	2016	Altogether, these results suggest that OMT at a dose of 320 mg/kg leads to liver damage and is related to the activation of JNK signalling pathway mediated by TNF-alpha in the liver of mice.	oxymatrine	39-42	mitogen-activated protein kinase 8	Mus musculus	124-127
27097917-6	2016	Altogether, these results suggest that OMT at a dose of 320 mg/kg leads to liver damage and is related to the activation of JNK signalling pathway mediated by TNF-alpha in the liver of mice.	oxymatrine	39-42	tumor necrosis factor	Mus musculus	159-168
27430890-6	2016	Mechanistically, we found that oxymatrine modulated the expression of EMT markers including E-cadherin, Snail and N-cadherin, and reduced expression of p65 which is crucial to NF-kappaB activation.	oxymatrine	31-41	cadherin 1	Homo sapiens	92-102
27430890-6	2016	Mechanistically, we found that oxymatrine modulated the expression of EMT markers including E-cadherin, Snail and N-cadherin, and reduced expression of p65 which is crucial to NF-kappaB activation.	oxymatrine	31-41	snail family transcriptional repressor 1	Homo sapiens	104-109
27430890-6	2016	Mechanistically, we found that oxymatrine modulated the expression of EMT markers including E-cadherin, Snail and N-cadherin, and reduced expression of p65 which is crucial to NF-kappaB activation.	oxymatrine	31-41	cadherin 2	Homo sapiens	114-124
27430890-6	2016	Mechanistically, we found that oxymatrine modulated the expression of EMT markers including E-cadherin, Snail and N-cadherin, and reduced expression of p65 which is crucial to NF-kappaB activation.	oxymatrine	31-41	RELA proto-oncogene, NF-kB subunit	Homo sapiens	152-155
28914031-0	2016	[Oxymatrine alleviates oxidative stress in fat-induced insulin resistance mice by suppressing p38MAPK pathway].	oxymatrine	1-11	mitogen-activated protein kinase 14	Mus musculus	94-101
28914031-11	2016	Compared with model group, HO-1, gamma-GCS mRNA and protein expression significantly increased in 50, 100 mg kg-1 oxymatrine group.	oxymatrine	114-124	heme oxygenase 1	Mus musculus	27-42
28914031-12	2016	The expression of p-p38MAPK decreased in oxymatrine group.	oxymatrine	41-51	mitogen-activated protein kinase 14	Mus musculus	20-27
28914031-13	2016	The results showed that oxymatrine alleviate oxidative stress in hepatic by inhibiting the phosphorylation of p38MAPK, to ameliorate fat-induced insulin resistance mice.	oxymatrine	24-34	mitogen-activated protein kinase 14	Mus musculus	110-117
27179304-0	2016	Oxymatrine attenuates CCl4-induced hepatic fibrosis via modulation of TLR4-dependent inflammatory and TGF-beta1 signaling pathways.	oxymatrine	0-10	C-C motif chemokine ligand 4	Rattus norvegicus	22-26
27179304-0	2016	Oxymatrine attenuates CCl4-induced hepatic fibrosis via modulation of TLR4-dependent inflammatory and TGF-beta1 signaling pathways.	oxymatrine	0-10	toll-like receptor 4	Rattus norvegicus	70-74
27179304-0	2016	Oxymatrine attenuates CCl4-induced hepatic fibrosis via modulation of TLR4-dependent inflammatory and TGF-beta1 signaling pathways.	oxymatrine	0-10	transforming growth factor, beta 1	Rattus norvegicus	102-111
27179304-5	2016	Moreover, lipopolysaccharides (LPS) and high mobility group box-1 (HMGB1), which activates Toll-like receptor 4 (TLR4) and modulate hepatic fibrogenesis through hepatic stellate cells (HSCs) or Kupffer cells, were significantly decreased by OMT treatment.	oxymatrine	241-244	high mobility group box 1	Rattus norvegicus	40-65
27179304-5	2016	Moreover, lipopolysaccharides (LPS) and high mobility group box-1 (HMGB1), which activates Toll-like receptor 4 (TLR4) and modulate hepatic fibrogenesis through hepatic stellate cells (HSCs) or Kupffer cells, were significantly decreased by OMT treatment.	oxymatrine	241-244	high mobility group box 1	Rattus norvegicus	67-72
27179304-5	2016	Moreover, lipopolysaccharides (LPS) and high mobility group box-1 (HMGB1), which activates Toll-like receptor 4 (TLR4) and modulate hepatic fibrogenesis through hepatic stellate cells (HSCs) or Kupffer cells, were significantly decreased by OMT treatment.	oxymatrine	241-244	toll-like receptor 4	Rattus norvegicus	91-111
27179304-5	2016	Moreover, lipopolysaccharides (LPS) and high mobility group box-1 (HMGB1), which activates Toll-like receptor 4 (TLR4) and modulate hepatic fibrogenesis through hepatic stellate cells (HSCs) or Kupffer cells, were significantly decreased by OMT treatment.	oxymatrine	241-244	toll-like receptor 4	Rattus norvegicus	113-117
27179304-9	2016	In conclusion, this study showed that OMT could effectively attenuate the CCl4-induced hepatic fibrosis, and this effect may be due to modulation of TLR4-dependent inflammatory and TGF-beta1 signaling pathways.	oxymatrine	38-41	C-C motif chemokine ligand 4	Rattus norvegicus	74-78
27179304-9	2016	In conclusion, this study showed that OMT could effectively attenuate the CCl4-induced hepatic fibrosis, and this effect may be due to modulation of TLR4-dependent inflammatory and TGF-beta1 signaling pathways.	oxymatrine	38-41	toll-like receptor 4	Rattus norvegicus	149-153
27179304-9	2016	In conclusion, this study showed that OMT could effectively attenuate the CCl4-induced hepatic fibrosis, and this effect may be due to modulation of TLR4-dependent inflammatory and TGF-beta1 signaling pathways.	oxymatrine	38-41	transforming growth factor, beta 1	Rattus norvegicus	181-190
27177246-0	2016	Oxymatrine protects against sepsis-induced myocardial injury via inhibition of the TNF-alpha/p38-MAPK/caspase-3 signaling pathway.	oxymatrine	0-10	tumor necrosis factor	Rattus norvegicus	83-92
27177246-0	2016	Oxymatrine protects against sepsis-induced myocardial injury via inhibition of the TNF-alpha/p38-MAPK/caspase-3 signaling pathway.	oxymatrine	0-10	mitogen activated protein kinase 14	Rattus norvegicus	93-96
27177246-0	2016	Oxymatrine protects against sepsis-induced myocardial injury via inhibition of the TNF-alpha/p38-MAPK/caspase-3 signaling pathway.	oxymatrine	0-10	mitogen activated protein kinase 14	Rattus norvegicus	97-101
27177246-0	2016	Oxymatrine protects against sepsis-induced myocardial injury via inhibition of the TNF-alpha/p38-MAPK/caspase-3 signaling pathway.	oxymatrine	0-10	caspase 3	Rattus norvegicus	102-111
27177246-12	2016	The present study concluded that OMT may offer substantial therapeutic potential for the treatment of septic shock-induced myocardial injury by inhibiting the TNF-alpha/p38-MAPK/caspase-3 signaling pathway.	oxymatrine	33-36	tumor necrosis factor	Rattus norvegicus	159-168
27177246-12	2016	The present study concluded that OMT may offer substantial therapeutic potential for the treatment of septic shock-induced myocardial injury by inhibiting the TNF-alpha/p38-MAPK/caspase-3 signaling pathway.	oxymatrine	33-36	mitogen activated protein kinase 14	Rattus norvegicus	169-172
27177246-12	2016	The present study concluded that OMT may offer substantial therapeutic potential for the treatment of septic shock-induced myocardial injury by inhibiting the TNF-alpha/p38-MAPK/caspase-3 signaling pathway.	oxymatrine	33-36	mitogen activated protein kinase 14	Rattus norvegicus	173-177
27177246-12	2016	The present study concluded that OMT may offer substantial therapeutic potential for the treatment of septic shock-induced myocardial injury by inhibiting the TNF-alpha/p38-MAPK/caspase-3 signaling pathway.	oxymatrine	33-36	caspase 3	Rattus norvegicus	178-187
27457615-0	2016	Oxymatrine inhibits aldosterone-induced rat cardiac fibroblast proliferation and differentiation by attenuating smad-2,-3 and-4 expression: an in vitro study.	oxymatrine	0-10	SMAD family member 2	Rattus norvegicus	112-127
27457615-11	2016	Western blotting revealed oxymatrine attenuated aldosterone-induced Smad-2, Smad-3, and Smad-4 expression in cardiac fibroblasts.	oxymatrine	26-36	SMAD family member 2	Rattus norvegicus	68-74
27457615-11	2016	Western blotting revealed oxymatrine attenuated aldosterone-induced Smad-2, Smad-3, and Smad-4 expression in cardiac fibroblasts.	oxymatrine	26-36	SMAD family member 3	Rattus norvegicus	76-82
27457615-11	2016	Western blotting revealed oxymatrine attenuated aldosterone-induced Smad-2, Smad-3, and Smad-4 expression in cardiac fibroblasts.	oxymatrine	26-36	SMAD family member 4	Rattus norvegicus	88-94
27457615-12	2016	CONCLUSION: Oxymatrine can inhibit cardiac fibroblast proliferation and differentiation into myofibroblasts via a mechanism linked to attenuation of the Smad signaling pathway.	oxymatrine	12-22	SMAD family member 4	Rattus norvegicus	153-157
27050799-0	2016	Oxymatrine inhibits renal fibrosis of obstructive nephropathy by downregulating the TGF-beta1-Smad3 pathway.	oxymatrine	0-10	SMAD family member 3	Mus musculus	94-99
27050799-6	2016	The results showed OMT significantly prevented kidney injury and fibrosis, as evidenced by decreased expression of collagen-1 and fibronectin.	oxymatrine	19-22	fibronectin 1	Mus musculus	115-141
27050799-7	2016	Furthermore, OMT administration inhibited the release of inflammatory factors including tumor necrosis factor-alpha, (TNF-alpha) interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), as well as phosphorylated NF-kappaB p65.	oxymatrine	13-16	tumor necrosis factor	Mus musculus	88-115
27050799-7	2016	Furthermore, OMT administration inhibited the release of inflammatory factors including tumor necrosis factor-alpha, (TNF-alpha) interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), as well as phosphorylated NF-kappaB p65.	oxymatrine	13-16	tumor necrosis factor	Mus musculus	118-127
27050799-7	2016	Furthermore, OMT administration inhibited the release of inflammatory factors including tumor necrosis factor-alpha, (TNF-alpha) interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), as well as phosphorylated NF-kappaB p65.	oxymatrine	13-16	interleukin 1 beta	Mus musculus	129-146
27050799-7	2016	Furthermore, OMT administration inhibited the release of inflammatory factors including tumor necrosis factor-alpha, (TNF-alpha) interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), as well as phosphorylated NF-kappaB p65.	oxymatrine	13-16	interleukin 1 beta	Mus musculus	148-156
27050799-7	2016	Furthermore, OMT administration inhibited the release of inflammatory factors including tumor necrosis factor-alpha, (TNF-alpha) interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), as well as phosphorylated NF-kappaB p65.	oxymatrine	13-16	interleukin 6	Mus musculus	163-176
27050799-7	2016	Furthermore, OMT administration inhibited the release of inflammatory factors including tumor necrosis factor-alpha, (TNF-alpha) interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), as well as phosphorylated NF-kappaB p65.	oxymatrine	13-16	interleukin 6	Mus musculus	178-182
27050799-7	2016	Furthermore, OMT administration inhibited the release of inflammatory factors including tumor necrosis factor-alpha, (TNF-alpha) interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), as well as phosphorylated NF-kappaB p65.	oxymatrine	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	211-220
27050799-7	2016	Furthermore, OMT administration inhibited the release of inflammatory factors including tumor necrosis factor-alpha, (TNF-alpha) interleukin-1beta (IL-1beta), and interleukin-6 (IL-6), as well as phosphorylated NF-kappaB p65.	oxymatrine	13-16	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	221-224
27050799-8	2016	In addition, OMT blocked the activation of myofibroblasts by inhibiting the TGF-beta/Smad3-signaling pathway.	oxymatrine	13-16	transforming growth factor, beta 1	Mus musculus	76-84
27050799-8	2016	In addition, OMT blocked the activation of myofibroblasts by inhibiting the TGF-beta/Smad3-signaling pathway.	oxymatrine	13-16	SMAD family member 3	Mus musculus	85-90
26009496-2	2016	The present study is conducted to investigate the anticancer activity and the underlying mechanisms of oxymatrine in human hepatoma cells (Hep-G2 and SMMC-7721) in vitro and in vivo Hep-G2 and SMMC-7721 cells were treated by oxymatrine and subjected to methyl thiazolyl tetrazolium analysis, Hoechst 33342 staining, annexin V/propidium iodide double staining, reverse transcription polymerase chain reaction, and Western blot analysis.	oxymatrine	103-113	annexin A5	Homo sapiens	316-325
26009496-3	2016	In addition, SMMC-7721 xenograft tumors were established in male nude BALB/c mice, and oxymatrine was intravenously administered to evaluate the anticancer capacity in vivo Our results showed that oxymatrine inhibited the proliferation and induced apoptosis of Hep-G2 and SMMC-7721 cells in a dose-dependent manner in vitro Furthermore, the RNA and protein expression of Bax and caspase 3 levels were significantly upregulated, whereas the expression of Bcl-2 was downregulated.	oxymatrine	197-207	BCL2 associated X, apoptosis regulator	Homo sapiens	371-374
26009496-3	2016	In addition, SMMC-7721 xenograft tumors were established in male nude BALB/c mice, and oxymatrine was intravenously administered to evaluate the anticancer capacity in vivo Our results showed that oxymatrine inhibited the proliferation and induced apoptosis of Hep-G2 and SMMC-7721 cells in a dose-dependent manner in vitro Furthermore, the RNA and protein expression of Bax and caspase 3 levels were significantly upregulated, whereas the expression of Bcl-2 was downregulated.	oxymatrine	197-207	caspase 3	Homo sapiens	379-388
26009496-3	2016	In addition, SMMC-7721 xenograft tumors were established in male nude BALB/c mice, and oxymatrine was intravenously administered to evaluate the anticancer capacity in vivo Our results showed that oxymatrine inhibited the proliferation and induced apoptosis of Hep-G2 and SMMC-7721 cells in a dose-dependent manner in vitro Furthermore, the RNA and protein expression of Bax and caspase 3 levels were significantly upregulated, whereas the expression of Bcl-2 was downregulated.	oxymatrine	197-207	BCL2 apoptosis regulator	Homo sapiens	454-459
26009496-6	2016	Immunohistochemistry analysis demonstrated an increase of Bax and caspase 3 and a decrease of Bcl-2 in tumor tissues following oxymatrine treatment which are consistent with the in vitro results.	oxymatrine	127-137	BCL2 associated X, apoptosis regulator	Homo sapiens	58-61
26009496-6	2016	Immunohistochemistry analysis demonstrated an increase of Bax and caspase 3 and a decrease of Bcl-2 in tumor tissues following oxymatrine treatment which are consistent with the in vitro results.	oxymatrine	127-137	caspase 3	Homo sapiens	66-75
26009496-6	2016	Immunohistochemistry analysis demonstrated an increase of Bax and caspase 3 and a decrease of Bcl-2 in tumor tissues following oxymatrine treatment which are consistent with the in vitro results.	oxymatrine	127-137	BCL2 apoptosis regulator	Homo sapiens	94-99
27183711-0	2016	Oxymatrine mediates Bax and Bcl-2 expression in human breast cancer MCF-7 cells.	oxymatrine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	20-23
27010330-0	2016	Oxymatrine Inhibits Renal Tubular EMT Induced by High Glucose via Upregulation of SnoN and Inhibition of TGF-beta1/Smad Signaling Pathway.	oxymatrine	0-10	transforming growth factor, beta 1	Rattus norvegicus	105-114
26687645-5	2016	Co-treatment with OMT and 5-Fu caused G0/G1 phase arrest by upregulating P21 and P27 and downregulating cyclin D, and induced apoptosis through increasing the production of reactive oxygen species (ROS) and decreasing the levels of p-ERK.	oxymatrine	18-21	H3 histone pseudogene 16	Homo sapiens	73-76
26687645-5	2016	Co-treatment with OMT and 5-Fu caused G0/G1 phase arrest by upregulating P21 and P27 and downregulating cyclin D, and induced apoptosis through increasing the production of reactive oxygen species (ROS) and decreasing the levels of p-ERK.	oxymatrine	18-21	interferon alpha inducible protein 27	Homo sapiens	81-84
26687645-5	2016	Co-treatment with OMT and 5-Fu caused G0/G1 phase arrest by upregulating P21 and P27 and downregulating cyclin D, and induced apoptosis through increasing the production of reactive oxygen species (ROS) and decreasing the levels of p-ERK.	oxymatrine	18-21	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	232-237
26687645-9	2016	Taken together, our findings indicated that OMT sensitizes HCC to 5-Fu treatment by the suppression of ERK activation through the overproduction of ROS, and combination treatment with OMT and 5-Fu would be a promising therapeutic strategy for HCC treatment.	oxymatrine	44-47	mitogen-activated protein kinase 1	Homo sapiens	103-106
28879743-13	2016	In conclusion, oxymatrine, sophocarpidine, sophocarpine and sophoridine combined with thymopolypeptides could inhibit HBsAg and HBeAg secretion in HepG2.2.15 cells and HBV DNA replication, and further promote the antiviral effect by promoting the expression of IFN-alpha.	oxymatrine	15-25	interferon alpha 1	Homo sapiens	261-270
27183711-0	2016	Oxymatrine mediates Bax and Bcl-2 expression in human breast cancer MCF-7 cells.	oxymatrine	0-10	BCL2 apoptosis regulator	Homo sapiens	28-33
27183711-4	2016	Real-time PCR was performed for the mRNA abundance of Bax and Bcl-2 after the cells were treated with oxymatrine at concentration of 0, 25, 50, and 100 microg/mL at the time points of 24, 48, and 72 h. Western blotting was performed when the cells were treated with oxymatrine at various concentrations for 72h.	oxymatrine	102-112	BCL2 associated X, apoptosis regulator	Homo sapiens	54-57
27183711-4	2016	Real-time PCR was performed for the mRNA abundance of Bax and Bcl-2 after the cells were treated with oxymatrine at concentration of 0, 25, 50, and 100 microg/mL at the time points of 24, 48, and 72 h. Western blotting was performed when the cells were treated with oxymatrine at various concentrations for 72h.	oxymatrine	102-112	BCL2 apoptosis regulator	Homo sapiens	62-67
27183711-4	2016	Real-time PCR was performed for the mRNA abundance of Bax and Bcl-2 after the cells were treated with oxymatrine at concentration of 0, 25, 50, and 100 microg/mL at the time points of 24, 48, and 72 h. Western blotting was performed when the cells were treated with oxymatrine at various concentrations for 72h.	oxymatrine	266-276	BCL2 associated X, apoptosis regulator	Homo sapiens	54-57
27183711-6	2016	Oxymatrine at 100 microg/mL up regulated Bax mRNA abundance by 169 % at 72 h (t = 18.32, p = 0.001), and reduced Bcl-2 mRNA abundance by 24 % at 72 h (t = 6.30, p = 0.001) compared with control.	oxymatrine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	41-44
27183711-6	2016	Oxymatrine at 100 microg/mL up regulated Bax mRNA abundance by 169 % at 72 h (t = 18.32, p = 0.001), and reduced Bcl-2 mRNA abundance by 24 % at 72 h (t = 6.30, p = 0.001) compared with control.	oxymatrine	0-10	BCL2 apoptosis regulator	Homo sapiens	113-118
27183711-7	2016	Oxymatrine enhanced the expression of Bax protein while reduced the expression of Bcl-2 protein.	oxymatrine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	38-41
27183711-7	2016	Oxymatrine enhanced the expression of Bax protein while reduced the expression of Bcl-2 protein.	oxymatrine	0-10	BCL2 apoptosis regulator	Homo sapiens	82-87
27183711-8	2016	Oxymatrine treatment showed pro-apoptotic effects in breast cancer MCF-7 cells, and these effects correlated with the up regulation of Bax transcription and protein expression and the down regulation of Bcl-2 transcription and protein expression in a time- and dose-dependent manner.	oxymatrine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	135-138
27183711-8	2016	Oxymatrine treatment showed pro-apoptotic effects in breast cancer MCF-7 cells, and these effects correlated with the up regulation of Bax transcription and protein expression and the down regulation of Bcl-2 transcription and protein expression in a time- and dose-dependent manner.	oxymatrine	0-10	BCL2 apoptosis regulator	Homo sapiens	203-208
27183711-9	2016	CONCLUSION: Oxymatrine had effects in promoting apoptosis in human breast cancer MCF-7 cells by mediating the mRNA and protein expression levels of Bax and Bcl-2.	oxymatrine	12-22	BCL2 associated X, apoptosis regulator	Homo sapiens	148-151
27183711-9	2016	CONCLUSION: Oxymatrine had effects in promoting apoptosis in human breast cancer MCF-7 cells by mediating the mRNA and protein expression levels of Bax and Bcl-2.	oxymatrine	12-22	BCL2 apoptosis regulator	Homo sapiens	156-161
26869434-3	2016	Furthermore, chemical inhibition experiments in rat liver microsomes were used to determine the principal cytochrome P450 (CYP) isoforms involved in OMT metabolism.	oxymatrine	149-152	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	106-121
26099492-0	2015	Oxymatrine suppresses proliferation and facilitates apoptosis of human ovarian cancer cells through upregulating microRNA-29b and downregulating matrix metalloproteinase-2 expression.	oxymatrine	0-10	matrix metallopeptidase 2	Homo sapiens	145-171
26459368-0	2015	Inhibition of pro-collagen I expression by oxymatrine in hepatic stellate cells is mediated via nuclear translocation of Y-box binding protein 1.	oxymatrine	43-53	Y-box binding protein 1	Homo sapiens	121-144
26459368-4	2015	The endogenic expression of pro-collagen I was decreased by OMT in a dose- and time-dependent manner, accompanied with the downregulation of Y-box binding protein 1 (YB-1), a vital transcription factor, particularly on the fourth day of incubation with a high concentration of OMT.	oxymatrine	277-280	Y-box binding protein 1	Homo sapiens	166-170
26459368-5	2015	To further explore the intracellular changes in YB-1 levels, nuclear/cytoplasmic proteins were extracted separately, and subsequent western blot analysis revealed a significant upregulation of YB-1 in the nucleus in parallel with its downregulation in the cytoplasm, indicating the nuclear translocation of YB-1 induced by OMT treatment.	oxymatrine	323-326	Y-box binding protein 1	Homo sapiens	193-197
26459368-5	2015	To further explore the intracellular changes in YB-1 levels, nuclear/cytoplasmic proteins were extracted separately, and subsequent western blot analysis revealed a significant upregulation of YB-1 in the nucleus in parallel with its downregulation in the cytoplasm, indicating the nuclear translocation of YB-1 induced by OMT treatment.	oxymatrine	323-326	Y-box binding protein 1	Homo sapiens	193-197
26459368-6	2015	In another experiment, knockdown of YB-1 using small interfering RNA led to elevated mRNA levels of collagen I, thereby reversing the effects of OMT treatment.	oxymatrine	145-148	Y-box binding protein 1	Homo sapiens	36-40
26869434-3	2016	Furthermore, chemical inhibition experiments in rat liver microsomes were used to determine the principal cytochrome P450 (CYP) isoforms involved in OMT metabolism.	oxymatrine	149-152	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	123-126
26869434-8	2016	The inhibitor of CYP3A2 had strong inhibitory effect on OMT metabolism in a concentration-dependent manner, and value was reduced to 29.73% of control.	oxymatrine	56-59	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	17-23
26869434-9	2016	The 2 perfusion techniques indicated that poor bioavailability of OMT in rats is due mostly to poor absorption and higher hepatic elimination and CYP3A2 appears to contribute to OMT metabolism in rat liver.	oxymatrine	178-181	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	146-152
26586934-0	2015	Reductive metabolism of oxymatrine is catalyzed by microsomal CYP3A4.	oxymatrine	24-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
26586934-4	2015	The current studies demonstrated that OMT could be metabolized to MT rapidly in HLMs and HIMs and CYP3A4 greatly contributed to this transformation.	oxymatrine	38-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
26099492-8	2015	Furthermore, oxymatrine decreased the protein levels of MMP-2 and increased the expression levels of miR-29b in OVCAR-3 cells.	oxymatrine	13-23	microRNA 29b-1	Homo sapiens	101-108
26099492-10	2015	In addition, anti-miR-29b antibodies were used to verify that the apoptotic effect of oxymatrine was due to upregulating miR-29b and downregulating MMP-2 expression.	oxymatrine	86-96	microRNA 29b-1	Homo sapiens	18-25
26099492-10	2015	In addition, anti-miR-29b antibodies were used to verify that the apoptotic effect of oxymatrine was due to upregulating miR-29b and downregulating MMP-2 expression.	oxymatrine	86-96	microRNA 29b-1	Homo sapiens	121-128
26099492-10	2015	In addition, anti-miR-29b antibodies were used to verify that the apoptotic effect of oxymatrine was due to upregulating miR-29b and downregulating MMP-2 expression.	oxymatrine	86-96	matrix metallopeptidase 2	Homo sapiens	148-153
26099492-11	2015	These results showed that oxymatrine suppresses the proliferation and facilitates apoptosis of human ovarian cancer cells through upregulating miR-29b and downregulating MMP-2 expression.	oxymatrine	26-36	microRNA 29b-1	Homo sapiens	143-150
26099492-11	2015	These results showed that oxymatrine suppresses the proliferation and facilitates apoptosis of human ovarian cancer cells through upregulating miR-29b and downregulating MMP-2 expression.	oxymatrine	26-36	matrix metallopeptidase 2	Homo sapiens	170-175
26099492-2	2015	Previous studies have revealed that oxymatrine can inhibit proliferation and metastasis of tumor cells through reducing matrix metalloproteinase-2 (MMP-2) mRNA expression.	oxymatrine	36-46	matrix metallopeptidase 2	Homo sapiens	120-146
26099492-2	2015	Previous studies have revealed that oxymatrine can inhibit proliferation and metastasis of tumor cells through reducing matrix metalloproteinase-2 (MMP-2) mRNA expression.	oxymatrine	36-46	matrix metallopeptidase 2	Homo sapiens	148-153
26099492-8	2015	Furthermore, oxymatrine decreased the protein levels of MMP-2 and increased the expression levels of miR-29b in OVCAR-3 cells.	oxymatrine	13-23	matrix metallopeptidase 2	Homo sapiens	56-61
25816398-0	2015	Oxymatrine suppresses proliferation and induces apoptosis of hemangioma cells through inhibition of HIF-1a signaling.	oxymatrine	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	100-106
26108031-0	2015	Oxymatrine ameliorates renal ischemia-reperfusion injury from oxidative stress through Nrf2/HO-1 pathway.	oxymatrine	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	87-91
26108031-0	2015	Oxymatrine ameliorates renal ischemia-reperfusion injury from oxidative stress through Nrf2/HO-1 pathway.	oxymatrine	0-10	heme oxygenase 1	Rattus norvegicus	92-96
26108031-1	2015	PURPOSE: To investigate if oxymatrine pretreatment could ameliorate renal I/R injury induced in rats and explore the possible role of oxymatrine in Nrf2/HO-1 pathway.	oxymatrine	134-144	NFE2 like bZIP transcription factor 2	Rattus norvegicus	148-152
26108031-6	2015	RESULTS: Oxymatrine pretreatment exhibited an improved renal functional recovery, alleviated histological injury and oxidative stress, inhibiting tubular apoptosis, and accompanied by upregulated the expression of Nrf2/HO-1 proteins.	oxymatrine	9-19	NFE2 like bZIP transcription factor 2	Rattus norvegicus	214-218
26108031-6	2015	RESULTS: Oxymatrine pretreatment exhibited an improved renal functional recovery, alleviated histological injury and oxidative stress, inhibiting tubular apoptosis, and accompanied by upregulated the expression of Nrf2/HO-1 proteins.	oxymatrine	9-19	heme oxygenase 1	Rattus norvegicus	219-223
26108031-7	2015	CONCLUSION: Oxymatrine may attenuate renal ischemia/reperfusion injury, and this renoprotective effect may be through activating the Nrf2/HO-1 pathway.	oxymatrine	12-22	NFE2 like bZIP transcription factor 2	Rattus norvegicus	133-137
26108031-7	2015	CONCLUSION: Oxymatrine may attenuate renal ischemia/reperfusion injury, and this renoprotective effect may be through activating the Nrf2/HO-1 pathway.	oxymatrine	12-22	heme oxygenase 1	Rattus norvegicus	138-142
26120022-10	2015	Western-blot analysis showed a marked decrease in Caspase-3 expression and increase in the ratio of Bcl-2/Bax after OMT (120 mg/kg) post-treatment as compared with hypoxic-ischemic group.	oxymatrine	116-119	BCL2, apoptosis regulator	Rattus norvegicus	100-105
26120022-10	2015	Western-blot analysis showed a marked decrease in Caspase-3 expression and increase in the ratio of Bcl-2/Bax after OMT (120 mg/kg) post-treatment as compared with hypoxic-ischemic group.	oxymatrine	116-119	BCL2 associated X, apoptosis regulator	Rattus norvegicus	106-109
25816398-7	2015	Taken together, our findings suggest that, the expression of HIF-1a and VEGF is increased in proliferating phase HA, and OMT suppresses cell proliferation and induces cell apoptosis and cycle arrest in proliferative phase HA through inhibition of the HIF-1a signaling pathway, suggesting OMT may provide a novel therapeutic strategy for the treatment of HA.	oxymatrine	121-124	hypoxia inducible factor 1 subunit alpha	Homo sapiens	251-257
25527205-0	2015	Oxymatrine targets EGFR(p-Tyr845) and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells.	oxymatrine	0-10	epidermal growth factor receptor	Homo sapiens	19-23
25986286-0	2015	Anti-asthmatic effects of oxymatrine in a mouse model of allergic asthma through regulating CD40 signaling.	oxymatrine	26-36	CD40 antigen	Mus musculus	92-96
25668061-0	2015	Oxymatrine inhibits lipopolysaccharide-induced inflammation by down-regulating Toll-like receptor 4/nuclear factor-kappa B in macrophages.	oxymatrine	0-10	toll-like receptor 4	Mus musculus	79-99
26159027-13	2015	3</protein-id> in brain tissues were decreased, and those of Cav2.2 were increased significantly in the OMT group (P &lt; 0.05).	oxymatrine	104-107	calcium channel, voltage-dependent, N type, alpha 1B subunit	Mus musculus	61-67
25527205-6	2015	In addition to inducing gastric cells apoptosis, oxymatrine significantly inhibited the migration and invasion of human gastric cancer cells by decreasing phospho-Cofilin (Ser3) and phospho-LIMK1 (Thr508) without changing the total Cofilin and LIMK1 expression.	oxymatrine	49-59	cofilin 1	Homo sapiens	163-170
25527205-0	2015	Oxymatrine targets EGFR(p-Tyr845) and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells.	oxymatrine	0-10	epidermal growth factor receptor	Homo sapiens	47-51
25527205-6	2015	In addition to inducing gastric cells apoptosis, oxymatrine significantly inhibited the migration and invasion of human gastric cancer cells by decreasing phospho-Cofilin (Ser3) and phospho-LIMK1 (Thr508) without changing the total Cofilin and LIMK1 expression.	oxymatrine	49-59	LIM domain kinase 1	Homo sapiens	190-195
25527205-5	2015	RESULTS: These results showed that oxymatrine inhibited the proliferation and invasion of gastric cells through inhibition of EGFR/Cyclin D1/CDK4/6, EGFR/Akt and MEK-1/ERK1/2/MMP2 pathway by inhibiting EGFR(p-Tyr845).	oxymatrine	35-45	epidermal growth factor receptor	Homo sapiens	126-130
25527205-6	2015	In addition to inducing gastric cells apoptosis, oxymatrine significantly inhibited the migration and invasion of human gastric cancer cells by decreasing phospho-Cofilin (Ser3) and phospho-LIMK1 (Thr508) without changing the total Cofilin and LIMK1 expression.	oxymatrine	49-59	cofilin 1	Homo sapiens	232-239
25527205-6	2015	In addition to inducing gastric cells apoptosis, oxymatrine significantly inhibited the migration and invasion of human gastric cancer cells by decreasing phospho-Cofilin (Ser3) and phospho-LIMK1 (Thr508) without changing the total Cofilin and LIMK1 expression.	oxymatrine	49-59	LIM domain kinase 1	Homo sapiens	244-249
25527205-5	2015	RESULTS: These results showed that oxymatrine inhibited the proliferation and invasion of gastric cells through inhibition of EGFR/Cyclin D1/CDK4/6, EGFR/Akt and MEK-1/ERK1/2/MMP2 pathway by inhibiting EGFR(p-Tyr845).	oxymatrine	35-45	cyclin D1	Homo sapiens	131-140
25527205-7	2015	CONCLUSION: Oxymatrine effectively suppressed the phosphorylation of EGFR (Tyr845), and EGFR was the target of oxymatrine.	oxymatrine	12-22	epidermal growth factor receptor	Homo sapiens	69-73
25527205-7	2015	CONCLUSION: Oxymatrine effectively suppressed the phosphorylation of EGFR (Tyr845), and EGFR was the target of oxymatrine.	oxymatrine	111-121	epidermal growth factor receptor	Homo sapiens	88-92
25527205-5	2015	RESULTS: These results showed that oxymatrine inhibited the proliferation and invasion of gastric cells through inhibition of EGFR/Cyclin D1/CDK4/6, EGFR/Akt and MEK-1/ERK1/2/MMP2 pathway by inhibiting EGFR(p-Tyr845).	oxymatrine	35-45	cyclin dependent kinase 4	Homo sapiens	141-147
25527205-5	2015	RESULTS: These results showed that oxymatrine inhibited the proliferation and invasion of gastric cells through inhibition of EGFR/Cyclin D1/CDK4/6, EGFR/Akt and MEK-1/ERK1/2/MMP2 pathway by inhibiting EGFR(p-Tyr845).	oxymatrine	35-45	epidermal growth factor receptor	Homo sapiens	149-153
25527205-5	2015	RESULTS: These results showed that oxymatrine inhibited the proliferation and invasion of gastric cells through inhibition of EGFR/Cyclin D1/CDK4/6, EGFR/Akt and MEK-1/ERK1/2/MMP2 pathway by inhibiting EGFR(p-Tyr845).	oxymatrine	35-45	AKT serine/threonine kinase 1	Homo sapiens	154-157
25527205-5	2015	RESULTS: These results showed that oxymatrine inhibited the proliferation and invasion of gastric cells through inhibition of EGFR/Cyclin D1/CDK4/6, EGFR/Akt and MEK-1/ERK1/2/MMP2 pathway by inhibiting EGFR(p-Tyr845).	oxymatrine	35-45	mitogen-activated protein kinase kinase 1	Homo sapiens	162-167
25527205-5	2015	RESULTS: These results showed that oxymatrine inhibited the proliferation and invasion of gastric cells through inhibition of EGFR/Cyclin D1/CDK4/6, EGFR/Akt and MEK-1/ERK1/2/MMP2 pathway by inhibiting EGFR(p-Tyr845).	oxymatrine	35-45	mitogen-activated protein kinase 3	Homo sapiens	168-174
25527205-5	2015	RESULTS: These results showed that oxymatrine inhibited the proliferation and invasion of gastric cells through inhibition of EGFR/Cyclin D1/CDK4/6, EGFR/Akt and MEK-1/ERK1/2/MMP2 pathway by inhibiting EGFR(p-Tyr845).	oxymatrine	35-45	matrix metallopeptidase 2	Homo sapiens	175-179
25527205-5	2015	RESULTS: These results showed that oxymatrine inhibited the proliferation and invasion of gastric cells through inhibition of EGFR/Cyclin D1/CDK4/6, EGFR/Akt and MEK-1/ERK1/2/MMP2 pathway by inhibiting EGFR(p-Tyr845).	oxymatrine	35-45	epidermal growth factor receptor	Homo sapiens	149-153
25171482-14	2014	Moreover, oxymatrine reduced the protein expression level of NF-kappaB p65, TNF-alpha, and IL-6, which were elevated in the vehicle-treated group.	oxymatrine	10-20	interleukin 6	Rattus norvegicus	91-95
26405930-11	2015	Oxymatrine can induce apoptosis of the A549 cells by regulating the expression of Bcl-2 and Bax.	oxymatrine	0-10	BCL2 apoptosis regulator	Homo sapiens	82-87
26405930-11	2015	Oxymatrine can induce apoptosis of the A549 cells by regulating the expression of Bcl-2 and Bax.	oxymatrine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	92-95
25310909-4	2014	After continuous preventive administration of oxymatrine for 7 days, significant isoproterenol-induced heart failure characterized by hypertrophy and dysfunction of left ventricle, and elevation of brain natruretic peptide (BNP, a heart failure biomarker) and cardiac troponin I (cTn-I, a cardiac injury biomarker) was observed.	oxymatrine	46-56	natriuretic peptide B	Rattus norvegicus	224-227
25310909-4	2014	After continuous preventive administration of oxymatrine for 7 days, significant isoproterenol-induced heart failure characterized by hypertrophy and dysfunction of left ventricle, and elevation of brain natruretic peptide (BNP, a heart failure biomarker) and cardiac troponin I (cTn-I, a cardiac injury biomarker) was observed.	oxymatrine	46-56	troponin I3, cardiac type	Rattus norvegicus	260-278
25310909-4	2014	After continuous preventive administration of oxymatrine for 7 days, significant isoproterenol-induced heart failure characterized by hypertrophy and dysfunction of left ventricle, and elevation of brain natruretic peptide (BNP, a heart failure biomarker) and cardiac troponin I (cTn-I, a cardiac injury biomarker) was observed.	oxymatrine	46-56	troponin I3, cardiac type	Rattus norvegicus	280-285
25310909-5	2014	Preventive oxymatrine significantly ameliorated the cardiac hypertrophy, improved the left ventricular dysfunction and reduced the increased BNP and cTn-I in serum of isoproterenol-treated rats.	oxymatrine	11-21	natriuretic peptide B	Rattus norvegicus	141-144
25310909-5	2014	Preventive oxymatrine significantly ameliorated the cardiac hypertrophy, improved the left ventricular dysfunction and reduced the increased BNP and cTn-I in serum of isoproterenol-treated rats.	oxymatrine	11-21	troponin I3, cardiac type	Rattus norvegicus	149-154
25310909-7	2014	Besides, prevention with oxymatrine significantly up-regulated the dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression, which was followed by decreased serum ADMA, but it had no effect on protein arginine methyltransferase1 (PRMT1) expression that is up-regulated in isoproterenol-induced heart failure rats.	oxymatrine	25-35	dimethylarginine dimethylaminohydrolase 2	Rattus norvegicus	67-108
25310909-7	2014	Besides, prevention with oxymatrine significantly up-regulated the dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression, which was followed by decreased serum ADMA, but it had no effect on protein arginine methyltransferase1 (PRMT1) expression that is up-regulated in isoproterenol-induced heart failure rats.	oxymatrine	25-35	dimethylarginine dimethylaminohydrolase 2	Rattus norvegicus	110-115
25310909-7	2014	Besides, prevention with oxymatrine significantly up-regulated the dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression, which was followed by decreased serum ADMA, but it had no effect on protein arginine methyltransferase1 (PRMT1) expression that is up-regulated in isoproterenol-induced heart failure rats.	oxymatrine	25-35	protein arginine methyltransferase 1	Rattus norvegicus	234-239
25034832-0	2014	Oxymatrine lightened the inflammatory response of LPS-induced mastitis in mice through affecting NF-kappaB and MAPKs signaling pathways.	oxymatrine	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	97-106
25034832-6	2014	Oxymatrine inhibited the phosphorylation of NF-kappaB p65 and IkappaB in NF-kappaB signal pathway and reduced the phosphorylation of p38, ERK, and JNK in mitogen-activated protein kinase (MAPKs) signal pathway.	oxymatrine	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	44-53
25034832-6	2014	Oxymatrine inhibited the phosphorylation of NF-kappaB p65 and IkappaB in NF-kappaB signal pathway and reduced the phosphorylation of p38, ERK, and JNK in mitogen-activated protein kinase (MAPKs) signal pathway.	oxymatrine	0-10	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	54-57
25034832-6	2014	Oxymatrine inhibited the phosphorylation of NF-kappaB p65 and IkappaB in NF-kappaB signal pathway and reduced the phosphorylation of p38, ERK, and JNK in mitogen-activated protein kinase (MAPKs) signal pathway.	oxymatrine	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	73-82
25034832-6	2014	Oxymatrine inhibited the phosphorylation of NF-kappaB p65 and IkappaB in NF-kappaB signal pathway and reduced the phosphorylation of p38, ERK, and JNK in mitogen-activated protein kinase (MAPKs) signal pathway.	oxymatrine	0-10	mitogen-activated protein kinase 14	Mus musculus	133-136
25034832-6	2014	Oxymatrine inhibited the phosphorylation of NF-kappaB p65 and IkappaB in NF-kappaB signal pathway and reduced the phosphorylation of p38, ERK, and JNK in mitogen-activated protein kinase (MAPKs) signal pathway.	oxymatrine	0-10	mitogen-activated protein kinase 1	Mus musculus	138-141
25034832-6	2014	Oxymatrine inhibited the phosphorylation of NF-kappaB p65 and IkappaB in NF-kappaB signal pathway and reduced the phosphorylation of p38, ERK, and JNK in mitogen-activated protein kinase (MAPKs) signal pathway.	oxymatrine	0-10	mitogen-activated protein kinase 8	Mus musculus	147-150
25034832-7	2014	The results showed that oxymatrine had a protective effect on LPS-induced mastitis, and the anti-inflammatory mechanism of oxymatrine was related to the inhibition of NF-kappaB and MAPKs signal pathways.	oxymatrine	123-133	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	167-176
24997623-5	2014	Oxymatrine also induced the cell apoptosis in a dose- and time-dependent manner as showed by the annexin V-FITC/PI double staining and TUNEL assay.	oxymatrine	0-10	annexin A5	Homo sapiens	97-106
24997623-6	2014	Furthermore, a disruption of mitochondrial membrane potential and an up-regulation of cleaved caspases-3, and-9 and downregulation of Bax/Bcl-2 was evidenced in the oxymatrine-treated cells.	oxymatrine	165-175	caspase 3	Homo sapiens	94-111
24997623-6	2014	Furthermore, a disruption of mitochondrial membrane potential and an up-regulation of cleaved caspases-3, and-9 and downregulation of Bax/Bcl-2 was evidenced in the oxymatrine-treated cells.	oxymatrine	165-175	BCL2 associated X, apoptosis regulator	Homo sapiens	134-137
24997623-6	2014	Furthermore, a disruption of mitochondrial membrane potential and an up-regulation of cleaved caspases-3, and-9 and downregulation of Bax/Bcl-2 was evidenced in the oxymatrine-treated cells.	oxymatrine	165-175	BCL2 apoptosis regulator	Homo sapiens	138-143
24696074-10	2014	Oxymatrine can protect against LIRI in rabbits by upregulating levels of IL-10 and downregulating levels of TNF-alpha and IL-8, inhibiting the alveolar cells apoptosis and inflammatory response, and attenuating the acute LIRI.	oxymatrine	0-10	interleukin-10	Oryctolagus cuniculus	73-78
24696074-10	2014	Oxymatrine can protect against LIRI in rabbits by upregulating levels of IL-10 and downregulating levels of TNF-alpha and IL-8, inhibiting the alveolar cells apoptosis and inflammatory response, and attenuating the acute LIRI.	oxymatrine	0-10	tumor necrosis factor	Oryctolagus cuniculus	108-117
24696074-10	2014	Oxymatrine can protect against LIRI in rabbits by upregulating levels of IL-10 and downregulating levels of TNF-alpha and IL-8, inhibiting the alveolar cells apoptosis and inflammatory response, and attenuating the acute LIRI.	oxymatrine	0-10	interleukin-8	Oryctolagus cuniculus	122-126
25171482-0	2014	Oxymatrine improves intestinal epithelial barrier function involving NF-kappaB-mediated signaling pathway in CCl4-induced cirrhotic rats.	oxymatrine	0-10	C-C motif chemokine ligand 4	Rattus norvegicus	109-113
25171482-3	2014	This study aimed to investigate the effect of oxymatrine on intestinal epithelial barrier function and the underlying mechanism in carbon tetrachloride (CCl4)-induced cirrhotic rats.	oxymatrine	46-56	C-C motif chemokine ligand 4	Rattus norvegicus	153-157
25171482-13	2014	Oxymatrine reversed the CCl4-induced histological changes and restored intestinal barrier integrity.	oxymatrine	0-10	C-C motif chemokine ligand 4	Rattus norvegicus	24-28
25171482-14	2014	Moreover, oxymatrine reduced the protein expression level of NF-kappaB p65, TNF-alpha, and IL-6, which were elevated in the vehicle-treated group.	oxymatrine	10-20	synaptotagmin 1	Rattus norvegicus	71-74
25171482-14	2014	Moreover, oxymatrine reduced the protein expression level of NF-kappaB p65, TNF-alpha, and IL-6, which were elevated in the vehicle-treated group.	oxymatrine	10-20	tumor necrosis factor	Rattus norvegicus	76-85
25480575-12	2014	Moreover, oxymatrine can attenuate the development of UC by regulating the DOR-beta-arrestin1-Bcl-2 signal transduction pathway.	oxymatrine	10-20	arrestin, beta 1	Rattus norvegicus	79-93
25480575-12	2014	Moreover, oxymatrine can attenuate the development of UC by regulating the DOR-beta-arrestin1-Bcl-2 signal transduction pathway.	oxymatrine	10-20	BCL2, apoptosis regulator	Rattus norvegicus	94-99
25171482-15	2014	In addition, the serum endotoxin level was significantly decreased after oxymatrine treatment in CCl4-induced cirrhotic rats.	oxymatrine	73-83	C-C motif chemokine ligand 4	Rattus norvegicus	97-101
24515270-1	2014	The aim was to develop a liposomal oxymatrine conjugating D-alpha tocopheryl polyethylene glycol 1000 succinate (OMT-LIP) for enhanced therapeutics of hepatic fibrosis.	oxymatrine	35-45	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	117-120
24563336-0	2014	Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells.	oxymatrine	0-10	BCL2 apoptosis regulator	Homo sapiens	44-49
24563336-0	2014	Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells.	oxymatrine	0-10	caspase 3	Homo sapiens	81-90
24563336-0	2014	Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells.	oxymatrine	0-10	caspase 9	Homo sapiens	91-100
24563336-4	2014	The increase in apoptosis upon treatment with oxymatrine was correlated with downregulation of anti-apoptotic Bcl-2 expression and upregulation of pro-apoptotic Bax expression.	oxymatrine	46-56	BCL2 apoptosis regulator	Homo sapiens	110-115
24563336-4	2014	The increase in apoptosis upon treatment with oxymatrine was correlated with downregulation of anti-apoptotic Bcl-2 expression and upregulation of pro-apoptotic Bax expression.	oxymatrine	46-56	BCL2 associated X, apoptosis regulator	Homo sapiens	161-164
24563336-5	2014	Furthermore, oxymatrine induced the activation of caspase-3 and caspase-9 and the cleavage of poly(ADP-ribose) polymerase (PARP) in HL-60 cells.	oxymatrine	13-23	caspase 3	Homo sapiens	50-59
24563336-5	2014	Furthermore, oxymatrine induced the activation of caspase-3 and caspase-9 and the cleavage of poly(ADP-ribose) polymerase (PARP) in HL-60 cells.	oxymatrine	13-23	caspase 9	Homo sapiens	64-73
24563336-5	2014	Furthermore, oxymatrine induced the activation of caspase-3 and caspase-9 and the cleavage of poly(ADP-ribose) polymerase (PARP) in HL-60 cells.	oxymatrine	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	94-121
24563336-5	2014	Furthermore, oxymatrine induced the activation of caspase-3 and caspase-9 and the cleavage of poly(ADP-ribose) polymerase (PARP) in HL-60 cells.	oxymatrine	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	123-127
24563336-6	2014	In addition, pretreatment with a specific caspase-3 (Z-DEVD-FMK) or caspase-9 (Z-LEHD-FMK) inhibitor significantly neutralized the pro-apoptotic activity of oxymatrine in HL-60 cells, demonstrating the important role of caspase-3 and caspase-9 in this process.	oxymatrine	157-167	caspase 3	Homo sapiens	42-51
24563336-6	2014	In addition, pretreatment with a specific caspase-3 (Z-DEVD-FMK) or caspase-9 (Z-LEHD-FMK) inhibitor significantly neutralized the pro-apoptotic activity of oxymatrine in HL-60 cells, demonstrating the important role of caspase-3 and caspase-9 in this process.	oxymatrine	157-167	caspase 9	Homo sapiens	68-77
24563336-6	2014	In addition, pretreatment with a specific caspase-3 (Z-DEVD-FMK) or caspase-9 (Z-LEHD-FMK) inhibitor significantly neutralized the pro-apoptotic activity of oxymatrine in HL-60 cells, demonstrating the important role of caspase-3 and caspase-9 in this process.	oxymatrine	157-167	caspase 3	Homo sapiens	220-229
24563336-6	2014	In addition, pretreatment with a specific caspase-3 (Z-DEVD-FMK) or caspase-9 (Z-LEHD-FMK) inhibitor significantly neutralized the pro-apoptotic activity of oxymatrine in HL-60 cells, demonstrating the important role of caspase-3 and caspase-9 in this process.	oxymatrine	157-167	caspase 9	Homo sapiens	234-243
24563336-7	2014	Taken together, these results indicated that oxymatrine-induced apoptosis may occur through the activation of the caspase-9/caspase-3-mediated intrinsic pathway.	oxymatrine	45-55	caspase 9	Homo sapiens	114-123
24563336-7	2014	Taken together, these results indicated that oxymatrine-induced apoptosis may occur through the activation of the caspase-9/caspase-3-mediated intrinsic pathway.	oxymatrine	45-55	caspase 3	Homo sapiens	124-133
24940428-6	2014	Following treatment with the combination of SF and OMT, the survival rate increased and the survival time was prolonged; CLP-induced increases in the lung W/D ratio and the levels of ALT, AST, LDH, CRP, IL-6, IFN-gamma and MDA were significantly reduced; and the SOD activity levels were increased, compared with those of the untreated animals with CLP-induced sepsis.	oxymatrine	51-54	interleukin 6	Mus musculus	203-207
24940428-6	2014	Following treatment with the combination of SF and OMT, the survival rate increased and the survival time was prolonged; CLP-induced increases in the lung W/D ratio and the levels of ALT, AST, LDH, CRP, IL-6, IFN-gamma and MDA were significantly reduced; and the SOD activity levels were increased, compared with those of the untreated animals with CLP-induced sepsis.	oxymatrine	51-54	interferon gamma	Mus musculus	209-218
25016875-0	2014	[Expressions of TERT during the development of rat liver cancer under the interventions of oxymatrine and selenium enriched yeast].	oxymatrine	91-101	telomerase reverse transcriptase	Rattus norvegicus	16-20
24440469-13	2014	Under hypoxic conditions, oxymatrine significantly upregulated Nrf2 and antioxidant protein SOD1 and HO-1 expression, but downregulated hydroperoxide levels in PASMCs.	oxymatrine	26-36	NFE2 like bZIP transcription factor 2	Rattus norvegicus	63-67
24440469-13	2014	Under hypoxic conditions, oxymatrine significantly upregulated Nrf2 and antioxidant protein SOD1 and HO-1 expression, but downregulated hydroperoxide levels in PASMCs.	oxymatrine	26-36	superoxide dismutase 1	Rattus norvegicus	92-96
24440469-13	2014	Under hypoxic conditions, oxymatrine significantly upregulated Nrf2 and antioxidant protein SOD1 and HO-1 expression, but downregulated hydroperoxide levels in PASMCs.	oxymatrine	26-36	heme oxygenase 1	Rattus norvegicus	101-105
25406654-0	2014	In vitro immunomodulatory activity of oxymatrine on Toll-like receptor 9 signal pathway in chronic hepatitis B.	oxymatrine	38-48	toll like receptor 9	Homo sapiens	52-72
24551180-11	2014	These findings indicated that OMT might be a potential cardioprotective-agent against excessive ALD-induced cardiotoxicity, at least in part, mediated through inhibition of calpain/AIF signaling.	oxymatrine	30-33	apoptosis inducing factor mitochondria associated 1	Homo sapiens	181-184
24946550-6	2014	RESULT: Oxymatrine (100,50 mg kg-1) significantly attenuated serum content of cTn I, improved left ventricle systolic and diastolic function and left ventricular remodeling, reduced the ISO-induced myocardial pathological changes compared with ISO group.	oxymatrine	8-18	troponin I3, cardiac type	Rattus norvegicus	78-83
24946550-10	2014	CONCLUSION: Oxymatrine could ameliorate the experimental ventricular remodeling in ISO-induced chronic heart failure in rats and the mechanism involved in reducing serum content of ADMA and increased DDAH2 expression.	oxymatrine	12-22	dimethylarginine dimethylaminohydrolase 2	Rattus norvegicus	200-205
24231526-6	2014	As the downregulated gene, inosine monophosphate dehydrogenase type II (IMPDH2) was responsible for oxymatrine-induced mitochondrial-related apoptosis.	oxymatrine	100-110	inosine monophosphate dehydrogenase 2	Homo sapiens	27-70
24231526-6	2014	As the downregulated gene, inosine monophosphate dehydrogenase type II (IMPDH2) was responsible for oxymatrine-induced mitochondrial-related apoptosis.	oxymatrine	100-110	inosine monophosphate dehydrogenase 2	Homo sapiens	72-78
24231526-8	2014	Functional analyses further showed that oxymatrine and tiazofurin, an inhibitor of IMPDH2, sensitized resistant HeLa/DDP cells to cisplatin.	oxymatrine	40-50	inosine monophosphate dehydrogenase 2	Homo sapiens	83-89
24231526-10	2014	Taken together, these findings suggest that targeting of IMPDH2 by potential pharmacological inhibitors, oxymatrine in combination with chemotherapy, might be a promising means of overcoming chemoresistance in cervical cancer with high IMPDH2 expression, and may thus provide new insights into the mechanism of oxyamtrine-induced anticancer effects.	oxymatrine	105-115	inosine monophosphate dehydrogenase 2	Homo sapiens	57-63
24231526-10	2014	Taken together, these findings suggest that targeting of IMPDH2 by potential pharmacological inhibitors, oxymatrine in combination with chemotherapy, might be a promising means of overcoming chemoresistance in cervical cancer with high IMPDH2 expression, and may thus provide new insights into the mechanism of oxyamtrine-induced anticancer effects.	oxymatrine	105-115	inosine monophosphate dehydrogenase 2	Homo sapiens	236-242
24078465-0	2014	Oxymatrine induces mitochondria dependent apoptosis in human osteosarcoma MNNG/HOS cells through inhibition of PI3K/Akt pathway.	oxymatrine	0-10	AKT serine/threonine kinase 1	Homo sapiens	116-119
24078465-8	2014	Furthermore, we found that oxymatrine considerably inhibited the expression of Bcl-2 whilst increasing that of Bax.	oxymatrine	27-37	BCL2 apoptosis regulator	Homo sapiens	79-84
24078465-8	2014	Furthermore, we found that oxymatrine considerably inhibited the expression of Bcl-2 whilst increasing that of Bax.	oxymatrine	27-37	BCL2 associated X, apoptosis regulator	Homo sapiens	111-114
24078465-10	2014	Moreover, addition of oxymatrine to MNNG/HOS cells also attenuated phosphatidylinositol 3-kinase (PI3K) /Akt signaling pathway cascade, evidenced by the dephosphorylation of P13K and Akt.	oxymatrine	22-32	AKT serine/threonine kinase 1	Homo sapiens	105-108
24078465-10	2014	Moreover, addition of oxymatrine to MNNG/HOS cells also attenuated phosphatidylinositol 3-kinase (PI3K) /Akt signaling pathway cascade, evidenced by the dephosphorylation of P13K and Akt.	oxymatrine	22-32	AKT serine/threonine kinase 1	Homo sapiens	183-186
25406654-6	2014	For the TLR9 signal pathway, Oxymatrine not only augmented the expressions of TLR9 signal transduction molecules, but also activated the TLR9 signal function.	oxymatrine	29-39	toll like receptor 9	Homo sapiens	8-12
25406654-6	2014	For the TLR9 signal pathway, Oxymatrine not only augmented the expressions of TLR9 signal transduction molecules, but also activated the TLR9 signal function.	oxymatrine	29-39	toll like receptor 9	Homo sapiens	78-82
25406654-6	2014	For the TLR9 signal pathway, Oxymatrine not only augmented the expressions of TLR9 signal transduction molecules, but also activated the TLR9 signal function.	oxymatrine	29-39	toll like receptor 9	Homo sapiens	78-82
25406654-7	2014	This study has clearly demonstrated that TLR9 ligand could stimulate peripheral lymphocytes that have been pretreated with Oxymatrine.	oxymatrine	123-133	toll like receptor 9	Homo sapiens	41-45
25406654-9	2014	The interaction between the Oxymatrine and the TLR9 ligand appears to be synergistic.	oxymatrine	28-38	toll like receptor 9	Homo sapiens	47-51
25406654-10	2014	This study suggests Oxymatrine could be a strong immunomodulator, influence TLR9 signaling transduction, and synergistically improve the immune efficacy of the TLR9 ligand against CHB.	oxymatrine	20-30	toll like receptor 9	Homo sapiens	76-80
25406654-10	2014	This study suggests Oxymatrine could be a strong immunomodulator, influence TLR9 signaling transduction, and synergistically improve the immune efficacy of the TLR9 ligand against CHB.	oxymatrine	20-30	toll like receptor 9	Homo sapiens	160-164
24291757-4	2014	Therefore, we assessed the inhibitory effects of matrine and oxymatrine on the function of hOCT1 (SLC22A1), hOCT2 (SLC22A2) and hOCT3 (SLC22A3) using stably transfected transporter-expressing cells.	oxymatrine	61-71	solute carrier family 22 member 1	Homo sapiens	91-96
24291757-4	2014	Therefore, we assessed the inhibitory effects of matrine and oxymatrine on the function of hOCT1 (SLC22A1), hOCT2 (SLC22A2) and hOCT3 (SLC22A3) using stably transfected transporter-expressing cells.	oxymatrine	61-71	solute carrier family 22 member 1	Homo sapiens	98-105
24291757-4	2014	Therefore, we assessed the inhibitory effects of matrine and oxymatrine on the function of hOCT1 (SLC22A1), hOCT2 (SLC22A2) and hOCT3 (SLC22A3) using stably transfected transporter-expressing cells.	oxymatrine	61-71	solute carrier family 22 member 3	Homo sapiens	128-133
24291757-5	2014	At 100-fold excess, oxymatrine exhibited marked inhibition of hOCT1-mediated substrate uptake (p&lt;0.05), while matrine failed to produce significant inhibition on hOCT1.	oxymatrine	20-30	solute carrier family 22 member 1	Homo sapiens	62-67
24291757-6	2014	The IC50 value for oxymatrine on hOCT1 was estimated as 513+-132 muM.	oxymatrine	19-29	solute carrier family 22 member 1	Homo sapiens	33-38
24291757-7	2014	While there was no significant inhibition of hOCT2 or hOCT3 at 100-fold excess, oxymatrine and matrine showed 42% and 88% inhibition of hOCT3-mediated substrate uptake at 3 and 6mM, respectively.	oxymatrine	80-90	solute carrier family 22 member 3	Homo sapiens	136-141
24291757-8	2014	Considering the potential intestinal lumen and reported plasma concentrations of matrine and oxymatrine, these data suggest that drug-drug interactions may occur during hOCT1-mediated hepatic and renal uptake and during hOCT3-mediated intestinal absorption.	oxymatrine	93-103	solute carrier family 22 member 1	Homo sapiens	169-174
24291757-8	2014	Considering the potential intestinal lumen and reported plasma concentrations of matrine and oxymatrine, these data suggest that drug-drug interactions may occur during hOCT1-mediated hepatic and renal uptake and during hOCT3-mediated intestinal absorption.	oxymatrine	93-103	solute carrier family 22 member 3	Homo sapiens	220-225
23746756-0	2013	Antinociceptive effects of oxymatrine from Sophora flavescens, through regulation of NR2B-containing NMDA receptor-ERK/CREB signaling in a mice model of neuropathic pain.	oxymatrine	27-37	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	85-89
23791610-0	2013	Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparalpha).	oxymatrine	0-10	sterol regulatory element binding transcription factor 1	Rattus norvegicus	132-188
23791610-0	2013	Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparalpha).	oxymatrine	0-10	sterol regulatory element binding transcription factor 1	Rattus norvegicus	190-196
23791610-0	2013	Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparalpha).	oxymatrine	0-10	peroxisome proliferator activated receptor alpha	Rattus norvegicus	216-264
23791610-0	2013	Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparalpha).	oxymatrine	0-10	peroxisome proliferator activated receptor alpha	Rattus norvegicus	266-275
23791610-8	2013	Besides, oxymatrine treatment decreased the mRNA expression of sterol regulatory element binding transcription factor 1(Srebf1), fatty acid synthase (Fasn), and acetyl CoA carboxylase (Acc), and increased the mRNA expression of peroxisome proliferator activated receptor alpha (Pparalpha), carnitine palmitoyltransferase 1A (Cpt1a), and acyl CoA oxidase (Acox1) in high fructose diet induced NAFLD rats.	oxymatrine	9-19	sterol regulatory element binding transcription factor 1	Rattus norvegicus	63-119
23791610-8	2013	Besides, oxymatrine treatment decreased the mRNA expression of sterol regulatory element binding transcription factor 1(Srebf1), fatty acid synthase (Fasn), and acetyl CoA carboxylase (Acc), and increased the mRNA expression of peroxisome proliferator activated receptor alpha (Pparalpha), carnitine palmitoyltransferase 1A (Cpt1a), and acyl CoA oxidase (Acox1) in high fructose diet induced NAFLD rats.	oxymatrine	9-19	sterol regulatory element binding transcription factor 1	Rattus norvegicus	120-126
23791610-8	2013	Besides, oxymatrine treatment decreased the mRNA expression of sterol regulatory element binding transcription factor 1(Srebf1), fatty acid synthase (Fasn), and acetyl CoA carboxylase (Acc), and increased the mRNA expression of peroxisome proliferator activated receptor alpha (Pparalpha), carnitine palmitoyltransferase 1A (Cpt1a), and acyl CoA oxidase (Acox1) in high fructose diet induced NAFLD rats.	oxymatrine	9-19	fatty acid synthase	Rattus norvegicus	129-148
23791610-8	2013	Besides, oxymatrine treatment decreased the mRNA expression of sterol regulatory element binding transcription factor 1(Srebf1), fatty acid synthase (Fasn), and acetyl CoA carboxylase (Acc), and increased the mRNA expression of peroxisome proliferator activated receptor alpha (Pparalpha), carnitine palmitoyltransferase 1A (Cpt1a), and acyl CoA oxidase (Acox1) in high fructose diet induced NAFLD rats.	oxymatrine	9-19	fatty acid synthase	Rattus norvegicus	150-154
23791610-8	2013	Besides, oxymatrine treatment decreased the mRNA expression of sterol regulatory element binding transcription factor 1(Srebf1), fatty acid synthase (Fasn), and acetyl CoA carboxylase (Acc), and increased the mRNA expression of peroxisome proliferator activated receptor alpha (Pparalpha), carnitine palmitoyltransferase 1A (Cpt1a), and acyl CoA oxidase (Acox1) in high fructose diet induced NAFLD rats.	oxymatrine	9-19	peroxisome proliferator activated receptor alpha	Rattus norvegicus	228-276
23791610-8	2013	Besides, oxymatrine treatment decreased the mRNA expression of sterol regulatory element binding transcription factor 1(Srebf1), fatty acid synthase (Fasn), and acetyl CoA carboxylase (Acc), and increased the mRNA expression of peroxisome proliferator activated receptor alpha (Pparalpha), carnitine palmitoyltransferase 1A (Cpt1a), and acyl CoA oxidase (Acox1) in high fructose diet induced NAFLD rats.	oxymatrine	9-19	peroxisome proliferator activated receptor alpha	Rattus norvegicus	278-287
23791610-8	2013	Besides, oxymatrine treatment decreased the mRNA expression of sterol regulatory element binding transcription factor 1(Srebf1), fatty acid synthase (Fasn), and acetyl CoA carboxylase (Acc), and increased the mRNA expression of peroxisome proliferator activated receptor alpha (Pparalpha), carnitine palmitoyltransferase 1A (Cpt1a), and acyl CoA oxidase (Acox1) in high fructose diet induced NAFLD rats.	oxymatrine	9-19	carnitine palmitoyltransferase 1A	Rattus norvegicus	290-323
23791610-8	2013	Besides, oxymatrine treatment decreased the mRNA expression of sterol regulatory element binding transcription factor 1(Srebf1), fatty acid synthase (Fasn), and acetyl CoA carboxylase (Acc), and increased the mRNA expression of peroxisome proliferator activated receptor alpha (Pparalpha), carnitine palmitoyltransferase 1A (Cpt1a), and acyl CoA oxidase (Acox1) in high fructose diet induced NAFLD rats.	oxymatrine	9-19	carnitine palmitoyltransferase 1A	Rattus norvegicus	325-330
23791610-8	2013	Besides, oxymatrine treatment decreased the mRNA expression of sterol regulatory element binding transcription factor 1(Srebf1), fatty acid synthase (Fasn), and acetyl CoA carboxylase (Acc), and increased the mRNA expression of peroxisome proliferator activated receptor alpha (Pparalpha), carnitine palmitoyltransferase 1A (Cpt1a), and acyl CoA oxidase (Acox1) in high fructose diet induced NAFLD rats.	oxymatrine	9-19	acyl-CoA oxidase 1	Rattus norvegicus	355-360
23791610-9	2013	These results suggested that the therapeutic effect of oxymatrine on the hepatic steatosis in high fructose diet induced fatty liver rats is partly due to down-regulating Srebf1 and up-regulating Pparalpha mediated metabolic pathways simultaneously.	oxymatrine	55-65	sterol regulatory element binding transcription factor 1	Rattus norvegicus	171-177
23791610-9	2013	These results suggested that the therapeutic effect of oxymatrine on the hepatic steatosis in high fructose diet induced fatty liver rats is partly due to down-regulating Srebf1 and up-regulating Pparalpha mediated metabolic pathways simultaneously.	oxymatrine	55-65	peroxisome proliferator activated receptor alpha	Rattus norvegicus	196-205
23746756-0	2013	Antinociceptive effects of oxymatrine from Sophora flavescens, through regulation of NR2B-containing NMDA receptor-ERK/CREB signaling in a mice model of neuropathic pain.	oxymatrine	27-37	mitogen-activated protein kinase 1	Mus musculus	115-118
23746756-0	2013	Antinociceptive effects of oxymatrine from Sophora flavescens, through regulation of NR2B-containing NMDA receptor-ERK/CREB signaling in a mice model of neuropathic pain.	oxymatrine	27-37	cAMP responsive element binding protein 1	Mus musculus	119-123
23746756-1	2013	PURPOSE: In this study we investigated antinociceptive effects of oxymatrine through regulation of NR2B-containing NMDA receptor-ERK/CREB signaling in a chronic neuropathic pain model induced by chronic constrictive injury (CCI) of the sciatic nerve.	oxymatrine	66-76	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	99-103
23746756-1	2013	PURPOSE: In this study we investigated antinociceptive effects of oxymatrine through regulation of NR2B-containing NMDA receptor-ERK/CREB signaling in a chronic neuropathic pain model induced by chronic constrictive injury (CCI) of the sciatic nerve.	oxymatrine	66-76	mitogen-activated protein kinase 1	Mus musculus	129-132
23746756-1	2013	PURPOSE: In this study we investigated antinociceptive effects of oxymatrine through regulation of NR2B-containing NMDA receptor-ERK/CREB signaling in a chronic neuropathic pain model induced by chronic constrictive injury (CCI) of the sciatic nerve.	oxymatrine	66-76	cAMP responsive element binding protein 1	Mus musculus	133-137
23754270-0	2013	Antiangiogenic effects of oxymatrine on pancreatic cancer by inhibition of the NF-kappaB-mediated VEGF signaling pathway.	oxymatrine	26-36	nuclear factor kappa B subunit 1	Homo sapiens	79-88
23754536-0	2013	Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-alpha activation.	oxymatrine	0-10	peroxisome proliferator activated receptor alpha	Rattus norvegicus	73-121
23754270-0	2013	Antiangiogenic effects of oxymatrine on pancreatic cancer by inhibition of the NF-kappaB-mediated VEGF signaling pathway.	oxymatrine	26-36	vascular endothelial growth factor A	Homo sapiens	98-102
23754270-6	2013	The results revealed that oxymatrine decreased the expression of angiogenesis-associated factors, including nuclear factor kappaB (NF-kappaB) and vascular endothelial growth factor (VEGF).	oxymatrine	26-36	nuclear factor kappa B subunit 1	Homo sapiens	123-129
23754270-6	2013	The results revealed that oxymatrine decreased the expression of angiogenesis-associated factors, including nuclear factor kappaB (NF-kappaB) and vascular endothelial growth factor (VEGF).	oxymatrine	26-36	nuclear factor kappa B subunit 1	Homo sapiens	131-140
23754270-6	2013	The results revealed that oxymatrine decreased the expression of angiogenesis-associated factors, including nuclear factor kappaB (NF-kappaB) and vascular endothelial growth factor (VEGF).	oxymatrine	26-36	vascular endothelial growth factor A	Homo sapiens	146-180
23754270-6	2013	The results revealed that oxymatrine decreased the expression of angiogenesis-associated factors, including nuclear factor kappaB (NF-kappaB) and vascular endothelial growth factor (VEGF).	oxymatrine	26-36	vascular endothelial growth factor A	Homo sapiens	182-186
23754270-8	2013	In conclusion, our studies for the first time suggest that oxymatrine has potential antitumor effects on pancreatic cancer via suppression of angiogenesis, probably through regulation of the expression of the NF-kappaB-mediated VEGF signaling pathway.	oxymatrine	59-69	nuclear factor kappa B subunit 1	Homo sapiens	209-218
23754270-8	2013	In conclusion, our studies for the first time suggest that oxymatrine has potential antitumor effects on pancreatic cancer via suppression of angiogenesis, probably through regulation of the expression of the NF-kappaB-mediated VEGF signaling pathway.	oxymatrine	59-69	vascular endothelial growth factor A	Homo sapiens	228-232
24228589-0	2013	[Effect of oxymatrine on JAK2/STAT3 signaling in renal tissues of rats with septic shock].	oxymatrine	11-21	Janus kinase 2	Rattus norvegicus	25-29
24228589-0	2013	[Effect of oxymatrine on JAK2/STAT3 signaling in renal tissues of rats with septic shock].	oxymatrine	11-21	signal transducer and activator of transcription 3	Rattus norvegicus	30-35
24228589-1	2013	OBJECTIVE: To explore the effect of oxymatrine (OMT) on JAK2/STAT3 signaling in renal tissues of rats with septic shock.	oxymatrine	36-46	Janus kinase 2	Rattus norvegicus	56-60
24228589-1	2013	OBJECTIVE: To explore the effect of oxymatrine (OMT) on JAK2/STAT3 signaling in renal tissues of rats with septic shock.	oxymatrine	36-46	signal transducer and activator of transcription 3	Rattus norvegicus	61-66
24228589-1	2013	OBJECTIVE: To explore the effect of oxymatrine (OMT) on JAK2/STAT3 signaling in renal tissues of rats with septic shock.	oxymatrine	48-51	Janus kinase 2	Rattus norvegicus	56-60
24228589-1	2013	OBJECTIVE: To explore the effect of oxymatrine (OMT) on JAK2/STAT3 signaling in renal tissues of rats with septic shock.	oxymatrine	48-51	signal transducer and activator of transcription 3	Rattus norvegicus	61-66
23211799-12	2013	OMT treatment lowered the blood pressure, reduced the concentrations of serum norepinephrine and myocardium Ang II, favorably decreased the measured gravimetric parameters, decreased the interstitial and perivascular collagen deposition, attenuated the collagen of type I and III accumulation, downregulated the mRNA expression of ACE and TGF-beta1, and suppressed the phosphorylation of ERK 1/2, JNK and p38 MAPK in SHRs.	oxymatrine	0-3	angiotensinogen	Rattus norvegicus	108-114
23404057-0	2013	Oxymatrine protects against myocardial injury via inhibition of JAK2/STAT3 signaling in rat septic shock.	oxymatrine	0-10	Janus kinase 2	Rattus norvegicus	64-68
23404057-0	2013	Oxymatrine protects against myocardial injury via inhibition of JAK2/STAT3 signaling in rat septic shock.	oxymatrine	0-10	signal transducer and activator of transcription 3	Rattus norvegicus	69-74
23404057-4	2013	OMT treatment was found to significantly inhibit the activation of JAK2 and STAT3 in myocardial tissue.	oxymatrine	0-3	Janus kinase 2	Rattus norvegicus	67-71
23404057-4	2013	OMT treatment was found to significantly inhibit the activation of JAK2 and STAT3 in myocardial tissue.	oxymatrine	0-3	signal transducer and activator of transcription 3	Rattus norvegicus	76-81
23404057-7	2013	The results indicate that OMT exhibits substantial therapeutic potential for the treatment of septic shock-induced myocardial injury through inhibition of the JAK2/STAT3 signaling pathway.	oxymatrine	26-29	Janus kinase 2	Rattus norvegicus	159-163
23404057-7	2013	The results indicate that OMT exhibits substantial therapeutic potential for the treatment of septic shock-induced myocardial injury through inhibition of the JAK2/STAT3 signaling pathway.	oxymatrine	26-29	signal transducer and activator of transcription 3	Rattus norvegicus	164-169
23219339-0	2013	Neuroprotective effects of oxymatrine against excitotoxicity partially through down-regulation of NR2B-containing NMDA receptors.	oxymatrine	27-37	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	98-102
23211799-12	2013	OMT treatment lowered the blood pressure, reduced the concentrations of serum norepinephrine and myocardium Ang II, favorably decreased the measured gravimetric parameters, decreased the interstitial and perivascular collagen deposition, attenuated the collagen of type I and III accumulation, downregulated the mRNA expression of ACE and TGF-beta1, and suppressed the phosphorylation of ERK 1/2, JNK and p38 MAPK in SHRs.	oxymatrine	0-3	angiotensin I converting enzyme	Rattus norvegicus	331-334
23219339-7	2013	Furthermore, OMT significantly reversed the up-regulation of NR2B and inhibited the calcium overload in the cultured neurons after challenging the NMDA.	oxymatrine	13-16	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	61-65
23211799-12	2013	OMT treatment lowered the blood pressure, reduced the concentrations of serum norepinephrine and myocardium Ang II, favorably decreased the measured gravimetric parameters, decreased the interstitial and perivascular collagen deposition, attenuated the collagen of type I and III accumulation, downregulated the mRNA expression of ACE and TGF-beta1, and suppressed the phosphorylation of ERK 1/2, JNK and p38 MAPK in SHRs.	oxymatrine	0-3	transforming growth factor, beta 1	Rattus norvegicus	339-348
23211799-12	2013	OMT treatment lowered the blood pressure, reduced the concentrations of serum norepinephrine and myocardium Ang II, favorably decreased the measured gravimetric parameters, decreased the interstitial and perivascular collagen deposition, attenuated the collagen of type I and III accumulation, downregulated the mRNA expression of ACE and TGF-beta1, and suppressed the phosphorylation of ERK 1/2, JNK and p38 MAPK in SHRs.	oxymatrine	0-3	mitogen activated protein kinase 3	Rattus norvegicus	388-395
23211799-12	2013	OMT treatment lowered the blood pressure, reduced the concentrations of serum norepinephrine and myocardium Ang II, favorably decreased the measured gravimetric parameters, decreased the interstitial and perivascular collagen deposition, attenuated the collagen of type I and III accumulation, downregulated the mRNA expression of ACE and TGF-beta1, and suppressed the phosphorylation of ERK 1/2, JNK and p38 MAPK in SHRs.	oxymatrine	0-3	mitogen-activated protein kinase 8	Rattus norvegicus	397-400
23103450-0	2013	Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression.	oxymatrine	84-94	ETS transcription factor ERG	Homo sapiens	25-29
23160948-0	2013	Kinetics and computational docking studies on the inhibition of tyrosinase induced by oxymatrine.	oxymatrine	86-96	tyrosinase	Homo sapiens	64-74
23160948-2	2013	We found that oxymatrine significantly inhibited tyrosinase, and that this reaction was not accompanied by detectable conformational changes.	oxymatrine	14-24	tyrosinase	Homo sapiens	49-59
23160948-3	2013	Kinetic analysis showed that oxymatrine reversibly inhibited tyrosinase in a mixed-type manner.	oxymatrine	29-39	tyrosinase	Homo sapiens	61-71
23160948-5	2013	We also conducted a docking simulation between tyrosinase and oxymatrine using two docking programs, Dock6.3 and AutoDock4.2 (binding energy was -118.81 kcal/mol for Dock6 and -8.04 kcal/mol for AutoDock4).	oxymatrine	62-72	tyrosinase	Homo sapiens	47-57
23160948-5	2013	We also conducted a docking simulation between tyrosinase and oxymatrine using two docking programs, Dock6.3 and AutoDock4.2 (binding energy was -118.81 kcal/mol for Dock6 and -8.04 kcal/mol for AutoDock4).	oxymatrine	62-72	dedicator of cytokinesis 6	Homo sapiens	101-106
23160948-5	2013	We also conducted a docking simulation between tyrosinase and oxymatrine using two docking programs, Dock6.3 and AutoDock4.2 (binding energy was -118.81 kcal/mol for Dock6 and -8.04 kcal/mol for AutoDock4).	oxymatrine	62-72	dedicator of cytokinesis 6	Homo sapiens	166-171
23160948-6	2013	The results also suggested that oxymatrine interacts mostly with the residues of CYS83 and HIS263 in the active site of tyrosinase.	oxymatrine	32-42	tyrosinase	Homo sapiens	120-130
23103450-8	2013	Long-term treatment with 1 muM matrine or oxymatrine increased expression of the hERG protein and rescued the hERG surface expression disrupted by As(2)O(3).	oxymatrine	42-52	ETS transcription factor ERG	Homo sapiens	81-85
23103450-8	2013	Long-term treatment with 1 muM matrine or oxymatrine increased expression of the hERG protein and rescued the hERG surface expression disrupted by As(2)O(3).	oxymatrine	42-52	ETS transcription factor ERG	Homo sapiens	110-114
23103450-11	2013	Therefore, matrine and oxymatrine may have the potential to cure LQT2 as a potassium channel activator by promoting hERG channel activation and increasing hERG channel expression.	oxymatrine	23-33	potassium voltage-gated channel subfamily H member 2	Homo sapiens	65-69
23103450-11	2013	Therefore, matrine and oxymatrine may have the potential to cure LQT2 as a potassium channel activator by promoting hERG channel activation and increasing hERG channel expression.	oxymatrine	23-33	ETS transcription factor ERG	Homo sapiens	116-120
23103450-11	2013	Therefore, matrine and oxymatrine may have the potential to cure LQT2 as a potassium channel activator by promoting hERG channel activation and increasing hERG channel expression.	oxymatrine	23-33	ETS transcription factor ERG	Homo sapiens	155-159
24250585-0	2013	Anti-inflammatory Effects of Oxymatrine Through Inhibition of Nuclear Factor-kappa B and Mitogen-activated Protein Kinase Activation in Lipopolysaccharide-induced BV2 Microglia Cells.	oxymatrine	29-39	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	62-84
23061466-4	2013	The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and hERG blocking activity.	oxymatrine	55-65	ETS transcription factor ERG	Homo sapiens	205-209
24250585-6	2013	It was shown that oxymatrine inhibited the productions of NO, PGE2, TNF-alpha, IL-1beta and IL-6, attenuated the mRNA levels of iNOS and COX-2, suppressed the phosphorylation of I-kappaBalpha in cytosol, decreased the nuclear levels of p65, and also blocked ERK, p38 and JNK pathway in LPS-stimulated BV2 microglial cells in a dose-dependent manner.	oxymatrine	18-28	interleukin 6	Mus musculus	92-96
24250585-3	2013	This study was designed to investigate the effects of oxymatrine on nuclear factor-kappa B (NF-kappaB) and mitogen-activated protein kinase (MAPK)-dependent inflammatory responses in lipopolysaccharide (LPS)-activated microglia.	oxymatrine	54-64	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	68-90
24250585-6	2013	It was shown that oxymatrine inhibited the productions of NO, PGE2, TNF-alpha, IL-1beta and IL-6, attenuated the mRNA levels of iNOS and COX-2, suppressed the phosphorylation of I-kappaBalpha in cytosol, decreased the nuclear levels of p65, and also blocked ERK, p38 and JNK pathway in LPS-stimulated BV2 microglial cells in a dose-dependent manner.	oxymatrine	18-28	nitric oxide synthase 2, inducible	Mus musculus	128-132
24250585-3	2013	This study was designed to investigate the effects of oxymatrine on nuclear factor-kappa B (NF-kappaB) and mitogen-activated protein kinase (MAPK)-dependent inflammatory responses in lipopolysaccharide (LPS)-activated microglia.	oxymatrine	54-64	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	92-101
24250585-6	2013	It was shown that oxymatrine inhibited the productions of NO, PGE2, TNF-alpha, IL-1beta and IL-6, attenuated the mRNA levels of iNOS and COX-2, suppressed the phosphorylation of I-kappaBalpha in cytosol, decreased the nuclear levels of p65, and also blocked ERK, p38 and JNK pathway in LPS-stimulated BV2 microglial cells in a dose-dependent manner.	oxymatrine	18-28	prostaglandin-endoperoxide synthase 2	Mus musculus	137-142
24250585-6	2013	It was shown that oxymatrine inhibited the productions of NO, PGE2, TNF-alpha, IL-1beta and IL-6, attenuated the mRNA levels of iNOS and COX-2, suppressed the phosphorylation of I-kappaBalpha in cytosol, decreased the nuclear levels of p65, and also blocked ERK, p38 and JNK pathway in LPS-stimulated BV2 microglial cells in a dose-dependent manner.	oxymatrine	18-28	tumor necrosis factor	Mus musculus	68-77
24250585-6	2013	It was shown that oxymatrine inhibited the productions of NO, PGE2, TNF-alpha, IL-1beta and IL-6, attenuated the mRNA levels of iNOS and COX-2, suppressed the phosphorylation of I-kappaBalpha in cytosol, decreased the nuclear levels of p65, and also blocked ERK, p38 and JNK pathway in LPS-stimulated BV2 microglial cells in a dose-dependent manner.	oxymatrine	18-28	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	178-191
24250585-6	2013	It was shown that oxymatrine inhibited the productions of NO, PGE2, TNF-alpha, IL-1beta and IL-6, attenuated the mRNA levels of iNOS and COX-2, suppressed the phosphorylation of I-kappaBalpha in cytosol, decreased the nuclear levels of p65, and also blocked ERK, p38 and JNK pathway in LPS-stimulated BV2 microglial cells in a dose-dependent manner.	oxymatrine	18-28	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	236-239
24250585-6	2013	It was shown that oxymatrine inhibited the productions of NO, PGE2, TNF-alpha, IL-1beta and IL-6, attenuated the mRNA levels of iNOS and COX-2, suppressed the phosphorylation of I-kappaBalpha in cytosol, decreased the nuclear levels of p65, and also blocked ERK, p38 and JNK pathway in LPS-stimulated BV2 microglial cells in a dose-dependent manner.	oxymatrine	18-28	mitogen-activated protein kinase 1	Mus musculus	258-261
24250585-6	2013	It was shown that oxymatrine inhibited the productions of NO, PGE2, TNF-alpha, IL-1beta and IL-6, attenuated the mRNA levels of iNOS and COX-2, suppressed the phosphorylation of I-kappaBalpha in cytosol, decreased the nuclear levels of p65, and also blocked ERK, p38 and JNK pathway in LPS-stimulated BV2 microglial cells in a dose-dependent manner.	oxymatrine	18-28	mitogen-activated protein kinase 14	Mus musculus	263-266
24250585-6	2013	It was shown that oxymatrine inhibited the productions of NO, PGE2, TNF-alpha, IL-1beta and IL-6, attenuated the mRNA levels of iNOS and COX-2, suppressed the phosphorylation of I-kappaBalpha in cytosol, decreased the nuclear levels of p65, and also blocked ERK, p38 and JNK pathway in LPS-stimulated BV2 microglial cells in a dose-dependent manner.	oxymatrine	18-28	mitogen-activated protein kinase 8	Mus musculus	271-274
24250585-6	2013	It was shown that oxymatrine inhibited the productions of NO, PGE2, TNF-alpha, IL-1beta and IL-6, attenuated the mRNA levels of iNOS and COX-2, suppressed the phosphorylation of I-kappaBalpha in cytosol, decreased the nuclear levels of p65, and also blocked ERK, p38 and JNK pathway in LPS-stimulated BV2 microglial cells in a dose-dependent manner.	oxymatrine	18-28	interleukin 1 beta	Mus musculus	79-87
25538757-4	2012	The results of the enzyme-linked immunosorbent assay and the real-time quantitative PCR showed that the secretion and mRNA expression of the pro-inflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha were significantly decreased in the hippocampus and cerebral cortex of model rats treated with oxymatrine.	oxymatrine	313-323	interleukin 1 beta	Rattus norvegicus	168-217
23568217-3	2013	Oxymatrine significantly decreased LPS-induced NF-kappaB-driven luciferase activity, correlating with diminished induction of Cxcl2, Tnfalpha and Il6 mRNA expression in rat IEC-6 and murine BMDC.	oxymatrine	0-10	C-X-C motif chemokine ligand 2	Rattus norvegicus	126-131
23568217-3	2013	Oxymatrine significantly decreased LPS-induced NF-kappaB-driven luciferase activity, correlating with diminished induction of Cxcl2, Tnfalpha and Il6 mRNA expression in rat IEC-6 and murine BMDC.	oxymatrine	0-10	tumor necrosis factor	Rattus norvegicus	133-141
23568217-3	2013	Oxymatrine significantly decreased LPS-induced NF-kappaB-driven luciferase activity, correlating with diminished induction of Cxcl2, Tnfalpha and Il6 mRNA expression in rat IEC-6 and murine BMDC.	oxymatrine	0-10	interleukin 6	Rattus norvegicus	146-149
23568217-4	2013	Although oxymatrine decreased LPS-induced p65 nuclear translocation and binding to the Cxcl2 gene promoter, this effect was independent of IkappaBalpha degradation/phosphorylation.	oxymatrine	9-19	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	42-45
23568217-4	2013	Although oxymatrine decreased LPS-induced p65 nuclear translocation and binding to the Cxcl2 gene promoter, this effect was independent of IkappaBalpha degradation/phosphorylation.	oxymatrine	9-19	chemokine (C-X-C motif) ligand 2	Mus musculus	87-92
25538757-5	2012	Western blot assay and real-time quantitative PCR analysis indicated that toll-like receptor 4 mRNA and protein expression were significantly decreased in the groups receiving different doses of oxymatrine.	oxymatrine	195-205	toll-like receptor 4	Rattus norvegicus	74-94
25538757-6	2012	Additionally, 120 and 90 mg/kg oxymatrine were shown to reduce protein levels of nuclear factor-kappaB p65 in the nucleus and of phosphorylated IkappaBalpha in the cytoplasm of brain cells, as detected by western blot assay.	oxymatrine	31-41	synaptotagmin 1	Rattus norvegicus	103-106
25538757-6	2012	Additionally, 120 and 90 mg/kg oxymatrine were shown to reduce protein levels of nuclear factor-kappaB p65 in the nucleus and of phosphorylated IkappaBalpha in the cytoplasm of brain cells, as detected by western blot assay.	oxymatrine	31-41	NFKB inhibitor alpha	Rattus norvegicus	144-156
25538757-7	2012	Experimental findings indicate that oxymatrine may inhibit neuroinflammation in rat brain via downregulating the expression of molecules in the toll-like receptor 4/nuclear factor-kappaB signaling pathway.	oxymatrine	36-46	toll-like receptor 4	Rattus norvegicus	144-164
23163153-0	2012	[Effects of oxymatrine on the expressions of pro-collagen and fibronectin of fibroblasts derived from human hyperplastic scars].	oxymatrine	12-22	fibronectin 1	Homo sapiens	62-73
22750437-6	2012	RESULTS: Oxymatrine at 120mg/kg significantly suppressed gene expressions of TLR-4 and NF-kappaB, decreased levels of TNF-alpha, interleukin-1beta and interleukin-6, inhibited synthesis of 12/15-LOX, phospho-p38 MAPK and cPLA2 protein, and mitigated apoptotic neuronal changes following ICH in rat.	oxymatrine	9-19	toll-like receptor 4	Rattus norvegicus	77-82
22750437-6	2012	RESULTS: Oxymatrine at 120mg/kg significantly suppressed gene expressions of TLR-4 and NF-kappaB, decreased levels of TNF-alpha, interleukin-1beta and interleukin-6, inhibited synthesis of 12/15-LOX, phospho-p38 MAPK and cPLA2 protein, and mitigated apoptotic neuronal changes following ICH in rat.	oxymatrine	9-19	interleukin 1 beta	Rattus norvegicus	129-146
22750437-6	2012	RESULTS: Oxymatrine at 120mg/kg significantly suppressed gene expressions of TLR-4 and NF-kappaB, decreased levels of TNF-alpha, interleukin-1beta and interleukin-6, inhibited synthesis of 12/15-LOX, phospho-p38 MAPK and cPLA2 protein, and mitigated apoptotic neuronal changes following ICH in rat.	oxymatrine	9-19	tumor necrosis factor	Rattus norvegicus	118-127
22750437-6	2012	RESULTS: Oxymatrine at 120mg/kg significantly suppressed gene expressions of TLR-4 and NF-kappaB, decreased levels of TNF-alpha, interleukin-1beta and interleukin-6, inhibited synthesis of 12/15-LOX, phospho-p38 MAPK and cPLA2 protein, and mitigated apoptotic neuronal changes following ICH in rat.	oxymatrine	9-19	interleukin 6	Rattus norvegicus	151-164
21714853-0	2011	Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c.	oxymatrine	0-10	BCL2 apoptosis regulator	Homo sapiens	95-100
22750437-6	2012	RESULTS: Oxymatrine at 120mg/kg significantly suppressed gene expressions of TLR-4 and NF-kappaB, decreased levels of TNF-alpha, interleukin-1beta and interleukin-6, inhibited synthesis of 12/15-LOX, phospho-p38 MAPK and cPLA2 protein, and mitigated apoptotic neuronal changes following ICH in rat.	oxymatrine	9-19	arachidonate 15-lipoxygenase	Rattus norvegicus	189-198
22750437-6	2012	RESULTS: Oxymatrine at 120mg/kg significantly suppressed gene expressions of TLR-4 and NF-kappaB, decreased levels of TNF-alpha, interleukin-1beta and interleukin-6, inhibited synthesis of 12/15-LOX, phospho-p38 MAPK and cPLA2 protein, and mitigated apoptotic neuronal changes following ICH in rat.	oxymatrine	9-19	mitogen activated protein kinase 14	Rattus norvegicus	208-211
22750437-6	2012	RESULTS: Oxymatrine at 120mg/kg significantly suppressed gene expressions of TLR-4 and NF-kappaB, decreased levels of TNF-alpha, interleukin-1beta and interleukin-6, inhibited synthesis of 12/15-LOX, phospho-p38 MAPK and cPLA2 protein, and mitigated apoptotic neuronal changes following ICH in rat.	oxymatrine	9-19	phospholipase A2 group IVA	Rattus norvegicus	221-226
22772914-14	2012	Compared with the model group, the expression of NF-kappa Bp65 was significantly decreased in the mesalazine group (P&lt;0.01) and oxymatrine treatment group (P&lt;0.01) while the expressions of beta2AR and beta-arrestin2 were significantly increased (P&lt;0.01).	oxymatrine	131-141	adrenoceptor beta 2	Rattus norvegicus	195-202
22772914-14	2012	Compared with the model group, the expression of NF-kappa Bp65 was significantly decreased in the mesalazine group (P&lt;0.01) and oxymatrine treatment group (P&lt;0.01) while the expressions of beta2AR and beta-arrestin2 were significantly increased (P&lt;0.01).	oxymatrine	131-141	arrestin, beta 2, pseudogene	Rattus norvegicus	207-221
22772914-17	2012	Oxymatrine attenuated ulcerative colitis through regulating the beta2AR-beta-arrestin2-NF-kappaB signal transduction pathway.	oxymatrine	0-10	adrenoceptor beta 2	Rattus norvegicus	64-71
22772914-17	2012	Oxymatrine attenuated ulcerative colitis through regulating the beta2AR-beta-arrestin2-NF-kappaB signal transduction pathway.	oxymatrine	0-10	arrestin, beta 2, pseudogene	Rattus norvegicus	72-86
22435440-0	2012	Oxymatrine inhibits collagen synthesis in keloid fibroblasts via inhibition of transforming growth factor-beta1/Smad signaling pathway.	oxymatrine	0-10	transforming growth factor beta 1	Homo sapiens	79-111
22435440-0	2012	Oxymatrine inhibits collagen synthesis in keloid fibroblasts via inhibition of transforming growth factor-beta1/Smad signaling pathway.	oxymatrine	0-10	SMAD family member 4	Homo sapiens	112-116
22435440-6	2012	RESULTS: We found that both collagen synthesis and Smad3 production were significantly suppressed in a dose-dependent administration of OMT.	oxymatrine	136-139	SMAD family member 3	Homo sapiens	51-56
22435440-8	2012	We also found that OMT reversed phosphorylation and nuclear translocation of Smad3 induced by TGF-beta1.	oxymatrine	19-22	SMAD family member 3	Homo sapiens	77-82
22435440-8	2012	We also found that OMT reversed phosphorylation and nuclear translocation of Smad3 induced by TGF-beta1.	oxymatrine	19-22	transforming growth factor beta 1	Homo sapiens	94-103
21069479-0	2011	Oxymatrine diminishes the side population and inhibits the expression of beta-catenin in MCF-7 breast cancer cells.	oxymatrine	0-10	catenin beta 1	Homo sapiens	73-85
21069479-7	2011	Wnt/beta-catenin signaling pathway was also examined by analyzing the expression of total beta-catenin and phosphorylated beta-catenin in cytoplasm, and the results showed that the growth inhibitory effects of oxymatrine treatment on MCF-7 cells may be due to the inhibition of SP and Wnt/beta-catenin signaling pathway.	oxymatrine	210-220	catenin beta 1	Homo sapiens	4-16
21069479-7	2011	Wnt/beta-catenin signaling pathway was also examined by analyzing the expression of total beta-catenin and phosphorylated beta-catenin in cytoplasm, and the results showed that the growth inhibitory effects of oxymatrine treatment on MCF-7 cells may be due to the inhibition of SP and Wnt/beta-catenin signaling pathway.	oxymatrine	210-220	catenin beta 1	Homo sapiens	90-102
21069479-7	2011	Wnt/beta-catenin signaling pathway was also examined by analyzing the expression of total beta-catenin and phosphorylated beta-catenin in cytoplasm, and the results showed that the growth inhibitory effects of oxymatrine treatment on MCF-7 cells may be due to the inhibition of SP and Wnt/beta-catenin signaling pathway.	oxymatrine	210-220	catenin beta 1	Homo sapiens	90-102
21069479-7	2011	Wnt/beta-catenin signaling pathway was also examined by analyzing the expression of total beta-catenin and phosphorylated beta-catenin in cytoplasm, and the results showed that the growth inhibitory effects of oxymatrine treatment on MCF-7 cells may be due to the inhibition of SP and Wnt/beta-catenin signaling pathway.	oxymatrine	210-220	catenin beta 1	Homo sapiens	90-102
21757347-1	2011	Oxymatrine (1) is a natural anti-hepatitis B virus (HBV) drug that down-regulates host heat-stress cognate 70 (Hsc70) expression through a mechanism different from that of nucleosides.	oxymatrine	0-10	heat shock protein family A (Hsp70) member 8	Homo sapiens	87-109
21757347-1	2011	Oxymatrine (1) is a natural anti-hepatitis B virus (HBV) drug that down-regulates host heat-stress cognate 70 (Hsc70) expression through a mechanism different from that of nucleosides.	oxymatrine	0-10	heat shock protein family A (Hsp70) member 8	Homo sapiens	111-116
22367596-0	2012	Oxymatrine attenuates bleomycin-induced pulmonary fibrosis in mice via             the inhibition of inducible nitric oxide synthase expression and the TGF-beta/Smad             signaling pathway.	oxymatrine	0-10	nitric oxide synthase 2, inducible	Mus musculus	101-132
22367596-0	2012	Oxymatrine attenuates bleomycin-induced pulmonary fibrosis in mice via             the inhibition of inducible nitric oxide synthase expression and the TGF-beta/Smad             signaling pathway.	oxymatrine	0-10	transforming growth factor, beta 1	Mus musculus	152-160
21633783-4	2012	Oxymatrine significantly reduced the plasma amylase, D-lactic acid and tumor necrosis factor alpha concentration, serum diamine oxidase and lipase activity, and pancreatic myeloperoxidase activity, which were increased in AP rats (P &lt; 0.05).	oxymatrine	0-10	amine oxidase, copper containing 1	Rattus norvegicus	120-135
21633783-4	2012	Oxymatrine significantly reduced the plasma amylase, D-lactic acid and tumor necrosis factor alpha concentration, serum diamine oxidase and lipase activity, and pancreatic myeloperoxidase activity, which were increased in AP rats (P &lt; 0.05).	oxymatrine	0-10	lipase G, endothelial type	Rattus norvegicus	140-146
21633783-6	2012	However, oxymatrine increased the expression of claudin-1 and CD45, but did not alter the expression of ZO-1 and occludin.	oxymatrine	9-19	claudin 1	Rattus norvegicus	48-57
21633783-6	2012	However, oxymatrine increased the expression of claudin-1 and CD45, but did not alter the expression of ZO-1 and occludin.	oxymatrine	9-19	protein tyrosine phosphatase, receptor type, C	Rattus norvegicus	62-66
21633783-7	2012	In conclusion, our results demonstrated that oxymatrine is potentially capably of protecting against L-arginine-induced AP and attenuating AP-associated intestinal barrier injury by up-regulation of claudin-1.	oxymatrine	45-55	claudin 1	Rattus norvegicus	199-208
22693908-0	2012	[Protective effect of TGF-beta-Smads signal-based oxymatrine on myocardial fibrosis induced by acute myocardial infarction in rats].	oxymatrine	50-60	transforming growth factor, beta 1	Rattus norvegicus	22-30
22693908-1	2012	OBJECTIVE: To study the protective effect of oxymatrine (OMT) on myocardial fibrosis induced by acute myocardial infarction in rats and its effect on TGF-beta-Smads signal pathway.	oxymatrine	45-55	transforming growth factor, beta 1	Rattus norvegicus	150-158
22693908-1	2012	OBJECTIVE: To study the protective effect of oxymatrine (OMT) on myocardial fibrosis induced by acute myocardial infarction in rats and its effect on TGF-beta-Smads signal pathway.	oxymatrine	57-60	transforming growth factor, beta 1	Rattus norvegicus	150-158
21714853-0	2011	Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c.	oxymatrine	0-10	alkaline phosphatase, intestinal	Homo sapiens	105-108
21714853-0	2011	Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c.	oxymatrine	0-10	cytochrome c, somatic	Homo sapiens	136-148
21714853-8	2011	Furthermore, oxymatrine treatment led to the release of cytochrome c and activation of caspase-3 proteins.	oxymatrine	13-23	cytochrome c, somatic	Homo sapiens	56-68
21714853-8	2011	Furthermore, oxymatrine treatment led to the release of cytochrome c and activation of caspase-3 proteins.	oxymatrine	13-23	caspase 3	Homo sapiens	87-96
21714853-9	2011	CONCLUSION: Oxymatrine can induce apoptotic cell death of human pancreatic cancer, which might be attributed to the regulation of Bcl-2 and IAP families, release of mitochondrial cytochrome c and activation of caspase-3.	oxymatrine	12-22	BCL2 apoptosis regulator	Homo sapiens	130-135
21714853-9	2011	CONCLUSION: Oxymatrine can induce apoptotic cell death of human pancreatic cancer, which might be attributed to the regulation of Bcl-2 and IAP families, release of mitochondrial cytochrome c and activation of caspase-3.	oxymatrine	12-22	alkaline phosphatase, intestinal	Homo sapiens	140-143
21714853-9	2011	CONCLUSION: Oxymatrine can induce apoptotic cell death of human pancreatic cancer, which might be attributed to the regulation of Bcl-2 and IAP families, release of mitochondrial cytochrome c and activation of caspase-3.	oxymatrine	12-22	cytochrome c, somatic	Homo sapiens	179-191
21714853-9	2011	CONCLUSION: Oxymatrine can induce apoptotic cell death of human pancreatic cancer, which might be attributed to the regulation of Bcl-2 and IAP families, release of mitochondrial cytochrome c and activation of caspase-3.	oxymatrine	12-22	caspase 3	Homo sapiens	210-219
21544720-2	2011	Formulated as an oxymatrine-phospholipid complex (OMT-PLC) can improve the lipid solubility and effectiveness of OMT.	oxymatrine	17-27	heparan sulfate proteoglycan 2	Homo sapiens	54-57
21190123-0	2011	Oxymatrine reduces neuronal cell apoptosis by inhibiting Toll-like receptor 4/nuclear factor kappa-B-dependent inflammatory responses in traumatic rat brain injury.	oxymatrine	0-10	toll-like receptor 4	Rattus norvegicus	57-77
21190123-1	2011	OBJECTIVE: To investigate the influence of oxymatrine (OMT) on Toll-like receptor 4 (TLR-4)/nuclear factor kappa-B (NF-kappaB)-dependent inflammatory responses and neuronal cell apoptosis after traumatic brain injury (TBI).	oxymatrine	43-53	toll-like receptor 4	Rattus norvegicus	63-83
21190123-1	2011	OBJECTIVE: To investigate the influence of oxymatrine (OMT) on Toll-like receptor 4 (TLR-4)/nuclear factor kappa-B (NF-kappaB)-dependent inflammatory responses and neuronal cell apoptosis after traumatic brain injury (TBI).	oxymatrine	43-53	toll-like receptor 4	Rattus norvegicus	85-90
21190123-1	2011	OBJECTIVE: To investigate the influence of oxymatrine (OMT) on Toll-like receptor 4 (TLR-4)/nuclear factor kappa-B (NF-kappaB)-dependent inflammatory responses and neuronal cell apoptosis after traumatic brain injury (TBI).	oxymatrine	55-58	toll-like receptor 4	Rattus norvegicus	63-83
21190123-1	2011	OBJECTIVE: To investigate the influence of oxymatrine (OMT) on Toll-like receptor 4 (TLR-4)/nuclear factor kappa-B (NF-kappaB)-dependent inflammatory responses and neuronal cell apoptosis after traumatic brain injury (TBI).	oxymatrine	55-58	toll-like receptor 4	Rattus norvegicus	85-90
21190123-5	2011	RESULTS: The administration of 120 mg/kg OMT could significantly suppress gene expressions of TLR-4 and NF-kappaB, lessen concentrations of TNF-alpha, IL-1beta and IL-6, and reduce the number of apoptotic neuronal cells in traumatic rat brain tissues by the Mann-Whitney U test (P &lt; 0.05), but the administration of 60 mg/kg OMT could not (P &gt; 0.05).	oxymatrine	41-44	toll-like receptor 4	Rattus norvegicus	94-99
21190123-5	2011	RESULTS: The administration of 120 mg/kg OMT could significantly suppress gene expressions of TLR-4 and NF-kappaB, lessen concentrations of TNF-alpha, IL-1beta and IL-6, and reduce the number of apoptotic neuronal cells in traumatic rat brain tissues by the Mann-Whitney U test (P &lt; 0.05), but the administration of 60 mg/kg OMT could not (P &gt; 0.05).	oxymatrine	41-44	tumor necrosis factor	Rattus norvegicus	140-149
21190123-5	2011	RESULTS: The administration of 120 mg/kg OMT could significantly suppress gene expressions of TLR-4 and NF-kappaB, lessen concentrations of TNF-alpha, IL-1beta and IL-6, and reduce the number of apoptotic neuronal cells in traumatic rat brain tissues by the Mann-Whitney U test (P &lt; 0.05), but the administration of 60 mg/kg OMT could not (P &gt; 0.05).	oxymatrine	41-44	interleukin 1 beta	Rattus norvegicus	151-159
21190123-5	2011	RESULTS: The administration of 120 mg/kg OMT could significantly suppress gene expressions of TLR-4 and NF-kappaB, lessen concentrations of TNF-alpha, IL-1beta and IL-6, and reduce the number of apoptotic neuronal cells in traumatic rat brain tissues by the Mann-Whitney U test (P &lt; 0.05), but the administration of 60 mg/kg OMT could not (P &gt; 0.05).	oxymatrine	41-44	interleukin 6	Rattus norvegicus	164-168
21272621-0	2011	Effects of oxymatrine on sympathoexcitatory reflex induced by myocardial ischemic signaling mediated by P2X3 receptors in rat SCG and DRG.	oxymatrine	11-21	purinergic receptor P2X 3	Rattus norvegicus	104-108
21272621-3	2011	The present study is aimed to explore the effects of oxymatrine (Oxy) on the transmission of myocardial ischemic signaling mediated by P2X3 receptors in rat superior cervical ganglia (SCG) and cervical dorsal root ganglia (DRG) in the sympathoexcitatory reflex after myocardial ischemic injury.	oxymatrine	53-63	purinergic receptor P2X 3	Rattus norvegicus	135-139
21272621-8	2011	After myocardial ischemic rats are treated with oxymatrine, the expression levels of P2X3 immunoreactivity, mRNA and protein are lower than those in myocardial ischemic rats.	oxymatrine	48-58	purinergic receptor P2X 3	Rattus norvegicus	85-89
21272621-9	2011	Oxymatrine may decrease the expression of P2X3 receptor and depress the aggravated sympathoexcitatory reflex induced by the nociceptive transmission of myocardial ischemic injury via P2X3 receptors of rat SCG and DRG neurons.	oxymatrine	0-10	purinergic receptor P2X 3	Rattus norvegicus	42-46
21272621-9	2011	Oxymatrine may decrease the expression of P2X3 receptor and depress the aggravated sympathoexcitatory reflex induced by the nociceptive transmission of myocardial ischemic injury via P2X3 receptors of rat SCG and DRG neurons.	oxymatrine	0-10	purinergic receptor P2X 3	Rattus norvegicus	183-187
21544720-2	2011	Formulated as an oxymatrine-phospholipid complex (OMT-PLC) can improve the lipid solubility and effectiveness of OMT.	oxymatrine	50-53	heparan sulfate proteoglycan 2	Homo sapiens	54-57
21544720-3	2011	The purpose of this study was to explore the utility of the combination of a microemulsion and an OMT-PLC as a topical delivery vehicle for enhancing the absorption and efficacy of OMT.	oxymatrine	98-101	heparan sulfate proteoglycan 2	Homo sapiens	102-105
21544720-7	2011	It possessed an average droplet size of 32.4 nm, a low viscosity of 113.7 mPa   s, and a high cloud point of 88 C. Compared to the control solution, ME4 provided better skin permeability in vitro and a higher retention ratio of OMT in skin in vivo.	oxymatrine	228-231	protocadherin beta 17 pseudogene	Homo sapiens	149-152
21409682-0	2011	Protective effect of oxymatrine on myocardial fibrosis induced by acute myocardial infarction in rats involved in TGF-beta1-Smads signal pathway.	oxymatrine	21-31	transforming growth factor, beta 1	Rattus norvegicus	114-123
20626959-10	2011	Consistent with these indices, the overexpressions of 12/15-LOX, phospho-p38 MAPK, and cPLA2 were significantly decreased in oxymatrine group.	oxymatrine	125-135	arachidonate 15-lipoxygenase	Rattus norvegicus	54-63
20626959-10	2011	Consistent with these indices, the overexpressions of 12/15-LOX, phospho-p38 MAPK, and cPLA2 were significantly decreased in oxymatrine group.	oxymatrine	125-135	mitogen activated protein kinase 14	Rattus norvegicus	73-76
20626959-10	2011	Consistent with these indices, the overexpressions of 12/15-LOX, phospho-p38 MAPK, and cPLA2 were significantly decreased in oxymatrine group.	oxymatrine	125-135	phospholipase A2 group IVA	Rattus norvegicus	87-92
20626959-12	2011	CONCLUSIONS: Oxymatrine protected the brain from damage caused by MCAO; this effect may be through down-regulation of 12/15-LOX, phospho-p38 MAPK, and cPLA2, but not through down-regulation of p38 MAPK.	oxymatrine	13-23	arachidonate 15-lipoxygenase	Rattus norvegicus	118-127
20626959-12	2011	CONCLUSIONS: Oxymatrine protected the brain from damage caused by MCAO; this effect may be through down-regulation of 12/15-LOX, phospho-p38 MAPK, and cPLA2, but not through down-regulation of p38 MAPK.	oxymatrine	13-23	mitogen activated protein kinase 14	Rattus norvegicus	137-140
20626959-12	2011	CONCLUSIONS: Oxymatrine protected the brain from damage caused by MCAO; this effect may be through down-regulation of 12/15-LOX, phospho-p38 MAPK, and cPLA2, but not through down-regulation of p38 MAPK.	oxymatrine	13-23	phospholipase A2 group IVA	Rattus norvegicus	151-156
20626959-12	2011	CONCLUSIONS: Oxymatrine protected the brain from damage caused by MCAO; this effect may be through down-regulation of 12/15-LOX, phospho-p38 MAPK, and cPLA2, but not through down-regulation of p38 MAPK.	oxymatrine	13-23	mitogen activated protein kinase 14	Rattus norvegicus	193-196
21563601-0	2011	[Retraction: Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells].	oxymatrine	24-34	vascular endothelial growth factor A	Homo sapiens	114-148
21565129-0	2011	Retraction: "Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells".	oxymatrine	24-34	vascular endothelial growth factor A	Homo sapiens	114-148
21532144-0	2011	The neuroprotection of oxymatrine in cerebral ischemia/reperfusion is related to nuclear factor erythroid 2-related factor 2 (nrf2)-mediated antioxidant response: role of nrf2 and hemeoxygenase-1 expression.	oxymatrine	23-33	NFE2 like bZIP transcription factor 2	Rattus norvegicus	81-124
21532144-0	2011	The neuroprotection of oxymatrine in cerebral ischemia/reperfusion is related to nuclear factor erythroid 2-related factor 2 (nrf2)-mediated antioxidant response: role of nrf2 and hemeoxygenase-1 expression.	oxymatrine	23-33	NFE2 like bZIP transcription factor 2	Rattus norvegicus	126-130
21532144-0	2011	The neuroprotection of oxymatrine in cerebral ischemia/reperfusion is related to nuclear factor erythroid 2-related factor 2 (nrf2)-mediated antioxidant response: role of nrf2 and hemeoxygenase-1 expression.	oxymatrine	23-33	NFE2 like bZIP transcription factor 2	Rattus norvegicus	171-175
21532144-4	2011	The present study was designed to investigate the potential effect of oxymatrine in ischemia-reperfusion injury in rat"s brain and to explore the possible role of oxymatrine in Nrf2 pathway.	oxymatrine	163-173	NFE2 like bZIP transcription factor 2	Rattus norvegicus	177-181
21365847-0	2010	[The effects of oxymatrine on expression of interleukin-6 and interleukin-1beta mRNA of human periodontal ligament cell stimulated by lipopolysaccharides].	oxymatrine	16-26	interleukin 6	Homo sapiens	44-57
21365847-0	2010	[The effects of oxymatrine on expression of interleukin-6 and interleukin-1beta mRNA of human periodontal ligament cell stimulated by lipopolysaccharides].	oxymatrine	16-26	interleukin 1 beta	Homo sapiens	62-79
21365847-1	2010	OBJECTIVE: To observe the effects of oxymatrine on the expression of interleukin-6 (IL-6), interleukin-1beta (IL-1beta) mRNA of human periodontal ligament cell (PDLC) stimulated by lipopolysaccharides (LPS), and to discuss oxymatrine"s inhibition mechanism on periodontal inflammation stimulated by LPS.	oxymatrine	37-47	interleukin 6	Homo sapiens	69-82
21365847-1	2010	OBJECTIVE: To observe the effects of oxymatrine on the expression of interleukin-6 (IL-6), interleukin-1beta (IL-1beta) mRNA of human periodontal ligament cell (PDLC) stimulated by lipopolysaccharides (LPS), and to discuss oxymatrine"s inhibition mechanism on periodontal inflammation stimulated by LPS.	oxymatrine	37-47	interleukin 6	Homo sapiens	84-88
21365847-1	2010	OBJECTIVE: To observe the effects of oxymatrine on the expression of interleukin-6 (IL-6), interleukin-1beta (IL-1beta) mRNA of human periodontal ligament cell (PDLC) stimulated by lipopolysaccharides (LPS), and to discuss oxymatrine"s inhibition mechanism on periodontal inflammation stimulated by LPS.	oxymatrine	37-47	interleukin 1 beta	Homo sapiens	91-108
21365847-1	2010	OBJECTIVE: To observe the effects of oxymatrine on the expression of interleukin-6 (IL-6), interleukin-1beta (IL-1beta) mRNA of human periodontal ligament cell (PDLC) stimulated by lipopolysaccharides (LPS), and to discuss oxymatrine"s inhibition mechanism on periodontal inflammation stimulated by LPS.	oxymatrine	37-47	interleukin 1 beta	Homo sapiens	110-118
21365847-5	2010	CONCLUSION: Oxymatrine can restrain the expression of IL-6 and IL-1beta mRNA of human PDLC stimulated by LPS.	oxymatrine	12-22	interleukin 6	Homo sapiens	54-58
21365847-5	2010	CONCLUSION: Oxymatrine can restrain the expression of IL-6 and IL-1beta mRNA of human PDLC stimulated by LPS.	oxymatrine	12-22	interleukin 1 beta	Homo sapiens	63-71
21078266-0	2010	[Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells].	oxymatrine	12-22	vascular endothelial growth factor A	Homo sapiens	102-136
20524938-5	2010	Interactions between matrine or oxymatrine and human constitutive androstane (CAR), pregnane X receptor were evaluated by means of the reporter gene assay in CV-1 cells.	oxymatrine	32-42	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	78-81
20524938-6	2010	Our study showed that matrine and oxymatrine significantly induced the activity and gene expression of CYP2B1 in a dose-dependent manner; matrine (150 mg/kg) slightly induced the mRNA and protein expression of CYP2E1 and mildly inhibited the mRNA and protein expression of CYP3A1 in rats.	oxymatrine	34-44	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	103-109
20524938-6	2010	Our study showed that matrine and oxymatrine significantly induced the activity and gene expression of CYP2B1 in a dose-dependent manner; matrine (150 mg/kg) slightly induced the mRNA and protein expression of CYP2E1 and mildly inhibited the mRNA and protein expression of CYP3A1 in rats.	oxymatrine	34-44	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	210-216
20524938-6	2010	Our study showed that matrine and oxymatrine significantly induced the activity and gene expression of CYP2B1 in a dose-dependent manner; matrine (150 mg/kg) slightly induced the mRNA and protein expression of CYP2E1 and mildly inhibited the mRNA and protein expression of CYP3A1 in rats.	oxymatrine	34-44	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	273-279
20524938-7	2010	Matrine or oxymatrine could activate human CAR and induce the CYP2B reporter construct in CV-1 cells.	oxymatrine	11-21	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	43-46
20524938-7	2010	Matrine or oxymatrine could activate human CAR and induce the CYP2B reporter construct in CV-1 cells.	oxymatrine	11-21	cytochrome P450 family 2 subfamily B member 7, pseudogene	Homo sapiens	62-67
20524938-8	2010	These results reveal that matrine and oxymatrine can induce the activity and expression of CYP2B1/2 in rats, and the underlying mechanism may be related to the activation of CAR.	oxymatrine	38-48	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	91-97
20524938-8	2010	These results reveal that matrine and oxymatrine can induce the activity and expression of CYP2B1/2 in rats, and the underlying mechanism may be related to the activation of CAR.	oxymatrine	38-48	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	174-177
21078266-0	2010	[Effects of oxymatrine injection combined with low-dose paclitaxel on mRNA and protein expressions of vascular endothelial growth factor and CXC chemokine receptor 4 in human gastric carcinoma SGC-7901 cells].	oxymatrine	12-22	C-X-C motif chemokine receptor 4	Homo sapiens	141-165
21078266-1	2010	OBJECTIVE: To investigate the effects of oxymatrine injection (OI) combined with low-dose paclitaxel on expressions of mRNAs and proteins of vascular endothelial growth factor (VEGF) and CXC chemokine receptor 4 (CXCR4) in human gastric carcinoma SGC-7901 cells.	oxymatrine	41-51	vascular endothelial growth factor A	Homo sapiens	141-175
21078266-1	2010	OBJECTIVE: To investigate the effects of oxymatrine injection (OI) combined with low-dose paclitaxel on expressions of mRNAs and proteins of vascular endothelial growth factor (VEGF) and CXC chemokine receptor 4 (CXCR4) in human gastric carcinoma SGC-7901 cells.	oxymatrine	41-51	vascular endothelial growth factor A	Homo sapiens	177-181
21078266-1	2010	OBJECTIVE: To investigate the effects of oxymatrine injection (OI) combined with low-dose paclitaxel on expressions of mRNAs and proteins of vascular endothelial growth factor (VEGF) and CXC chemokine receptor 4 (CXCR4) in human gastric carcinoma SGC-7901 cells.	oxymatrine	41-51	C-X-C motif chemokine receptor 4	Homo sapiens	187-211
21078266-1	2010	OBJECTIVE: To investigate the effects of oxymatrine injection (OI) combined with low-dose paclitaxel on expressions of mRNAs and proteins of vascular endothelial growth factor (VEGF) and CXC chemokine receptor 4 (CXCR4) in human gastric carcinoma SGC-7901 cells.	oxymatrine	41-51	C-X-C motif chemokine receptor 4	Homo sapiens	213-218
20587445-0	2010	Oxymatrine inhibits development of morphine-induced tolerance associated with decreased expression of P-glycoprotein in rats.	oxymatrine	0-10	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	102-116
20813689-8	2010	CONCLUSION: The effect of oxymatrine against hepatic fibrosis is mediated by lowering the levels of TGF-beta1 and TNF-alpha and increasing the level of IL-10 in CHB patients.	oxymatrine	26-36	transforming growth factor beta 1	Homo sapiens	100-109
20813689-8	2010	CONCLUSION: The effect of oxymatrine against hepatic fibrosis is mediated by lowering the levels of TGF-beta1 and TNF-alpha and increasing the level of IL-10 in CHB patients.	oxymatrine	26-36	tumor necrosis factor	Homo sapiens	114-123
20813689-8	2010	CONCLUSION: The effect of oxymatrine against hepatic fibrosis is mediated by lowering the levels of TGF-beta1 and TNF-alpha and increasing the level of IL-10 in CHB patients.	oxymatrine	26-36	interleukin 10	Homo sapiens	152-157
20124987-0	2010	The role of endogenous reactive oxygen species in oxymatrine-induced caspase-3-dependent apoptosis in human melanoma A375 cells.	oxymatrine	50-60	caspase 3	Homo sapiens	69-78
20124987-5	2010	In addition, oxymatrine induced a remarkable change in mitochondrial membrane potential and triggered the release of cytochrome c from mitochondria to cytosol.	oxymatrine	13-23	cytochrome c, somatic	Homo sapiens	117-129
20124987-6	2010	Furthermore, this small compound resulted in a marked activation of capase-3, caspase-9, and poly (ADP-ribose) polymerase, while caspase-3 inhibitor Z-DEVD-FMK significantly reversed the proapoptotic effect of oxymatrine in A375 cells.	oxymatrine	210-220	poly(ADP-ribose) polymerase 1	Homo sapiens	93-121
20124987-6	2010	Furthermore, this small compound resulted in a marked activation of capase-3, caspase-9, and poly (ADP-ribose) polymerase, while caspase-3 inhibitor Z-DEVD-FMK significantly reversed the proapoptotic effect of oxymatrine in A375 cells.	oxymatrine	210-220	caspase 3	Homo sapiens	129-138
20124987-8	2010	In conclusion, our findings suggest that oxymatrine triggers oxidative stress, resulting in the collapse of the mitochondrial transmembrane potential, which in turn leads to cytochrome c release and apoptosis through the intrinsic caspase-9/caspase-3 pathway in human melanoma A375 cells.	oxymatrine	41-51	cytochrome c, somatic	Homo sapiens	174-186
20124987-8	2010	In conclusion, our findings suggest that oxymatrine triggers oxidative stress, resulting in the collapse of the mitochondrial transmembrane potential, which in turn leads to cytochrome c release and apoptosis through the intrinsic caspase-9/caspase-3 pathway in human melanoma A375 cells.	oxymatrine	41-51	caspase 9	Homo sapiens	231-240
20124987-8	2010	In conclusion, our findings suggest that oxymatrine triggers oxidative stress, resulting in the collapse of the mitochondrial transmembrane potential, which in turn leads to cytochrome c release and apoptosis through the intrinsic caspase-9/caspase-3 pathway in human melanoma A375 cells.	oxymatrine	41-51	caspase 3	Homo sapiens	241-250
20587445-4	2010	A high dose of oxymatrine (30 mg/kg) also significantly inhibited the dramatic increase in expression of morphine-induced P-glycoprotein (P-gp), an ATP-dependent efflux pump acting at the blood-brain barrier, by Western blot analysis.	oxymatrine	15-25	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	122-136
20587445-4	2010	A high dose of oxymatrine (30 mg/kg) also significantly inhibited the dramatic increase in expression of morphine-induced P-glycoprotein (P-gp), an ATP-dependent efflux pump acting at the blood-brain barrier, by Western blot analysis.	oxymatrine	15-25	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	138-142
20587445-6	2010	These results imply that oxymatrine prevention of the development of tolerance of morphine may be related to a considerable inhibition of P-gp expression.	oxymatrine	25-35	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	138-142
19771878-7	2009	CONCLUSION: Oxymatrine could notably inhibit the HepG2 cells proliferation probably via upregulating the expression of the Bax and downregulating the expression of Bcl-2 and P53.	oxymatrine	12-22	BCL2 associated X, apoptosis regulator	Homo sapiens	123-126
20176893-6	2010	Using an Hsc70 mRNA screening assay, the natural compound oxymatrine (OMTR) was found to be a selective inhibitor for Hsc70 expression.	oxymatrine	58-68	heat shock protein family A (Hsp70) member 8	Homo sapiens	9-14
20176893-6	2010	Using an Hsc70 mRNA screening assay, the natural compound oxymatrine (OMTR) was found to be a selective inhibitor for Hsc70 expression.	oxymatrine	58-68	heat shock protein family A (Hsp70) member 8	Homo sapiens	118-123
21063089-0	2010	The novel mechanism of oxymatrine affecting HERG currents at different temperatures.	oxymatrine	23-33	potassium voltage-gated channel subfamily H member 2	Homo sapiens	44-48
21063089-2	2010	Our studies were to investigate the effects of oxymatrine (one of the natural constituents extracted from Chinese herb Sophora flavescens Ait) on hERG-encoded K(+) channels at different temperatures and its underlying mechanism.	oxymatrine	47-57	ETS transcription factor ERG	Homo sapiens	146-150
21063089-3	2010	METHODS: The effects of oxymatrine were examined on hERG channels stably expressed in HEK293 cells using a whole-cell patch clamp technique.	oxymatrine	24-34	ETS transcription factor ERG	Homo sapiens	52-56
21063089-4	2010	RESULTS: At the temperature 30 C, oxymatrine inhibited hERG current in a concentration-dependent manner and the IC(50) was ~665 muM.	oxymatrine	34-44	ETS transcription factor ERG	Homo sapiens	55-59
21063089-4	2010	RESULTS: At the temperature 30 C, oxymatrine inhibited hERG current in a concentration-dependent manner and the IC(50) was ~665 muM.	oxymatrine	34-44	latexin	Homo sapiens	128-131
21063089-5	2010	However at the temperature of 20 C, low concentration oxymatrine C&lt;=100 muM increased hERG current density.	oxymatrine	54-64	latexin	Homo sapiens	75-78
21063089-5	2010	However at the temperature of 20 C, low concentration oxymatrine C&lt;=100 muM increased hERG current density.	oxymatrine	54-64	ETS transcription factor ERG	Homo sapiens	89-93
21063089-6	2010	However, high concentration oxymatrine C&gt;100 muM inhibited the hERG current density significantly.	oxymatrine	28-38	latexin	Homo sapiens	48-51
21063089-6	2010	However, high concentration oxymatrine C&gt;100 muM inhibited the hERG current density significantly.	oxymatrine	28-38	ETS transcription factor ERG	Homo sapiens	66-70
21063089-7	2010	Oxymatrine only affected the activation kinetic of hERG channels at all temperatures and had a high binding affinity for open state of hERG channels except the 300 muM-20 C group which had a high binding affinity for inactive state of hERG channels.	oxymatrine	0-10	ETS transcription factor ERG	Homo sapiens	51-55
21063089-7	2010	Oxymatrine only affected the activation kinetic of hERG channels at all temperatures and had a high binding affinity for open state of hERG channels except the 300 muM-20 C group which had a high binding affinity for inactive state of hERG channels.	oxymatrine	0-10	ETS transcription factor ERG	Homo sapiens	135-139
21063089-7	2010	Oxymatrine only affected the activation kinetic of hERG channels at all temperatures and had a high binding affinity for open state of hERG channels except the 300 muM-20 C group which had a high binding affinity for inactive state of hERG channels.	oxymatrine	0-10	ETS transcription factor ERG	Homo sapiens	135-139
21063089-8	2010	CONCLUSION: Oxymatrine is a low potency blocker of hERG K+ channels at 30 C, low concentration oxymatrine affect the hERG activation gating with accelerating hERG tail current at 20 C, oxymatrine is a potential hERG activator at low temperatures.	oxymatrine	12-22	ETS transcription factor ERG	Homo sapiens	51-55
21063089-8	2010	CONCLUSION: Oxymatrine is a low potency blocker of hERG K+ channels at 30 C, low concentration oxymatrine affect the hERG activation gating with accelerating hERG tail current at 20 C, oxymatrine is a potential hERG activator at low temperatures.	oxymatrine	12-22	ETS transcription factor ERG	Homo sapiens	117-121
21063089-8	2010	CONCLUSION: Oxymatrine is a low potency blocker of hERG K+ channels at 30 C, low concentration oxymatrine affect the hERG activation gating with accelerating hERG tail current at 20 C, oxymatrine is a potential hERG activator at low temperatures.	oxymatrine	12-22	ETS transcription factor ERG	Homo sapiens	117-121
21063089-8	2010	CONCLUSION: Oxymatrine is a low potency blocker of hERG K+ channels at 30 C, low concentration oxymatrine affect the hERG activation gating with accelerating hERG tail current at 20 C, oxymatrine is a potential hERG activator at low temperatures.	oxymatrine	12-22	ETS transcription factor ERG	Homo sapiens	117-121
21063089-8	2010	CONCLUSION: Oxymatrine is a low potency blocker of hERG K+ channels at 30 C, low concentration oxymatrine affect the hERG activation gating with accelerating hERG tail current at 20 C, oxymatrine is a potential hERG activator at low temperatures.	oxymatrine	95-105	ETS transcription factor ERG	Homo sapiens	117-121
21063089-8	2010	CONCLUSION: Oxymatrine is a low potency blocker of hERG K+ channels at 30 C, low concentration oxymatrine affect the hERG activation gating with accelerating hERG tail current at 20 C, oxymatrine is a potential hERG activator at low temperatures.	oxymatrine	95-105	ETS transcription factor ERG	Homo sapiens	117-121
21063089-8	2010	CONCLUSION: Oxymatrine is a low potency blocker of hERG K+ channels at 30 C, low concentration oxymatrine affect the hERG activation gating with accelerating hERG tail current at 20 C, oxymatrine is a potential hERG activator at low temperatures.	oxymatrine	95-105	ETS transcription factor ERG	Homo sapiens	117-121
20349727-6	2010	TNF-alpha and IL-6 levels in pulmonary tissue homogenate decreased markedly (TNF-alpha decreased 36%, 26%, 16% and IL-6 decreased 46%, 39%, 24% on CLP + OMT 52, 26 mg x kg(-1) and 13 mg x kg(-1) groups.	oxymatrine	153-156	tumor necrosis factor	Rattus norvegicus	0-9
20349727-6	2010	TNF-alpha and IL-6 levels in pulmonary tissue homogenate decreased markedly (TNF-alpha decreased 36%, 26%, 16% and IL-6 decreased 46%, 39%, 24% on CLP + OMT 52, 26 mg x kg(-1) and 13 mg x kg(-1) groups.	oxymatrine	153-156	interleukin 6	Rattus norvegicus	14-18
20349727-6	2010	TNF-alpha and IL-6 levels in pulmonary tissue homogenate decreased markedly (TNF-alpha decreased 36%, 26%, 16% and IL-6 decreased 46%, 39%, 24% on CLP + OMT 52, 26 mg x kg(-1) and 13 mg x kg(-1) groups.	oxymatrine	153-156	interleukin 6	Rattus norvegicus	115-119
19812878-8	2010	The results also indicated that oxymatrine was the least active compound for inhibition of AChE and ATPase.	oxymatrine	32-42	acetylcholinesterase	Apis mellifera	91-95
20654016-13	2010	Compared with normal control group 2, captopril group and oxymatrine group, CVF levels and the expressions of TGF-beta1 were significantly increased in CVMC control group (P &lt; 0.01 for all comparisons) on day 70.	oxymatrine	58-68	transforming growth factor, beta 1	Mus musculus	110-119
20654016-15	2010	CONCLUSION: Oxymatrine can inhibit myocardial fibrosis in CVMC, and the mechanisms of its antifibrotic effects might be related with the down-regulation of TGF-beta1 expression.	oxymatrine	12-22	transforming growth factor, beta 1	Mus musculus	156-165
21063089-8	2010	CONCLUSION: Oxymatrine is a low potency blocker of hERG K+ channels at 30 C, low concentration oxymatrine affect the hERG activation gating with accelerating hERG tail current at 20 C, oxymatrine is a potential hERG activator at low temperatures.	oxymatrine	185-195	ETS transcription factor ERG	Homo sapiens	117-121
21063089-8	2010	CONCLUSION: Oxymatrine is a low potency blocker of hERG K+ channels at 30 C, low concentration oxymatrine affect the hERG activation gating with accelerating hERG tail current at 20 C, oxymatrine is a potential hERG activator at low temperatures.	oxymatrine	185-195	ETS transcription factor ERG	Homo sapiens	117-121
21063089-8	2010	CONCLUSION: Oxymatrine is a low potency blocker of hERG K+ channels at 30 C, low concentration oxymatrine affect the hERG activation gating with accelerating hERG tail current at 20 C, oxymatrine is a potential hERG activator at low temperatures.	oxymatrine	185-195	ETS transcription factor ERG	Homo sapiens	117-121
19567170-0	2009	Effect of oxymatrine on the p38 mitogen-activated protein kinases signalling pathway in rats with CCl4 induced hepatic fibrosis.	oxymatrine	10-20	mitogen activated protein kinase 14	Rattus norvegicus	28-31
19567170-2	2009	This study explored the antifibrotic effect of oxymatrine on tetrachloromethane induced liver fibrosis in rats and its modulation on the p38 MAPK signalling pathway.	oxymatrine	47-57	mitogen activated protein kinase 14	Rattus norvegicus	137-140
19567170-8	2009	CONCLUSIONS: Oxymatrine is effective in reducing the production and deposition of collagen in the liver tissue of experimental rats in ways which relate to modulating the fibrogenic signal transduction via p38 MAPK signalling pathway.	oxymatrine	13-23	mitogen activated protein kinase 14	Rattus norvegicus	206-209
19771878-7	2009	CONCLUSION: Oxymatrine could notably inhibit the HepG2 cells proliferation probably via upregulating the expression of the Bax and downregulating the expression of Bcl-2 and P53.	oxymatrine	12-22	BCL2 apoptosis regulator	Homo sapiens	164-169
19771878-7	2009	CONCLUSION: Oxymatrine could notably inhibit the HepG2 cells proliferation probably via upregulating the expression of the Bax and downregulating the expression of Bcl-2 and P53.	oxymatrine	12-22	tumor protein p53	Homo sapiens	174-177
19166015-0	2008	[Effect of matrine and oxymatrine on proliferation and expression of Stat3 and Stat5 in SMMC-7721 cell line].	oxymatrine	23-33	signal transducer and activator of transcription 3	Homo sapiens	69-74
18775799-2	2008	The comparative study showed that all sophora alkaloids tested here, including matrine, oxymatrine, sophocarpine, sophoramine, and sophoridine, inhibited TNF-alpha and IL-6 production in both RAW264.7 cells and murine primary macrophages, and sophocarpine showed the most potent inhibitory effect among them.	oxymatrine	88-98	tumor necrosis factor	Mus musculus	154-163
18775799-2	2008	The comparative study showed that all sophora alkaloids tested here, including matrine, oxymatrine, sophocarpine, sophoramine, and sophoridine, inhibited TNF-alpha and IL-6 production in both RAW264.7 cells and murine primary macrophages, and sophocarpine showed the most potent inhibitory effect among them.	oxymatrine	88-98	interleukin 6	Mus musculus	168-172
20182634-0	2009	Oxymatrine downregulates TLR4, TLR2, MyD88, and NF-kappaB and protects rat brains against focal ischemia.	oxymatrine	0-10	toll-like receptor 4	Rattus norvegicus	25-29
20182634-0	2009	Oxymatrine downregulates TLR4, TLR2, MyD88, and NF-kappaB and protects rat brains against focal ischemia.	oxymatrine	0-10	toll-like receptor 2	Rattus norvegicus	31-35
20182634-0	2009	Oxymatrine downregulates TLR4, TLR2, MyD88, and NF-kappaB and protects rat brains against focal ischemia.	oxymatrine	0-10	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	37-42
19166015-0	2008	[Effect of matrine and oxymatrine on proliferation and expression of Stat3 and Stat5 in SMMC-7721 cell line].	oxymatrine	23-33	signal transducer and activator of transcription 5A	Homo sapiens	79-84
19166015-3	2008	RESULT: Matrine and oxymatrine could inhibit the proliferation and induce the apoptosis of SMMC-7721 cells and it was time and dose dependent, the expression of Stat3 and Stat5 mRNA in SMMC-7721 cell with matrine and oxymatrine were significantly lower than those in control group (P&lt;0.05 or P&lt;0.01).	oxymatrine	20-30	signal transducer and activator of transcription 3	Homo sapiens	161-166
19166015-3	2008	RESULT: Matrine and oxymatrine could inhibit the proliferation and induce the apoptosis of SMMC-7721 cells and it was time and dose dependent, the expression of Stat3 and Stat5 mRNA in SMMC-7721 cell with matrine and oxymatrine were significantly lower than those in control group (P&lt;0.05 or P&lt;0.01).	oxymatrine	20-30	signal transducer and activator of transcription 5A	Homo sapiens	171-176
19166015-3	2008	RESULT: Matrine and oxymatrine could inhibit the proliferation and induce the apoptosis of SMMC-7721 cells and it was time and dose dependent, the expression of Stat3 and Stat5 mRNA in SMMC-7721 cell with matrine and oxymatrine were significantly lower than those in control group (P&lt;0.05 or P&lt;0.01).	oxymatrine	217-227	signal transducer and activator of transcription 3	Homo sapiens	161-166
19166015-3	2008	RESULT: Matrine and oxymatrine could inhibit the proliferation and induce the apoptosis of SMMC-7721 cells and it was time and dose dependent, the expression of Stat3 and Stat5 mRNA in SMMC-7721 cell with matrine and oxymatrine were significantly lower than those in control group (P&lt;0.05 or P&lt;0.01).	oxymatrine	217-227	signal transducer and activator of transcription 5A	Homo sapiens	171-176
19166015-5	2008	CONCLUSION: Matrine and oxymatrine inhibited the proliferation and induced the of SMMC-7721 cells significantly, the mechanism of which might be related to the down-regulation of stat3 and stat5 mRNA and inhibition of the signaling transduction pathway.	oxymatrine	24-34	signal transducer and activator of transcription 3	Homo sapiens	179-184
19166015-5	2008	CONCLUSION: Matrine and oxymatrine inhibited the proliferation and induced the of SMMC-7721 cells significantly, the mechanism of which might be related to the down-regulation of stat3 and stat5 mRNA and inhibition of the signaling transduction pathway.	oxymatrine	24-34	signal transducer and activator of transcription 5A	Homo sapiens	189-194
18684219-6	2008	In addition, bleomycin injection resulted in a marked increase of myeloperoxidase activity and malondialdehyde level that was attenuated by oxymatrine.	oxymatrine	140-150	myeloperoxidase	Mus musculus	66-81
18684219-7	2008	Administration of oxymatrine inhibited the proliferation of murine lung fibroblasts, arrested the cells at G(0)/G(1) phase and reduced the expression of cell cycle regulatory protein, cyclin D1 in vitro.	oxymatrine	18-28	cyclin D1	Mus musculus	184-193
18395914-0	2008	Effect of Oxymatrine on the TGFbeta-Smad signaling pathway in rats with CCl4-induced hepatic fibrosis.	oxymatrine	10-20	SMAD family member 7	Rattus norvegicus	36-40
18704302-4	2008	The level of IL-2 was increased and that of IL-10 was decreased in colon tissue in the rat model, which was reversed by the treatment of oxymatrine.	oxymatrine	137-147	interleukin 2	Rattus norvegicus	13-17
18704302-4	2008	The level of IL-2 was increased and that of IL-10 was decreased in colon tissue in the rat model, which was reversed by the treatment of oxymatrine.	oxymatrine	137-147	interleukin 10	Rattus norvegicus	44-49
18704302-5	2008	Moreover, the elevated expression of NF-kappaB p65 in colon tissue in the model was also improved by oxymatrine treatment.	oxymatrine	101-111	synaptotagmin 1	Rattus norvegicus	47-50
18704302-6	2008	Our results suggest that oxymatrine might be beneficial for the abnormal immune responses and inflammation by regulating the unbalance of Th1 and Th2 cytokines secretion and inhibiting the expression of NF-kappaB p65 in colon tissue.	oxymatrine	25-35	synaptotagmin 1	Rattus norvegicus	213-216
18395914-0	2008	Effect of Oxymatrine on the TGFbeta-Smad signaling pathway in rats with CCl4-induced hepatic fibrosis.	oxymatrine	10-20	transforming growth factor, beta 1	Rattus norvegicus	28-35
18704302-0	2008	Oxymatrine improves TNBS-induced colitis in rats by inhibiting the expression of NF-kappaB p65.	oxymatrine	0-10	synaptotagmin 1	Rattus norvegicus	91-94
18389484-6	2008	The beneficial effects of oxymatrine were likely mediated by an inhibition of lipid peroxidation (MDA production) and an increase in endogenous antioxidant activity (SOD), activation of the survival signaling molecule (Bcl-2), and a reduction of apoptotic mediator (Fas) and intracellular Ca2+ overload.	oxymatrine	26-36	BCL2, apoptosis regulator	Rattus norvegicus	219-224
18395914-0	2008	Effect of Oxymatrine on the TGFbeta-Smad signaling pathway in rats with CCl4-induced hepatic fibrosis.	oxymatrine	10-20	C-C motif chemokine ligand 4	Rattus norvegicus	72-76
18395914-1	2008	AIM: To explore the anti-fibrotic effect of Oxymatrine on CCl4-induced liver fibrosis in rats and its modulation on the TGFbeta-Smad signaling pathway.	oxymatrine	44-54	C-C motif chemokine ligand 4	Rattus norvegicus	58-62
18395914-1	2008	AIM: To explore the anti-fibrotic effect of Oxymatrine on CCl4-induced liver fibrosis in rats and its modulation on the TGFbeta-Smad signaling pathway.	oxymatrine	44-54	transforming growth factor, beta 1	Rattus norvegicus	120-127
18395914-1	2008	AIM: To explore the anti-fibrotic effect of Oxymatrine on CCl4-induced liver fibrosis in rats and its modulation on the TGFbeta-Smad signaling pathway.	oxymatrine	44-54	SMAD family member 7	Rattus norvegicus	128-132
18395914-16	2008	Oxymatrine could promote the expression of Smad 7 and inhibit the expression of Smad 3 and CBP in CCl4-induced hepatic fibrosis in SD rats, could modulate the fibrogenic signal transduction of TGFbeta-Smad pathway.	oxymatrine	0-10	SMAD family member 7	Rattus norvegicus	43-49
18395914-16	2008	Oxymatrine could promote the expression of Smad 7 and inhibit the expression of Smad 3 and CBP in CCl4-induced hepatic fibrosis in SD rats, could modulate the fibrogenic signal transduction of TGFbeta-Smad pathway.	oxymatrine	0-10	SMAD family member 3	Rattus norvegicus	80-86
18395914-16	2008	Oxymatrine could promote the expression of Smad 7 and inhibit the expression of Smad 3 and CBP in CCl4-induced hepatic fibrosis in SD rats, could modulate the fibrogenic signal transduction of TGFbeta-Smad pathway.	oxymatrine	0-10	CREB binding protein	Rattus norvegicus	91-94
18395914-16	2008	Oxymatrine could promote the expression of Smad 7 and inhibit the expression of Smad 3 and CBP in CCl4-induced hepatic fibrosis in SD rats, could modulate the fibrogenic signal transduction of TGFbeta-Smad pathway.	oxymatrine	0-10	C-C motif chemokine ligand 4	Rattus norvegicus	98-102
18395914-16	2008	Oxymatrine could promote the expression of Smad 7 and inhibit the expression of Smad 3 and CBP in CCl4-induced hepatic fibrosis in SD rats, could modulate the fibrogenic signal transduction of TGFbeta-Smad pathway.	oxymatrine	0-10	transforming growth factor, beta 1	Rattus norvegicus	193-200
18395914-16	2008	Oxymatrine could promote the expression of Smad 7 and inhibit the expression of Smad 3 and CBP in CCl4-induced hepatic fibrosis in SD rats, could modulate the fibrogenic signal transduction of TGFbeta-Smad pathway.	oxymatrine	0-10	SMAD family member 7	Rattus norvegicus	43-47
18418962-8	2008	CONCLUSION: Oxymatrine could lower the levels of cytokines, including TGF-beta1, IL-6, etc.	oxymatrine	12-22	transforming growth factor beta 1	Homo sapiens	70-79
18418962-8	2008	CONCLUSION: Oxymatrine could lower the levels of cytokines, including TGF-beta1, IL-6, etc.	oxymatrine	12-22	interleukin 6	Homo sapiens	81-85
17518040-0	2007	[Effects of matrine, oxymatrine and resveratrol on HERG channel expression].	oxymatrine	21-31	potassium voltage-gated channel subfamily H member 2	Homo sapiens	51-55
18820869-9	2008	Moreover, oxymatrine inhibited the production of lipid peroxides (LPO), decreased the serum levels of tumor necrosis factor (TNF)-alpha, and downregulated expression of phosphorylated p38 mitogen-activated protein kinase, Fas, and FasL, which had been elevated by I/R.	oxymatrine	10-20	tumor necrosis factor	Rattus norvegicus	102-135
18820869-9	2008	Moreover, oxymatrine inhibited the production of lipid peroxides (LPO), decreased the serum levels of tumor necrosis factor (TNF)-alpha, and downregulated expression of phosphorylated p38 mitogen-activated protein kinase, Fas, and FasL, which had been elevated by I/R.	oxymatrine	10-20	Fas ligand	Rattus norvegicus	231-235
17988533-4	2007	RESULTS: Shorten the course of the disease of the patients in the oxymatrine treatment group, make an improvement after the recovery and obviously reduce the magnitude of serum urination-regulated protein (THP) and beta(2) microglobulin and show a striking difference in magnitude of serum IL-15 and sICAM-1 after the treatment compared with that of the patients in the control group.	oxymatrine	66-76	beta-2-microglobulin	Homo sapiens	215-236
17988533-4	2007	RESULTS: Shorten the course of the disease of the patients in the oxymatrine treatment group, make an improvement after the recovery and obviously reduce the magnitude of serum urination-regulated protein (THP) and beta(2) microglobulin and show a striking difference in magnitude of serum IL-15 and sICAM-1 after the treatment compared with that of the patients in the control group.	oxymatrine	66-76	interleukin 15	Homo sapiens	290-295
17518040-1	2007	Because HERG potassium channel has important effects on both proarrhythmia and antiarrhythmia, we use immunofluorescence and Western blotting methods to detect the expression of HERG channel of HERG-HEK cells in different concentrations of matrine, oxymatrine and resveratrol.	oxymatrine	249-259	potassium voltage-gated channel subfamily H member 2	Homo sapiens	178-182
17518040-1	2007	Because HERG potassium channel has important effects on both proarrhythmia and antiarrhythmia, we use immunofluorescence and Western blotting methods to detect the expression of HERG channel of HERG-HEK cells in different concentrations of matrine, oxymatrine and resveratrol.	oxymatrine	249-259	potassium voltage-gated channel subfamily H member 2	Homo sapiens	178-182
17518040-2	2007	The findings showed that both matrine (1 micromol x L(-1) ) and oxymatrine ( 1micromol x L (-1) ) increased HERG channel expression ( n = 5, P &lt; 0.	oxymatrine	64-74	potassium voltage-gated channel subfamily H member 2	Homo sapiens	108-112
17518040-5	2007	In conclusion, different concentrations of matrine and oxymatrine affect HERG channel expression, while there is no relationship between resveratrol and HERG channel expression.	oxymatrine	55-65	potassium voltage-gated channel subfamily H member 2	Homo sapiens	73-77
16458489-2	2006	To investigate the possible mechanism of oxymatrine"s role on cancer cells, in the present study, we examined further the effects of oxymatrine on the growth, proliferation, apoptosis and expression of bcl-2 and p53 gene in human hepatoma SMMC-7721 cells in vitro.	oxymatrine	41-51	BCL2 apoptosis regulator	Homo sapiens	202-207
16458489-2	2006	To investigate the possible mechanism of oxymatrine"s role on cancer cells, in the present study, we examined further the effects of oxymatrine on the growth, proliferation, apoptosis and expression of bcl-2 and p53 gene in human hepatoma SMMC-7721 cells in vitro.	oxymatrine	41-51	tumor protein p53	Homo sapiens	212-215
16458489-2	2006	To investigate the possible mechanism of oxymatrine"s role on cancer cells, in the present study, we examined further the effects of oxymatrine on the growth, proliferation, apoptosis and expression of bcl-2 and p53 gene in human hepatoma SMMC-7721 cells in vitro.	oxymatrine	133-143	BCL2 apoptosis regulator	Homo sapiens	202-207
16458489-2	2006	To investigate the possible mechanism of oxymatrine"s role on cancer cells, in the present study, we examined further the effects of oxymatrine on the growth, proliferation, apoptosis and expression of bcl-2 and p53 gene in human hepatoma SMMC-7721 cells in vitro.	oxymatrine	133-143	tumor protein p53	Homo sapiens	212-215
16458489-6	2006	Oxymatrine induce apoptosis of SMMC-7721 cells and apoptotic rate amount to about 60% after treatment with 1.0 mg/ml oxymatrine for 48 h. We also find that oxymatrine down-regulate expression of bcl-2 gene while up-regulate expression of p53 gene.	oxymatrine	0-10	BCL2 apoptosis regulator	Homo sapiens	195-200
16458489-6	2006	Oxymatrine induce apoptosis of SMMC-7721 cells and apoptotic rate amount to about 60% after treatment with 1.0 mg/ml oxymatrine for 48 h. We also find that oxymatrine down-regulate expression of bcl-2 gene while up-regulate expression of p53 gene.	oxymatrine	0-10	tumor protein p53	Homo sapiens	238-241
16458489-6	2006	Oxymatrine induce apoptosis of SMMC-7721 cells and apoptotic rate amount to about 60% after treatment with 1.0 mg/ml oxymatrine for 48 h. We also find that oxymatrine down-regulate expression of bcl-2 gene while up-regulate expression of p53 gene.	oxymatrine	117-127	BCL2 apoptosis regulator	Homo sapiens	195-200
16458489-6	2006	Oxymatrine induce apoptosis of SMMC-7721 cells and apoptotic rate amount to about 60% after treatment with 1.0 mg/ml oxymatrine for 48 h. We also find that oxymatrine down-regulate expression of bcl-2 gene while up-regulate expression of p53 gene.	oxymatrine	117-127	tumor protein p53	Homo sapiens	238-241
16458489-6	2006	Oxymatrine induce apoptosis of SMMC-7721 cells and apoptotic rate amount to about 60% after treatment with 1.0 mg/ml oxymatrine for 48 h. We also find that oxymatrine down-regulate expression of bcl-2 gene while up-regulate expression of p53 gene.	oxymatrine	156-166	BCL2 apoptosis regulator	Homo sapiens	195-200
16458489-6	2006	Oxymatrine induce apoptosis of SMMC-7721 cells and apoptotic rate amount to about 60% after treatment with 1.0 mg/ml oxymatrine for 48 h. We also find that oxymatrine down-regulate expression of bcl-2 gene while up-regulate expression of p53 gene.	oxymatrine	156-166	tumor protein p53	Homo sapiens	238-241
16458489-7	2006	These results demonstrate that oxymatrine inhibit the proliferation and induce apoptosis of human hepatoma SMMC-7721 cells, and suggest that this effect was mediated probably by a significant cell cycle blockage in G2/M and S phase, down-regulation of bcl-2 and up-regulation of p53.	oxymatrine	31-41	BCL2 apoptosis regulator	Homo sapiens	252-257
16458489-7	2006	These results demonstrate that oxymatrine inhibit the proliferation and induce apoptosis of human hepatoma SMMC-7721 cells, and suggest that this effect was mediated probably by a significant cell cycle blockage in G2/M and S phase, down-regulation of bcl-2 and up-regulation of p53.	oxymatrine	31-41	tumor protein p53	Homo sapiens	279-282
15763380-8	2005	These findings suggest that oxymatrine has a beneficial effect on acute lung injury induced by oleic acid in mice and may inhibit the production of proinflammatory cytokine, TNF-alpha, by means of the inhibition of p38 MAPK.	oxymatrine	28-38	tumor necrosis factor	Mus musculus	174-183
16355613-0	2005	[Effect of oxymatrine on serum matrix metalloproteinase-2 and its inhibitor in patients with chronic hepatitis B and liver cirrhosis].	oxymatrine	11-21	matrix metallopeptidase 2	Homo sapiens	31-57
16355613-1	2005	OBJECTIVE: To observe the effect of oxymatrine on the level of serum matrix metalloproteinase-2 (MMP-2) and its inhibitor (TIMP-2) in patients with chronic hepatitis B (CHB) and post-hepatitis B liver cirrhosis (LC), as well as on liver fibrosis indexes as hyaluronic acid (HA), laminin (LN) and IV type collagen (IV C).	oxymatrine	36-46	matrix metallopeptidase 2	Homo sapiens	69-95
16355613-1	2005	OBJECTIVE: To observe the effect of oxymatrine on the level of serum matrix metalloproteinase-2 (MMP-2) and its inhibitor (TIMP-2) in patients with chronic hepatitis B (CHB) and post-hepatitis B liver cirrhosis (LC), as well as on liver fibrosis indexes as hyaluronic acid (HA), laminin (LN) and IV type collagen (IV C).	oxymatrine	36-46	matrix metallopeptidase 2	Homo sapiens	97-102
16355613-1	2005	OBJECTIVE: To observe the effect of oxymatrine on the level of serum matrix metalloproteinase-2 (MMP-2) and its inhibitor (TIMP-2) in patients with chronic hepatitis B (CHB) and post-hepatitis B liver cirrhosis (LC), as well as on liver fibrosis indexes as hyaluronic acid (HA), laminin (LN) and IV type collagen (IV C).	oxymatrine	36-46	TIMP metallopeptidase inhibitor 2	Homo sapiens	123-129
16355613-3	2005	RESULTS: Oxymatrine could decrease the levels of MMP-2, HA, LN and IV C in patients with severe or moderate CHB and LC of Child-pugh A, B and C grade, as compared with the data before treatment (P &lt; 0.05).	oxymatrine	9-19	matrix metallopeptidase 2	Homo sapiens	49-54
16097071-8	2005	RESULTS: Compared with DSS control group, the inflammatory symptoms and histological damages of colonic mucosa in oxymatrine-treated group were significantly improved, the serum levels of TNF-alpha, IL-6, and the expression of NF-kappaB, ICAM-1 in colonic mucosa were significantly reduced.	oxymatrine	114-124	tumor necrosis factor	Rattus norvegicus	188-197
16097071-8	2005	RESULTS: Compared with DSS control group, the inflammatory symptoms and histological damages of colonic mucosa in oxymatrine-treated group were significantly improved, the serum levels of TNF-alpha, IL-6, and the expression of NF-kappaB, ICAM-1 in colonic mucosa were significantly reduced.	oxymatrine	114-124	interleukin 6	Rattus norvegicus	199-203
16097071-8	2005	RESULTS: Compared with DSS control group, the inflammatory symptoms and histological damages of colonic mucosa in oxymatrine-treated group were significantly improved, the serum levels of TNF-alpha, IL-6, and the expression of NF-kappaB, ICAM-1 in colonic mucosa were significantly reduced.	oxymatrine	114-124	intercellular adhesion molecule 1	Rattus norvegicus	238-244
16097071-9	2005	CONCLUSION: The fact that oxymatrine can reduce the serum levels of TNF-alpha, IL-6, and the expression of NF-kappaB and ICAM-1 in colonic mucosa in DSS-induced colitis of rats indicates that oxymatrine may ameliorate the colonic inflammation and thus alleviate diarrhea and bloody stool.	oxymatrine	26-36	tumor necrosis factor	Rattus norvegicus	68-77
16097071-9	2005	CONCLUSION: The fact that oxymatrine can reduce the serum levels of TNF-alpha, IL-6, and the expression of NF-kappaB and ICAM-1 in colonic mucosa in DSS-induced colitis of rats indicates that oxymatrine may ameliorate the colonic inflammation and thus alleviate diarrhea and bloody stool.	oxymatrine	26-36	interleukin 6	Rattus norvegicus	79-83
16097071-9	2005	CONCLUSION: The fact that oxymatrine can reduce the serum levels of TNF-alpha, IL-6, and the expression of NF-kappaB and ICAM-1 in colonic mucosa in DSS-induced colitis of rats indicates that oxymatrine may ameliorate the colonic inflammation and thus alleviate diarrhea and bloody stool.	oxymatrine	26-36	intercellular adhesion molecule 1	Rattus norvegicus	121-127
17357477-0	2006	Inhibitory effect of oxymatrine on quartz-induced secretion of TNF-alpha by the pulmonary alveolar macrophages in the fibroblast proliferation.	oxymatrine	21-31	tumor necrosis factor	Rattus norvegicus	63-72
16222447-11	2005	The anti-apoptotic activity of oxymatrine depends mainly on downregulation of Fas and Fas ligand.	oxymatrine	31-41	Fas ligand	Rattus norvegicus	86-96
15763380-0	2005	Attenuation of acute lung injury in mice by oxymatrine is associated with inhibition of phosphorylated p38 mitogen-activated protein kinase.	oxymatrine	44-54	mitogen-activated protein kinase 14	Mus musculus	103-106
15763380-7	2005	Furthermore, pretreatment with oxymatrine significantly alleviated oleic acid-induced lung injury accompanied by reduction of lung index and wet-to-dry weight ratio, decreases in serum TNF-alpha level and inhibition of phosphorylated p38 MAPK.	oxymatrine	31-41	tumor necrosis factor	Mus musculus	185-194
15763380-7	2005	Furthermore, pretreatment with oxymatrine significantly alleviated oleic acid-induced lung injury accompanied by reduction of lung index and wet-to-dry weight ratio, decreases in serum TNF-alpha level and inhibition of phosphorylated p38 MAPK.	oxymatrine	31-41	mitogen-activated protein kinase 14	Mus musculus	234-242
15763380-8	2005	These findings suggest that oxymatrine has a beneficial effect on acute lung injury induced by oleic acid in mice and may inhibit the production of proinflammatory cytokine, TNF-alpha, by means of the inhibition of p38 MAPK.	oxymatrine	28-38	mitogen-activated protein kinase 14	Mus musculus	215-223
15640867-0	2004	[Effects of oxymatrine on serum levels of Th1/Th2 type cytokines in HBsAg transgenic mice].	oxymatrine	12-22	negative elongation factor complex member C/D, Th1l	Mus musculus	42-45
15667553-6	2005	CONCLUSIONS: Oxymatrine has dose-dependent killing effects on SW1116 cells and its antineoplastic activity might be attributed to inhibition of telomerase activity by means of its effects on hTERT and the upstream regulating genes.	oxymatrine	13-23	telomerase reverse transcriptase	Homo sapiens	191-196
15640867-0	2004	[Effects of oxymatrine on serum levels of Th1/Th2 type cytokines in HBsAg transgenic mice].	oxymatrine	12-22	heart and neural crest derivatives expressed 2	Mus musculus	46-49
15640867-1	2004	OBJECTIVE: To explore the effects of oxymatrine on serum levels of Th1/Th2 cytokines in HBsAg transgenic mice.	oxymatrine	37-47	negative elongation factor complex member C/D, Th1l	Mus musculus	67-70
15640867-1	2004	OBJECTIVE: To explore the effects of oxymatrine on serum levels of Th1/Th2 cytokines in HBsAg transgenic mice.	oxymatrine	37-47	heart and neural crest derivatives expressed 2	Mus musculus	71-74
15640867-6	2004	While in oxymatrine group, the levels of IFN-gamma before and after treatment were (3.108+/-3.172) pg/ml and (11.059+/-6.971) pg/ml; those of IL-4 were (29.045+/-13.235) pg/ml and (13.024+/-9.002) pg/ml (both P less than 0.001).	oxymatrine	9-19	interferon gamma	Mus musculus	41-50
15640867-6	2004	While in oxymatrine group, the levels of IFN-gamma before and after treatment were (3.108+/-3.172) pg/ml and (11.059+/-6.971) pg/ml; those of IL-4 were (29.045+/-13.235) pg/ml and (13.024+/-9.002) pg/ml (both P less than 0.001).	oxymatrine	9-19	interleukin 4	Mus musculus	142-146
15640867-7	2004	After treatment, the levels of IL-2 in control and oxymatrine group were (1.070+/-0.447) pg/ml and (5.537+/-2.887) pg/ml (P less than 0.000 1); and those of IL-10 were (97.226+/-73.306) pg/ml and (33.607+/-23.154) pg/ml (P less than 0.01).	oxymatrine	51-61	interleukin 2	Mus musculus	31-35
15640867-7	2004	After treatment, the levels of IL-2 in control and oxymatrine group were (1.070+/-0.447) pg/ml and (5.537+/-2.887) pg/ml (P less than 0.000 1); and those of IL-10 were (97.226+/-73.306) pg/ml and (33.607+/-23.154) pg/ml (P less than 0.01).	oxymatrine	51-61	interleukin 10	Mus musculus	157-162
15640867-8	2004	CONCLUSION: After injection of oxymatrine to HBsAg transgenic mice, the serum concentration of Th1 cytokines increased while the Th2 cytokines decreased.	oxymatrine	31-41	negative elongation factor complex member C/D, Th1l	Mus musculus	95-98
15640867-8	2004	CONCLUSION: After injection of oxymatrine to HBsAg transgenic mice, the serum concentration of Th1 cytokines increased while the Th2 cytokines decreased.	oxymatrine	31-41	heart and neural crest derivatives expressed 2	Mus musculus	129-132
14761294-0	2004	[Effects of Oxymatrine on the expression of tissue inhibitor of metalloproteinase-1 and alpha-smooth muscle actin in the livers of rats with hepatic fibrosis].	oxymatrine	12-22	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	44-83
15340514-0	2004	[Clinical research on the effect of Oxymatrine on serum cholinesterase].	oxymatrine	36-46	butyrylcholinesterase	Homo sapiens	56-70
15340514-1	2004	BACKGROUND: To investigate the effect of Oxymatrine (OM) on serum cholinesterase (ChE) during the treatment of viral hepatitis and the relationship between the change of ChE and the change of albumin (ALB), prothrombin activity (PTA) and other liver function tests.	oxymatrine	41-51	butyrylcholinesterase	Homo sapiens	66-80
15340514-1	2004	BACKGROUND: To investigate the effect of Oxymatrine (OM) on serum cholinesterase (ChE) during the treatment of viral hepatitis and the relationship between the change of ChE and the change of albumin (ALB), prothrombin activity (PTA) and other liver function tests.	oxymatrine	41-51	butyrylcholinesterase	Homo sapiens	82-85
14761294-0	2004	[Effects of Oxymatrine on the expression of tissue inhibitor of metalloproteinase-1 and alpha-smooth muscle actin in the livers of rats with hepatic fibrosis].	oxymatrine	12-22	actin gamma 2, smooth muscle	Rattus norvegicus	88-113
12133306-10	2002	CONCLUSIONS: Oxymatrine protects mice from fulminant hepatitis induced by GalN/LPS and may block hepatocyte apoptosis and subsequent necrosis through downregulating the production of serum tumor necrosis factor alpha and the expression of Fas and Fas ligand in liver tissue.	oxymatrine	13-23	tumor necrosis factor	Mus musculus	189-216
12423275-6	2002	RESULTS: The serum levels of IFN-gamma in transgenic mice before or after oxymatrine treatment were 3.108 +/- 3.172 and 11.059 +/- 6.971 pg/mL, respectively.	oxymatrine	74-84	interferon gamma	Mus musculus	29-38
12423275-7	2002	In contrast, serum levels before and after oxymatrine treatment for IL-4 were 29.045 +/- 13.235 and 13.024 +/- 9.002 pg/mL, respectively (P &lt; 0.001).	oxymatrine	43-53	interleukin 4	Homo sapiens	68-72
12423275-8	2002	The serum levels of IL-2 in the control (saline injection) and oxymatrine-treated mice were 1.070 +/- 0.447 and 5.537 +/- 2.887 pg/mL, respectively (P &lt; 0.0001); and that of IL-10 were 97.226 +/- 73.306 and 33.607 +/- 23.154 pg/mL, respectively (P &lt; 0.01).	oxymatrine	63-73	interleukin 2	Mus musculus	20-24
12423275-8	2002	The serum levels of IL-2 in the control (saline injection) and oxymatrine-treated mice were 1.070 +/- 0.447 and 5.537 +/- 2.887 pg/mL, respectively (P &lt; 0.0001); and that of IL-10 were 97.226 +/- 73.306 and 33.607 +/- 23.154 pg/mL, respectively (P &lt; 0.01).	oxymatrine	63-73	interleukin 10	Mus musculus	177-182
12113677-3	2002	RESULTS: There was a decline of liver hydroxyline and serum AST and ALT in oxymatrine group compared to those of the D-GalN group.	oxymatrine	75-85	galanin and GMAP prepropeptide	Rattus norvegicus	119-123
11509127-2	2001	METHODS: SMMC-7721 cells transfected with pBK-HCV using lipofectin transfection protocal were treated with oxymatrine.	oxymatrine	107-117	PDZ binding kinase	Homo sapiens	42-45
34517275-0	2021	Oxymatrine inhibits neuroinflammation byRegulating M1/M2 polarization in N9 microglia through the TLR4/NF-kappaB pathway.	oxymatrine	0-10	toll like receptor 4	Homo sapiens	98-102
34749441-8	2021	In vivo studies showed that inhibition of autophagy by oxymatrine promoted scar repair, resulting in a significantly improved final outcome of the hypertrophic scars, a smaller scar area, decreased epidermal and dermal thickness, and a significant downregulation of CK10, P63, collagen I, alpha-SMA, and TGF-beta1.	oxymatrine	55-65	keratin 10	Homo sapiens	266-270
34749441-8	2021	In vivo studies showed that inhibition of autophagy by oxymatrine promoted scar repair, resulting in a significantly improved final outcome of the hypertrophic scars, a smaller scar area, decreased epidermal and dermal thickness, and a significant downregulation of CK10, P63, collagen I, alpha-SMA, and TGF-beta1.	oxymatrine	55-65	tumor protein p63	Homo sapiens	272-275
34749441-8	2021	In vivo studies showed that inhibition of autophagy by oxymatrine promoted scar repair, resulting in a significantly improved final outcome of the hypertrophic scars, a smaller scar area, decreased epidermal and dermal thickness, and a significant downregulation of CK10, P63, collagen I, alpha-SMA, and TGF-beta1.	oxymatrine	55-65	actin alpha 1, skeletal muscle	Homo sapiens	289-298
34749441-8	2021	In vivo studies showed that inhibition of autophagy by oxymatrine promoted scar repair, resulting in a significantly improved final outcome of the hypertrophic scars, a smaller scar area, decreased epidermal and dermal thickness, and a significant downregulation of CK10, P63, collagen I, alpha-SMA, and TGF-beta1.	oxymatrine	55-65	transforming growth factor beta 1	Homo sapiens	304-313
34749441-9	2021	In summary, oxymatrine promoted hypertrophic scar repair by decreasing HSF viability and collagen, and inducing apoptosis via autophagy inhibition.	oxymatrine	12-22	interleukin 6	Homo sapiens	71-74
34517275-0	2021	Oxymatrine inhibits neuroinflammation byRegulating M1/M2 polarization in N9 microglia through the TLR4/NF-kappaB pathway.	oxymatrine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	103-112
34517275-8	2021	Immunofluorescence, flow cytometry, and western blotting were performed to evaluate the effects of OMT on the following markers of M1 and M2 microglia: CD16/32, CD206, Arginase-10 (Arg-1), and inducible nitric oxide synthase (iNOS).	oxymatrine	99-102	Fc gamma receptor IIIa	Homo sapiens	152-156
34858949-3	2021	Here, by using a combination of surface plasmon resonance, electrospray ionization mass spectrometry, circular dichroism, Western blot, luciferase assay, and reverse transcriptase stop assay, we observed a small molecule, namely, oxymatrine (OMT) that could selectively bind to the RNA G-quadruplex in 5"-untranslated regions (UTRs) of human vascular endothelial growth factor (hVEGF), but could not bind to other G-quadruplexes.	oxymatrine	230-240	vascular endothelial growth factor A	Homo sapiens	342-376
34858949-3	2021	Here, by using a combination of surface plasmon resonance, electrospray ionization mass spectrometry, circular dichroism, Western blot, luciferase assay, and reverse transcriptase stop assay, we observed a small molecule, namely, oxymatrine (OMT) that could selectively bind to the RNA G-quadruplex in 5"-untranslated regions (UTRs) of human vascular endothelial growth factor (hVEGF), but could not bind to other G-quadruplexes.	oxymatrine	230-240	vascular endothelial growth factor A	Homo sapiens	378-383
34454287-8	2021	In the in vivo study, OMT exerted allograft protective effects by prolonging survival time, alleviating pathological damages to the cardiac allograft, decreasing intragraft CD3+ cell and increasing intragraft Foxp3+ cell infiltration, decreasing the percentages of mature DCs, increasing the percentages of Tregs and Bregs, and inhibiting the function of DCs.	oxymatrine	22-25	forkhead box P3	Homo sapiens	209-214
34305593-7	2021	Furthermore, flow cytometry analysis revealed that OMT + DOX co-treatment enhanced cell apoptosis as a result of ROS generation, whereas NAC attenuated OMT + DOX-induced apoptosis.	oxymatrine	152-155	X-linked Kx blood group	Homo sapiens	137-140
34755667-0	2021	(Oxymatrine improves renal fibrosis and inflammation in diabetic rats by modulating CHK1/2 phosphorylation).	oxymatrine	1-11	checkpoint kinase 2	Rattus norvegicus	84-90
34755667-1	2021	OBJECTIVE: To explore the role of cell cycle checkpoint kinase 1/2 (CHK1/2) in mediating the inhibitory effect of oxymatrine (OMT) against renal inflammation and fibrosis in diabetic rats.	oxymatrine	114-124	checkpoint kinase 1	Rattus norvegicus	45-66
34755667-1	2021	OBJECTIVE: To explore the role of cell cycle checkpoint kinase 1/2 (CHK1/2) in mediating the inhibitory effect of oxymatrine (OMT) against renal inflammation and fibrosis in diabetic rats.	oxymatrine	114-124	checkpoint kinase 2	Rattus norvegicus	68-74
34755667-1	2021	OBJECTIVE: To explore the role of cell cycle checkpoint kinase 1/2 (CHK1/2) in mediating the inhibitory effect of oxymatrine (OMT) against renal inflammation and fibrosis in diabetic rats.	oxymatrine	126-129	checkpoint kinase 1	Rattus norvegicus	45-66
34755667-1	2021	OBJECTIVE: To explore the role of cell cycle checkpoint kinase 1/2 (CHK1/2) in mediating the inhibitory effect of oxymatrine (OMT) against renal inflammation and fibrosis in diabetic rats.	oxymatrine	126-129	checkpoint kinase 2	Rattus norvegicus	68-74
34755667-8	2021	OMT treatment significantly decreased the protein expression levels of p-CHK1, p-CHK2, Col-III, Col-IV and FN in the renal tissue of diabetic rats and in NRK-52E cells exposed to high glucose (P < 0.05).	oxymatrine	0-3	checkpoint kinase 2	Rattus norvegicus	81-85
34755667-10	2021	CONCLUSION: The inhibitory effects of OMT against renal inflammation and fibrosis in diabetic rats are mediated probably by lowered phosphorylation levels of CHK1 and CHK2, which result in reduced release of the downstream inflammatory mediators and decreased secretion and deposition of extracellular matrix.	oxymatrine	38-41	checkpoint kinase 2	Rattus norvegicus	167-171
34368883-0	2021	Oxymatrine attenuates oxidized low-density lipoprotein-induced HUVEC injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via the activation of the SIRT1/Nrf2 signaling pathway.	oxymatrine	0-10	NLR family pyrin domain containing 3	Homo sapiens	90-95
34368883-0	2021	Oxymatrine attenuates oxidized low-density lipoprotein-induced HUVEC injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via the activation of the SIRT1/Nrf2 signaling pathway.	oxymatrine	0-10	sirtuin 1	Homo sapiens	155-160
34368883-0	2021	Oxymatrine attenuates oxidized low-density lipoprotein-induced HUVEC injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via the activation of the SIRT1/Nrf2 signaling pathway.	oxymatrine	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	161-165
34368883-3	2021	The present study was undertaken to investigate whether oxymatrine attenuates oxidized low-density lipoprotein (ox-LDL)-induced human umbilical vein endothelial cell (HUVEC) injury, an in vitro cell model of atherosclerosis, by inhibiting NLRP3 inflammasome-mediated pyroptosis, and elucidate the role of the sirtuin (SIRT)1/nuclear factor-erythroid 2-related factor 2 (Nrf2) signaling pathway in this process.	oxymatrine	56-66	NLR family pyrin domain containing 3	Homo sapiens	239-244
34368883-3	2021	The present study was undertaken to investigate whether oxymatrine attenuates oxidized low-density lipoprotein (ox-LDL)-induced human umbilical vein endothelial cell (HUVEC) injury, an in vitro cell model of atherosclerosis, by inhibiting NLRP3 inflammasome-mediated pyroptosis, and elucidate the role of the sirtuin (SIRT)1/nuclear factor-erythroid 2-related factor 2 (Nrf2) signaling pathway in this process.	oxymatrine	56-66	NFE2 like bZIP transcription factor 2	Homo sapiens	317-368
34368883-3	2021	The present study was undertaken to investigate whether oxymatrine attenuates oxidized low-density lipoprotein (ox-LDL)-induced human umbilical vein endothelial cell (HUVEC) injury, an in vitro cell model of atherosclerosis, by inhibiting NLRP3 inflammasome-mediated pyroptosis, and elucidate the role of the sirtuin (SIRT)1/nuclear factor-erythroid 2-related factor 2 (Nrf2) signaling pathway in this process.	oxymatrine	56-66	NFE2 like bZIP transcription factor 2	Homo sapiens	370-374
34517275-12	2021	The results of the present study indicated that OMT inhibited the over-activation of microglia, increased the levels of the M2 marker IL-10, decreased the levels of the M1 markers NO, TNF-alpha, IL-6, and IL-1beta, promoted the polarization of N9 microglia to the M2 phenotype, and regulated M1/M2 polarization in the microglia by inhibiting TLR4/NF-kappaB signalling, which effectively attenuated the LPS-induced inflammatory response.	oxymatrine	48-51	interleukin 10	Homo sapiens	134-139
34517275-12	2021	The results of the present study indicated that OMT inhibited the over-activation of microglia, increased the levels of the M2 marker IL-10, decreased the levels of the M1 markers NO, TNF-alpha, IL-6, and IL-1beta, promoted the polarization of N9 microglia to the M2 phenotype, and regulated M1/M2 polarization in the microglia by inhibiting TLR4/NF-kappaB signalling, which effectively attenuated the LPS-induced inflammatory response.	oxymatrine	48-51	tumor necrosis factor	Homo sapiens	184-193
34517275-12	2021	The results of the present study indicated that OMT inhibited the over-activation of microglia, increased the levels of the M2 marker IL-10, decreased the levels of the M1 markers NO, TNF-alpha, IL-6, and IL-1beta, promoted the polarization of N9 microglia to the M2 phenotype, and regulated M1/M2 polarization in the microglia by inhibiting TLR4/NF-kappaB signalling, which effectively attenuated the LPS-induced inflammatory response.	oxymatrine	48-51	interleukin 6	Homo sapiens	195-199
34517275-12	2021	The results of the present study indicated that OMT inhibited the over-activation of microglia, increased the levels of the M2 marker IL-10, decreased the levels of the M1 markers NO, TNF-alpha, IL-6, and IL-1beta, promoted the polarization of N9 microglia to the M2 phenotype, and regulated M1/M2 polarization in the microglia by inhibiting TLR4/NF-kappaB signalling, which effectively attenuated the LPS-induced inflammatory response.	oxymatrine	48-51	interleukin 1 alpha	Homo sapiens	205-213
34517275-12	2021	The results of the present study indicated that OMT inhibited the over-activation of microglia, increased the levels of the M2 marker IL-10, decreased the levels of the M1 markers NO, TNF-alpha, IL-6, and IL-1beta, promoted the polarization of N9 microglia to the M2 phenotype, and regulated M1/M2 polarization in the microglia by inhibiting TLR4/NF-kappaB signalling, which effectively attenuated the LPS-induced inflammatory response.	oxymatrine	48-51	toll like receptor 4	Homo sapiens	342-346
34517275-12	2021	The results of the present study indicated that OMT inhibited the over-activation of microglia, increased the levels of the M2 marker IL-10, decreased the levels of the M1 markers NO, TNF-alpha, IL-6, and IL-1beta, promoted the polarization of N9 microglia to the M2 phenotype, and regulated M1/M2 polarization in the microglia by inhibiting TLR4/NF-kappaB signalling, which effectively attenuated the LPS-induced inflammatory response.	oxymatrine	48-51	nuclear factor kappa B subunit 1	Homo sapiens	347-356
34951180-2	2021	The present study investigated the anti-rheumatoid arthritis effect of oxymatrine(OMT), the active component of Sophorae Flavescentis Radix by observing its effect on the function of B lymphocytes in collagen-induced arthritis(CIA) mice through the Toll-like receptor 9(TLR9)/myeloid differentiation factor 88(MyD88)/signal transducer and activator of transcription 3(STAT3) pathway.	oxymatrine	71-81	toll-like receptor 9	Mus musculus	249-269
34951180-2	2021	The present study investigated the anti-rheumatoid arthritis effect of oxymatrine(OMT), the active component of Sophorae Flavescentis Radix by observing its effect on the function of B lymphocytes in collagen-induced arthritis(CIA) mice through the Toll-like receptor 9(TLR9)/myeloid differentiation factor 88(MyD88)/signal transducer and activator of transcription 3(STAT3) pathway.	oxymatrine	71-81	toll-like receptor 9	Mus musculus	270-274
34951180-2	2021	The present study investigated the anti-rheumatoid arthritis effect of oxymatrine(OMT), the active component of Sophorae Flavescentis Radix by observing its effect on the function of B lymphocytes in collagen-induced arthritis(CIA) mice through the Toll-like receptor 9(TLR9)/myeloid differentiation factor 88(MyD88)/signal transducer and activator of transcription 3(STAT3) pathway.	oxymatrine	71-81	myeloid differentiation primary response gene 88	Mus musculus	310-315
34951180-2	2021	The present study investigated the anti-rheumatoid arthritis effect of oxymatrine(OMT), the active component of Sophorae Flavescentis Radix by observing its effect on the function of B lymphocytes in collagen-induced arthritis(CIA) mice through the Toll-like receptor 9(TLR9)/myeloid differentiation factor 88(MyD88)/signal transducer and activator of transcription 3(STAT3) pathway.	oxymatrine	71-81	signal transducer and activator of transcription 3	Mus musculus	317-367
34951180-2	2021	The present study investigated the anti-rheumatoid arthritis effect of oxymatrine(OMT), the active component of Sophorae Flavescentis Radix by observing its effect on the function of B lymphocytes in collagen-induced arthritis(CIA) mice through the Toll-like receptor 9(TLR9)/myeloid differentiation factor 88(MyD88)/signal transducer and activator of transcription 3(STAT3) pathway.	oxymatrine	71-81	signal transducer and activator of transcription 3	Mus musculus	368-373
34368883-10	2021	Concurrently, oxymatrine inhibited ox-LDL-induced NLRP3 inflammasome-mediated pyroptosis in HUVECs, as evidenced by the significant decreases in the expression of NLRP3, apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC), cleaved caspase-1, interleukin (IL)-1beta and IL-18 in HUVECs.	oxymatrine	14-24	NLR family pyrin domain containing 3	Homo sapiens	50-55
34368883-10	2021	Concurrently, oxymatrine inhibited ox-LDL-induced NLRP3 inflammasome-mediated pyroptosis in HUVECs, as evidenced by the significant decreases in the expression of NLRP3, apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC), cleaved caspase-1, interleukin (IL)-1beta and IL-18 in HUVECs.	oxymatrine	14-24	NLR family pyrin domain containing 3	Homo sapiens	163-168
34368883-10	2021	Concurrently, oxymatrine inhibited ox-LDL-induced NLRP3 inflammasome-mediated pyroptosis in HUVECs, as evidenced by the significant decreases in the expression of NLRP3, apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC), cleaved caspase-1, interleukin (IL)-1beta and IL-18 in HUVECs.	oxymatrine	14-24	caspase 1	Homo sapiens	276-285
34368883-10	2021	Concurrently, oxymatrine inhibited ox-LDL-induced NLRP3 inflammasome-mediated pyroptosis in HUVECs, as evidenced by the significant decreases in the expression of NLRP3, apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC), cleaved caspase-1, interleukin (IL)-1beta and IL-18 in HUVECs.	oxymatrine	14-24	interleukin 1 alpha	Homo sapiens	287-309
34368883-10	2021	Concurrently, oxymatrine inhibited ox-LDL-induced NLRP3 inflammasome-mediated pyroptosis in HUVECs, as evidenced by the significant decreases in the expression of NLRP3, apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC), cleaved caspase-1, interleukin (IL)-1beta and IL-18 in HUVECs.	oxymatrine	14-24	interleukin 18	Homo sapiens	314-319
34368883-12	2021	Furthermore, oxymatrine promoted SIRT1/Nrf2 signaling pathway activation in HUVECs subjected to ox-LDL treatment, and SIRT1 deficiency induced by SIRT1 siRNA transfection abolished the protective effect of oxymatrine against ox-LDL-induced injury.	oxymatrine	13-23	sirtuin 1	Homo sapiens	33-38
34368883-12	2021	Furthermore, oxymatrine promoted SIRT1/Nrf2 signaling pathway activation in HUVECs subjected to ox-LDL treatment, and SIRT1 deficiency induced by SIRT1 siRNA transfection abolished the protective effect of oxymatrine against ox-LDL-induced injury.	oxymatrine	13-23	NFE2 like bZIP transcription factor 2	Homo sapiens	39-43
34368883-12	2021	Furthermore, oxymatrine promoted SIRT1/Nrf2 signaling pathway activation in HUVECs subjected to ox-LDL treatment, and SIRT1 deficiency induced by SIRT1 siRNA transfection abolished the protective effect of oxymatrine against ox-LDL-induced injury.	oxymatrine	206-216	sirtuin 1	Homo sapiens	118-123
34368883-12	2021	Furthermore, oxymatrine promoted SIRT1/Nrf2 signaling pathway activation in HUVECs subjected to ox-LDL treatment, and SIRT1 deficiency induced by SIRT1 siRNA transfection abolished the protective effect of oxymatrine against ox-LDL-induced injury.	oxymatrine	206-216	sirtuin 1	Homo sapiens	146-151
34368883-13	2021	SIRT1 siRNA also mitigated the oxymatrine-induced decreases in ROS generation and MDA content, and the increases in MMP as well as the activities of SOD, CAT and GSH-Px in HUVECs.	oxymatrine	31-41	sirtuin 1	Homo sapiens	0-5
34368883-13	2021	SIRT1 siRNA also mitigated the oxymatrine-induced decreases in ROS generation and MDA content, and the increases in MMP as well as the activities of SOD, CAT and GSH-Px in HUVECs.	oxymatrine	31-41	superoxide dismutase 1	Homo sapiens	149-152
34368883-13	2021	SIRT1 siRNA also mitigated the oxymatrine-induced decreases in ROS generation and MDA content, and the increases in MMP as well as the activities of SOD, CAT and GSH-Px in HUVECs.	oxymatrine	31-41	catalase	Homo sapiens	154-157
34368883-14	2021	Moreover, SIRT1 siRNA transfection blocked the inhibitory effect of oxymatrine on NLRP3 inflammasome-mediated pyroptosis in ox-LDL-treated HUVECs.	oxymatrine	68-78	sirtuin 1	Homo sapiens	10-15
34368883-14	2021	Moreover, SIRT1 siRNA transfection blocked the inhibitory effect of oxymatrine on NLRP3 inflammasome-mediated pyroptosis in ox-LDL-treated HUVECs.	oxymatrine	68-78	NLR family pyrin domain containing 3	Homo sapiens	82-87
34368883-15	2021	Collectively, these results indicated that oxymatrine may attenuate ox-LDL-induced HUVEC injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via activating the SIRT1/Nrf2 signaling pathway.	oxymatrine	43-53	NLR family pyrin domain containing 3	Homo sapiens	110-115
34368883-15	2021	Collectively, these results indicated that oxymatrine may attenuate ox-LDL-induced HUVEC injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via activating the SIRT1/Nrf2 signaling pathway.	oxymatrine	43-53	sirtuin 1	Homo sapiens	168-173
34368883-15	2021	Collectively, these results indicated that oxymatrine may attenuate ox-LDL-induced HUVEC injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via activating the SIRT1/Nrf2 signaling pathway.	oxymatrine	43-53	NFE2 like bZIP transcription factor 2	Homo sapiens	174-178
35609310-0	2022	Oxymatrine induces anti-tumor response in cervical cancer by modulating circ_0008460/miR-197-3p/ribonucleotide reductase subunit M2 (RRM2).	oxymatrine	0-10	microRNA 197	Homo sapiens	85-92
35609310-0	2022	Oxymatrine induces anti-tumor response in cervical cancer by modulating circ_0008460/miR-197-3p/ribonucleotide reductase subunit M2 (RRM2).	oxymatrine	0-10	ribonucleotide reductase regulatory subunit M2	Homo sapiens	96-131
35609310-0	2022	Oxymatrine induces anti-tumor response in cervical cancer by modulating circ_0008460/miR-197-3p/ribonucleotide reductase subunit M2 (RRM2).	oxymatrine	0-10	ribonucleotide reductase regulatory subunit M2	Homo sapiens	133-137
35252223-4	2021	To that end, we experimentally elucidated the role of OMT, a TGFbeta1 antagonist, that is known to play antiinflammatory and antioxidant roles in the steroid-induced glaucoma model in experimental rats, and using the enzyme-linked immunosorbent assay (ELISA), we observed a direct inhibitory effect of OMT on the pathogenesis of glaucoma.	oxymatrine	54-57	transforming growth factor, beta 1	Rattus norvegicus	61-69
34136493-0	2021	Oxymatrine Attenuates Osteoclastogenesis via Modulation of ROS-Mediated SREBP2 Signaling and Counteracts Ovariectomy-Induced Osteoporosis.	oxymatrine	0-10	sterol regulatory element binding transcription factor 2	Homo sapiens	72-78
34136493-5	2021	Further, OMT significantly suppressed RANKL-induced sterol regulatory element-binding protein 2 (SREBP2) activation and the expression of the nuclear factor of activated T cells 1 (NFATc1).	oxymatrine	9-12	sterol regulatory element binding transcription factor 2	Homo sapiens	52-95
34136493-5	2021	Further, OMT significantly suppressed RANKL-induced sterol regulatory element-binding protein 2 (SREBP2) activation and the expression of the nuclear factor of activated T cells 1 (NFATc1).	oxymatrine	9-12	sterol regulatory element binding transcription factor 2	Homo sapiens	97-103
34136493-5	2021	Further, OMT significantly suppressed RANKL-induced sterol regulatory element-binding protein 2 (SREBP2) activation and the expression of the nuclear factor of activated T cells 1 (NFATc1).	oxymatrine	9-12	nuclear factor of activated T cells 1	Homo sapiens	142-179
34136493-5	2021	Further, OMT significantly suppressed RANKL-induced sterol regulatory element-binding protein 2 (SREBP2) activation and the expression of the nuclear factor of activated T cells 1 (NFATc1).	oxymatrine	9-12	nuclear factor of activated T cells 1	Homo sapiens	181-187
34136493-6	2021	Moreover, OMT inhibited the generation of RANKL-induced reactive oxygen species (ROS), and the upregulation of ROS could rescue the inhibition of SREBP2 by OMT.	oxymatrine	10-13	TNF superfamily member 11	Homo sapiens	42-47
34136493-6	2021	Moreover, OMT inhibited the generation of RANKL-induced reactive oxygen species (ROS), and the upregulation of ROS could rescue the inhibition of SREBP2 by OMT.	oxymatrine	10-13	sterol regulatory element binding transcription factor 2	Homo sapiens	146-152
34136493-6	2021	Moreover, OMT inhibited the generation of RANKL-induced reactive oxygen species (ROS), and the upregulation of ROS could rescue the inhibition of SREBP2 by OMT.	oxymatrine	156-159	TNF superfamily member 11	Homo sapiens	42-47
34136493-6	2021	Moreover, OMT inhibited the generation of RANKL-induced reactive oxygen species (ROS), and the upregulation of ROS could rescue the inhibition of SREBP2 by OMT.	oxymatrine	156-159	sterol regulatory element binding transcription factor 2	Homo sapiens	146-152
34094027-9	2021	After the INS-1 cells were treated with oxymatrine for 12 and 24 hr, KV2.1 channel protein was up-regulated (P<0.01 vs Control).	oxymatrine	40-50	potassium voltage-gated channel subfamily B member 1	Rattus norvegicus	69-74
35477544-0	2022	Oxymatrine inhibits the pyroptosis in rat insulinoma cells by affecting nuclear factor kappa B and nuclear factor (erythroid-derived 2)-like 2 protein/heme oxygenase-1 pathways.	oxymatrine	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	99-142
35477544-0	2022	Oxymatrine inhibits the pyroptosis in rat insulinoma cells by affecting nuclear factor kappa B and nuclear factor (erythroid-derived 2)-like 2 protein/heme oxygenase-1 pathways.	oxymatrine	0-10	heme oxygenase 1	Rattus norvegicus	151-167
35477544-9	2022	The increased levels of nuclear Nrf2 and heme oxygenase-1 (HO-1) in the HG + PA cells were further elevated after oxymatrine treatment, whereas cytoplasmic Nrf2 and Keleh-like ECH-associated protein levels decreased.	oxymatrine	114-124	NFE2 like bZIP transcription factor 2	Rattus norvegicus	32-36
35477544-9	2022	The increased levels of nuclear Nrf2 and heme oxygenase-1 (HO-1) in the HG + PA cells were further elevated after oxymatrine treatment, whereas cytoplasmic Nrf2 and Keleh-like ECH-associated protein levels decreased.	oxymatrine	114-124	heme oxygenase 1	Rattus norvegicus	41-57
35477544-9	2022	The increased levels of nuclear Nrf2 and heme oxygenase-1 (HO-1) in the HG + PA cells were further elevated after oxymatrine treatment, whereas cytoplasmic Nrf2 and Keleh-like ECH-associated protein levels decreased.	oxymatrine	114-124	heme oxygenase 1	Rattus norvegicus	59-63
35477544-10	2022	Additionally, the elevated transcriptional activity of p65 in HG + PA cells was reduced by oxymatrine, whereas that of Nrf2 increased.	oxymatrine	91-101	synaptotagmin 1	Rattus norvegicus	55-58
35477544-11	2022	The results indicate that the inhibition of pyroptosis in INS-1 cells by oxymatrine, a key factor in its glucose metabolism regulation, involves the suppression of the NF-kappaB pathway and activation of the Nrf2/HO-1 pathway.	oxymatrine	73-83	NFE2 like bZIP transcription factor 2	Rattus norvegicus	208-212
35477544-11	2022	The results indicate that the inhibition of pyroptosis in INS-1 cells by oxymatrine, a key factor in its glucose metabolism regulation, involves the suppression of the NF-kappaB pathway and activation of the Nrf2/HO-1 pathway.	oxymatrine	73-83	heme oxygenase 1	Rattus norvegicus	213-217
35432866-8	2022	The use of oxymatrine and diphenyl sulfoxide for (11C)CH2O production prevented deterioration of the molar activity of (11C)HCN.	oxymatrine	11-21	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	124-127
35252223-0	2021	Oxymatrine Protects TGFbeta1-Induced Retinal Fibrosis in an Animal Model of Glaucoma.	oxymatrine	0-10	transforming growth factor, beta 1	Rattus norvegicus	20-28
35290143-0	2022	Oxymatrine attenuates TNBS-induced colinutis in rats through TLR9/Myd88/NF-kappaB signal pathway.	oxymatrine	0-10	toll-like receptor 9	Rattus norvegicus	61-65
35290143-0	2022	Oxymatrine attenuates TNBS-induced colinutis in rats through TLR9/Myd88/NF-kappaB signal pathway.	oxymatrine	0-10	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	66-71
35290143-4	2022	Moreover, TLR9/Myd88/NF-kappaB signal pathway is a part of the most important pathways for regulating the immune response.Methods: We explored the influence of OMT with different dosages on UC by establishing a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis model.	oxymatrine	160-163	toll-like receptor 9	Rattus norvegicus	10-14
35290143-4	2022	Moreover, TLR9/Myd88/NF-kappaB signal pathway is a part of the most important pathways for regulating the immune response.Methods: We explored the influence of OMT with different dosages on UC by establishing a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis model.	oxymatrine	160-163	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	15-20